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Abstract  
V. vulnificus is a Gram negative opportunistic pathogen that is ubiquitous in the 
marine environment. Of the three main biotypes, biotype 1 is most commonly 
associated with human infection and is the causative agent of septicaemia, 
gastroenteritis and wound infection. In the United States V. vulnificus is the leading 
cause of seafood related deaths and is commonly associated with ingestion of raw or 
undercooked oysters. However, despite the abundant prevalence of this bacterium in 
the environment, the number of severe human infections is low. This has led to the 
hypothesis that not all strains of this pathogen are equal in virulence, with some 
strains better adapted to causing human disease than others.  
Therefore the current study tested a panel of 10 V. vulnificus strains in several 
phenotypic experiments that assayed the strains for known virulence factors, with the 
aim of identifying a marker for strains hazardous to human health. However, not one 
assay correlated with either virulence potential of the strains, as determined by an in 
vivo mouse model of virulence, or source of isolation.  
As the study hypothesised that the varying virulence potentials displayed by the 
strains may be due to genetic differences, whole genome sequencing (WGS) was 
performed. Bioinformatic comparison of the strains demonstrated many genetic 
differences between the strains. However, in unison with the WGS comparison, 
WGS gene annotation was also performed. This identified the presence of two 
previously undescribed type 6 secretion systems (T6SS). Therefore the current study 
continued investigation into the T6SSs. 
The two T6SSs identified were termed T6SS1 and T6SS2. T6SS2 was found in all 
sequenced isolates, whereas T6SS1 was only present in a sub-set of strains.  As 
T6SS1 shared synteny with the previously described T6SS in V. cholerae, T6SS1 
was chosen for further investigation. During this study T6SS1 was shown to be 
functional and displayed thermoregulation. Further investigation into T6SS1 by 
construction and characterising of a T6SS1 mutant, demonstrated that T6SS1 
contained anti-prokaryotic properties.  
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1.1 An overview of Vibrio vulnificus  
V. vulnificus was first reported by the Centre of Disease Control in 1975 [1], 
described as “similar but not identical to Vibrio parahaemolyticus and Vibrio 
alginolyticus”, it was initially named lactose positive (L+) Vibrio [2], however this was 
later changed to Benecka vulnifuca [3]. It was later reported in 1979 that, due to the 
lack of use of the term Benecka vulnifuca by microbiologists, the organism should be 
referred to as V. vulnificus, the naming nomenclature now commonly used today [4].  
V. vulnificus is a Gram negative bacterium which is naturally part of the marine 
microflora and is ubiquitous in aquatic and estuarine environments [5]. As the 
original naming nomenclature of V. vulnificus would suggest, this micro-organism is 
able to ferment lactose and like many other Vibrios, it is a halophilic, facultative 
anaerobe [6-8]. Morphologically it is a rod shaped organism, between 1.5-3.0 µm in 
length and ~1.0 µm in diameter [9], with a single polar flagellum. Genetically, V. 
vulnificus strains are inherently diverse [10, 11]; they harbour two chromosomes, 
which on average total ~5MB with a 46-48% GC content. A select number of strains 
contain an additional plasmid, such as the reference strain YJ016 [12].  
In addition to their genetic diversity, V. vulnificus isolates have been shown to vary 
tremendously in their pathogenicity potential [13], and as such, disease symptoms 
associated with this organism can include gastroenteritis, septicaemia and wound 
infections [14]. Unlike other species of the Vibrio genus, the disease symptoms 
associated with V. vulnificus are often rapid and fulminating, this has led to V. 
vulnificus being considered as one of the most fatal human pathogens [15-18]. In the 
United States V. vulnificus is the leading cause of seafood related deaths [13, 19], 
with a mortality rate that often exceeds 50%, and can rise to 100% if left untreated 
for longer than 72 hours [20].   
1.2 Typing of V. vulnificus isolates 
Historically there have been several approaches to sub-categorise V. vulnificus 
strains further than the species level. One such approach is biotyping, and there are 
currently three main biotypes of V. vulnificus. Biotype groups are based on  
characteristics that include; host range, serological characteristics and biochemical 
features [10, 21-25]. Biotype 1 is mainly associated with human infection [7], 
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whereas biotype 2 is associated with disease in eels and occasionally causes human 
disease [26]. Biotype 3  is the most recently identified biotype and has been shown 
to be a hybrid of both biotypes 1 and 2 [14, 27]. Table 1.1 details the difference in 
biochemical properties between the three main biotypes [27].  
Table 1.1 Biochemical properties of the three V. vulnificus biotypes  
Biochemical test Biotype 
 
1 
 
2 
 
3 
Oxidase + + + 
Arginine dihydrolase - - - 
Lysine 
decarboxylase 
+ + + 
Sucrose 
fermentation 
- - - 
Ornithine 
decarboxylase  
+ - + 
Indole production + - + 
D-mannitol 
fermentation 
+ - - 
D-sorbitol 
fermentation 
- + - 
Citrate (Simmon’s) + + - 
Salicin fermentation  + + - 
Cellobiose 
fermentation 
+ + - 
Lactose 
fermentation 
+ + - 
o-nitrophenyl-β-D-
galactopyranoside 
+ + - 
 
The literature documents that V. vulnificus biotype1 strains, those that predominantly 
account for human infections, display high intra-species diversity, as well as 
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dramatically different virulence potentials [8, 10, 28, 29]. Therefore, several research 
groups have attempted to group V. vulnificus biotype 1 strains genotypically, with the 
aim of distinguishing hyper and lesser virulent strains. Currently, the most commonly 
referred to genotyping protocol for this approach is the “vcg” or “virulence correlated 
gene” typing method. The vcg typing system was developed as a way to distinguish 
between clinical and environmental isolates [30], as it was suggested that clinical 
and environmental isolates vary genetically [21]. This was proposed following a 
comparison of clinical and environmental isolates by Random Amplified Polymorphic 
DNA PCR (RAPD-PCR). This study found that all of the clinical strains tested 
produced a 200bp band that was generally, but not exclusively, absent from 
environmental isolates [21]. Analysis of this region at the DNA level identified that V. 
vulnificus strains could be divided into two groups, C-types and E-types. Therefore a 
PCR based method was established that could readily distinguish between the C-
types and E-types [21]. Clinical isolates were grouped as C-type and reported to be 
“a strong indicator of potential virulence”, whereas environmental isolates were 
grouped as E-type [30].  
Alternative genotyping methods for V. vulnificus isolates also include analysing 
polymorphisms in the 16S ribosomal RNA. Analysis of the 16S ribosomal RNA led to 
the identification of two groups of V. vulnificus isolates, type A and type B. Type A 
generally formed clusters of environmental isolates, whereas type B formed clusters 
of clinical isolates [25, 29]. Alternatively, Bisharat et al., [31] used Multi-Locus 
Sequence Typing (MLST) using housekeeping genes to type V. vulnificus isolates. 
The MLST typing method grouped V. vulnificus isolates into clusters, cluster one 
which was mainly made up of environmental isolates and cluster two which was 
predominantly made up of clinical isolates [31]. Similarly, Cohen et al., [32] published 
work on MLST using housekeeping genes to group V. vulnificus strains. The analysis 
again produced two groups which were termed lineages, lineage one was mainly 
made up of clinical isolates, whereas lineage two mostly consisted of environmental 
isolates [32].  
An additional published typing method for V. vulnificus is the pilF typing system. This 
system is based on the finding there is a difference in the DNA sequence of the pilF 
gene between pathogenic and non-pathogenic strains [33]. Due to this finding a PCR 
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method was developed to distinguish between V. vulnificus strains that are 
hazardous to human health, from those that are not. Pathogenic strains are reported 
to produce a PCR band that is 338bps in length, whereas non-pathogenic strains are 
PCR negative and do not produce a band [33]. The pilF PCR method was later 
followed up with a real-time PCR method to distinguish between hyper and lesser 
virulent strains [7]. The real-time PCR method was reported to be highly sensitive 
and accurate [7]. However, the real-time PCR pilF typing method, like many of the 
typing methods mentioned earlier, is limited in that it is unable to distinguish 
pathogenic from non-pathogenic strains with 100% accuracy. Often there will be 
pathogenic strains that will cluster with non-pathogenic strains and vice versa [7, 10, 
13, 30].  
Therefore, in order to validate the genotyping methods developed for V. vulnificus, a 
research group analysed 69 biotype 1 V. vulnificus strains in an iron overloaded 
mouse model of infection, and reported the virulence of each strain in vivo [13]. The 
strains were grouped from one to five according to virulence, whereby group one 
was the least virulent and group five the most virulent. Virulence was evaluated for 
each strain based on the following markers of disease; skin infection, liver infection, 
body temperature and death. The study then identified whether the current 
genotyping methods for V. vulnificus could accurately predict virulence. The study 
found that although there was a correlation between genotype and virulence, none of 
the genotyping methods tested were able to accurately predict virulence for the 
strains [13], and concluded that further investigation was needed into V. vulnificus 
virulence to identify genetic markers of human disease.  
1.3 Epidemiology 
V. vulnificus is mainly isolated from marine environments such as estuarine water, 
fish and shellfish [7, 34, 35]. This, coupled with the common practice in many 
cultures to eat shellfish such as oysters raw, means V. vulnificus infection is often 
associated with the ingestion of raw oysters [36, 37]. Therefore from a food security 
angle it is of interest to be able to distinguish hyper virulent V. vulnificus strains from 
lesser virulent strains, particularly as V. vulnificus infection has a mortality rate often 
exceeding 50% [14, 36].   
6 
 
A retrospective study between 1988 and 1996 in the US demonstrated that out of 
422 V. vulnificus infections 45% were wound infections, 43% were primary 
septicaemia and a small 5% portion were gastroenteritis, the remaining 7% were 
unidentified exposure routes [37, 38]. The majority of V. vulnificus infections occur 
during the warmer months of May to October and only sporadic cases during the 
colder months of November to March [36, 37]. This has been linked to the fact that 
this pathogen’s growth displays a seasonal pattern, whereby there is an increase in 
the ability to isolate and culture the organism during the warmer months [39-41]. As 
V. vulnificus environmental growth is linked to temperature, it is believed that climate 
change may cause an increase in V. vulnificus infections [42, 43]. For example, The 
Baltic Sea was originally thought to be an unfavourable environment for V. vulnificus, 
however due to climate change causing an increase in surface sea water 
temperature, the originally cooler Baltic Sea has now been demonstrated as a region 
from which V. vulnificus can be isolated [44].  
In addition to the Baltic Sea Region, V. vulnificus has also been isolated from several 
other European countries including, Spain [45], Turkey [46], Belgium [47], Israel [27], 
Greece [48], Denmark [49], Sweden [50] and the Netherlands [51]. As well as 
Europe, V. vulnificus has also been isolated from Asian regions such as Malaysia 
[52], Nepal [53], Korea [54] and Taiwan [35].  In the US, the bacterium is 
predominantly isolated from the Gulf of Mexico and neighbouring states as well as 
North East America and the Northern Pacific Coast [38, 55]. It is also found in 
regions such as California [56] and Florida [57].  
As demonstrated, V. vulnificus can be isolated from a range of countries throughout 
the world and it is believed that temperature is a major factor regarding V. vulnificus 
environmental concentrations [6]. In addition to temperature, several reports also 
suggest that salinity levels are an important parameter for the isolation of the 
bacterium. It has been found that optimum environmental salinity concentrations for 
isolation of this bacterium, are between 5-10 ppt [41].  
1.4 Clinical presentation and infectivity   
V. vulnificus is known to be a fatal pathogen often causing fulminating systemic 
disease symptoms, yet the infectious dose for humans is currently undetermined 
[38]. Clinical presentation is often dependent on the route of infection, ingestion for 
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example can lead to gastroenteritis, diarrhoea, vomiting and nausea. [58, 59]. In 
severe cases, gastroenteritis will develop into primary septicaemia a condition in 
which the mortality rate can exceed 50% [43]. V. vulnificus can also enter humans 
via wound infection, this occurs when open wounds come into contact with 
contaminated fish or water [38, 60]. Characteristic symptoms of wound infection 
include oedema, necrosis and swelling. Secondary cutaneous lesions can occur and 
large blistered regions may present along with cellulitis and pain. The mortality rate 
associated with wound infection is ~25% [7, 58, 60]. [61, 62]. It is also not 
uncommon for wound infection patients to require amputation of infected sites [14]. 
As with ingestion of the bacterium, wound infection can also lead to life threatening 
septicaemia [14, 63]. Both wound infection and primary septicemia can present with 
fever and chills, and occasionally hypotension [64, 65].  
As well as the possible link of environmental temperatures affecting V. vulnificus 
infection rate [42], the immune state of a patient has also been shown to play a 
significant role in the disease outcome [36, 59]. For example, patients suffering from 
liver disease are at particular risk of dying from infection [20, 38, 66]. On average, 
80% of fatal V. vulnificus infections occur in individuals who have chronic liver 
disease [14, 38, 67]. Chronic liver diseases can include, cirrhosis, hepatitis and 
alcoholic liver disease [20, 43]. In addition to patients suffering with chronic liver 
problems, individuals who have high iron serum levels or weakened immune 
systems, such as AIDS and chemotherapy patients are also at risk of infection [12, 
36, 68, 69]. Males are most at risk of infection with the majority of cases occuring in 
males over the age of 40 [43]. One possible link to account for the small number of 
females contracting the infection is that oestrogen has been shown to be protective 
against the effects of the bacterium’s lipopolysaccharide (LPS) [70]. However, the 
exact reason why more males contract V. vulnificus infection has not been fully 
elucidated.   
As V. vulnificus has an extremely high mortality rate and ubiquitous prevalence in the 
environment, it would be expected that the number of fatal human infections would 
be high. Conversely, the literature reports that the number of severe infections each 
year is exceptionally low [13, 21]. For example, the number of “considered at risk” 
individuals consuming raw oysters in Florida is around 70,000, yet there are only on 
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average five to ten V. vulnificus infections a year in this region [38, 71]. This trend of 
low infection compared to the availability of the bacterium in the environment is 
typical in all areas where V. vulnificus has been isolated [14]. Why there are so few 
fatal infections, despite the high mortality rate and natural prevalence of this 
pathogen, has been a question which has perplexed scientists for many years [13, 
21].  
1.5 Diagnosis and treatment 
When V. vulnificus infection is suspected, the general procedure is to perform 
bacterial culture on wound, blood or stool samples with the use of thiosulfate–citrate-
bile-salts-sucrose (TCBS) agar to isolate the bacterium [72]. Additionally it is advised 
that a Gram stain should be performed to identify characteristic comma shaped cells 
[20, 59, 73]. Although TCBS agar is a selective agar for Vibrio growth, care should 
be taken when isolating V. vulnificus as although the majority (~85%) of V. vulnificus 
strains will appear green on TCBS agar, there are a subset (~15%) of strains that will 
appear yellow [74]. This is due to the ability of these latter strains to ferment sucrose 
in the TCBS agar, causing a pH shift that generates yellow colonies [74].  
Antibiotic therapy for V. vulnificus infection should be administered promptly, as 
speed of diagnosis and treatment is directly linked to prognosis. For example, a 
delay in medication by up to 72 hours can increase mortality from 50% to 100% [59, 
75]. Although V. vulnificus is susceptible to a range of antimicrobials in vitro, the 
recommended treatment is doxycycline, 100 mg intravenously or orally twice a day 
plus ceftazidime, 2 g intravenously every eight hours or ciprofloxacin, 750 mg orally 
or 400 mg intravenously twice a day [36]. In addition to antibiotics, severely infected 
patients may require amputation of affected limbs to prevent systemic spread of the 
pathogen [20, 59].  
1.6 The viable but non culturable state of V. vulnificus  
As exemplified in the previous section, cultivation of a bacterial pathogen is a 
fundamental step in diagnostic microbiology [76]. In 1982 however, it was shown that 
bacterial cells could enter a state whereby they were non-culturable on standard 
laboratory media, yet bacterial staining methods demonstrated that the cells were 
still alive [76, 77]. As the cells were not dead, but had entered a non-culturable 
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stage, this novel microbiological phenomenon was termed viable but non culturable 
(VBNC) [77].  
The VBNC state of bacterial cells is thought to be trigged by an extreme change in 
their environmental surroundings [76]. Examples of some known VBNC triggers are; 
changes in temperature [78], osmolality [79], nutrient starvation [80] and chlorination 
[81]. When cells enter a VBNC state they undergo various changes which can 
include, changes to their cellular morphologies, an increase or decrease in 
metabolism and alterations to their cell wall and membrane compositions [76]. Unlike 
dead cells however, VBNC cells are metabolically active, transcribe genes, utilise 
nutrients and carry out respiration [82, 83].  
V. vulnificus is known to enter a VBNC state [18]; which is reported to aid the 
bacterium in withstanding environmental stresses such as temperature shifts [84]. 
For example, a decrease in temperature to 5oC can induce V. vulnificus cells to 
become VBNC [85]. During this period the cells undergo cellular membrane changes 
and reduced amino acid transport [85, 86]. As previously mentioned, the ability to 
culture V. vulnificus cells from the environment during the winter months is greatly 
reduced. It is believed that this is due to the pathogen’s ability to become VBNC. 
Accordingly the effect of temperature on the ability to culture V. vulnificus from the 
environment has been demonstrated experimentally [87, 88]. This was done by 
placing chambers filled with VBNC cells into estuarine water during August to 
November, when the water temperature was above 5oC. When the cells were taken 
out again and plated onto laboratory media, the cells were culturable, demonstrating 
the resuscitation ability of temperature on the VBNC cells. However, when laboratory 
culturable cells of V. vulnificus were placed into estuarine water that was below 
15oC, when the cells were taken out again, the cells were no longer culturable on 
standard laboratory media, further demonstrating the effects of environmental 
temperatures in inducing the VBNC state of V. vulnificus [89].  
In addition to warm temperatures resuscitating VBNC cells, the quorum sensing 
auto-inducer molecule, AI-2, has also been shown to play a crucial role [90]. This 
was demonstrated by adding the cell free supernatant from culturable V. vulnificus 
cells, to VBNC cells, causing the VBNC population to be resuscitated and become 
culturable. The molecule AI-2 was shown to be the important factor, as cell free 
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supernatants from V. vulnificus cells that were unable to secrete AI-2, failed to 
resuscitate VBNC cells  [90].  
To assess the virulence of VBNC V. vulnificus cells, iron over loaded mice were 
challenged with a VBNC population. The results showed that even after entering a 
VBNC state, V. vulnificus remains virulent, and able to cause disease [91].  
1.7 Regulation and quorum sensing  
Bacteria have many regulatory systems which aid in the coordinate expression of 
genes in response to environmental stimuli [92]. Iron for example is important for the 
survival and virulence of many different bacterial species [93], therefore the ability for 
bacteria to respond to environmental changes in iron is important [94]. It has been 
suggested that the shift from a high to low iron environment may signal to bacteria 
that they have entered a mammalian host [95, 96]. This is demonstrated in 
enterohaemorrhagic E. coli, whereby under low iron conditions virulence factors such 
as the expression of the shiga-like toxin is upregulated [97, 98]. The regulation of 
virulence genes in response to iron has been shown to be controlled by the fur gene, 
whereby when sufficient iron levels are reached, the fur gene is activated causing a 
down-regulation of gene expression for certain genes [99].  
An early study looking for the presence of the fur gene in V. vulnificus identified fur 
homologues by Southern hybridisation. Construction of a fur mutant in V. vulnificus 
demonstrated that outer membrane proteins such as HupA and VuuA are iron 
regulated and were over-expressed in a fur mutant strain [99-101]. Studies have also 
shown that fur is regulated by the Sigma S factor, RpoS. This was shown by 
comparing the proteomic secretome of wild-type V. vulnificus with the secretome of 
V. vulnificus containing a mutation in the rpoS gene [102]. It was found that the Fur 
protein was significantly down regulated in an rpoS mutant. As well as rpoS 
regulation, the study found that Fur can also regulate its own expression under iron-
limited conditions [102]. It was later shown experimentally using a transcriptional 
fusion that fur contains an upstream region, this upstream region was shown to bind 
Fur during iron limited conditions to control expression [103]. Fur is also known to act 
on virulence genes in V. vulnificus such as the haemolysin/cytolysin encoded by 
vvhA. A study found that Fur effected the expression of vvhA by causing a decrease 
in levels of VvhA as well as repressing the expression of vvpE [104].  Following on 
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from the identification that Fur can control the expression of vvpE, it was found that 
Fur can control the expression of SmcR [105]. SmcR (homologous to LuxR) is a 
quorum sensing regulator which can control the expression of virulence factors in V. 
vulnificus [106].  
Quorum sensing (QS) is the ability for bacterial populations to sense environmental 
surroundings using signalling molecules [107]. Bacterial cells are able to use 
signalling molecules known as auto-inducers to modulate the cells within the 
bacterial population. This can affect activities such as motility, biofilm  formation, 
extracellular secretion, luminescence, virulence and secondary metabolites [107, 
108]. Studies have found that V. vulnificus produces the quorum sensing molecules, 
acylated homoserine lactones and the auto-inducer, AI-2 [109, 110]. It has been 
shown experimentally that the AI-2 molecule of V. vulnificus is able to stimulate the 
quorum sensing system two in V. harveyi [111]. The AI-2 synthase gene luxS is 
believed to be involved with coordinating the expression of virulence factors in V. 
vulnificus, as a luxS mutant has been shown to be attenuated both in vivo and in 
vitro. For example, the luxS mutant was less lethal in a mouse model of infection, as 
well as displaying attenuation towards HeLa cells in tissue culture. It was also noted 
that the luxS mutant displayed a decrease in the production of extracellular protease 
including VvpE) compared to the wild-type strain. Conversely, the luxS mutant 
produced an increase in the haemolysin/cytolysin compared to the wild-type strain 
[111].  
An alternative study also demonstrated that a luxS mutant showed a weak 
attenuation towards a macrophage cell line, like-wise a mutation in smcR also 
produced a weakly cytotoxic effect towards macrophages, compared to the wild-type 
strain [112]. A study using luxS and smcR mutants have shown that macrophages 
activated with these mutants displaying differing gene expression profiles compared 
to macrophages activated with a wild-type strain. Differential expression was seen in 
genes involved with removal of toxins, cytokine production and the complement 
pathway. The authors concluded that V. vulnificus quorum sensing may therefore be 
involved in pathogenesis and survival of the bacterium by changing the expression 
profiles of host immunity genes [113].  
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1.8 Virulence mechanisms of V. vulnificus 
1.8.1 Evasion of host defenses by V. vulnificus  
V. vulnificus disease symptoms are generally dependent on the route of infection, 
which can either be through ingestion or wound infection [59, 60, 114]. Once inside 
the human host, V. vulnificus will be required to evade host immune defences in 
order to survive [12, 14, 92]. Depending on the route of infection, the bacterium may 
experience the acidic conditions of the stomach. Therefore in order to continue its 
journey through the body, the bacterium will be required to neutralise the acidic 
conditions in the stomach [12, 92]. Likewise, arrival of the bacterium in the 
bloodstream does not guarantee survival for V. vulnificus cells, as the bacterium will 
meet macrophages, and will therefore be required to evade phagocytosis. To 
overcome the host’s immune system and establish an infection, V. vulnificus has 
evolved several virulence factors to aid in the disease process. Many of these 
virulence factors are outlined in more detail below.   
 1.8.1.1 Acid neutralisation  
As V. vulnificus is an acid-sensitive bacterium [115], it is imperative that the 
organism is able to neutralise gastric acids [116]. Neutralisation of acidic conditions 
is achieved by the synthesis of cytoplasmic amino acid decarboxylases [92]. The 
cadBA operon of V. vulnificus encodes a lysine/cadaverine antiporter and a lysine 
decarboxylase, which both aid in countering acidification by the synthesis and 
excretion of cadaverine [117]. Mutagenesis studies demonstrated that lysine 
decarboxylase encoded by the cadA gene plays an important role in acid tolerance, 
as a cadA mutant is more sensitive to acidic conditions than the wild-type strain. In 
order for the cadBA operon to be induced and provide cells with the ability to 
withstand acidic conditions, prior exposure of the cells to a low pH is required. This 
was an important finding for V. vulnificus, as previous food safety practice involved 
exposing seafood to acidic conditions. This was done to suppress bacterial growth, 
however the method could have potentially been prepping V. vulnificus cells to 
withstand human host defenses  [116].  
Initial work on understanding the mechanism by which the bacterium survives acidic 
conditions was followed up by understanding the regulation and activation of the 
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cadBA operon. Activation of the cadBA operon in V. vulnificus was found to be 
activated by CadC, cadC activity is pH dependent as it is not expressed at neutral 
pH. Mutagenesis studies in the aphB gene demonstrated that cadC is activated by 
aphB, which causes an increase in cellular levels of CadC [117]. This ultimately 
leads to the production of lysine/cadaverine antiport and lysine decarboxylase, both 
of which are able to neutralise acid [118].  
1.8.1.2 Capsule  
It is well documented in the literature that capsule is involved in protecting bacteria 
from the host immune system and concealing pathogen associated molecular 
patterns (PAMPS), such as outer membrane proteins [119]. The capsular 
polysaccharide of V. vulnificus is described as one of the main virulence factors of 
this extracellular pathogen [12, 120, 121]. Mutagenesis studies have demonstrated 
the importance of the capsule as strains with mutations in capsule genes or genes 
involved in the expression of capsule are attenuated in animal models of infection 
[121, 122].  
It is documented in the literature that V. vulnificus cells display two differing colony 
morphologies, designated opaque and translucent [123], due to the surface 
expression of capsule [120]. Opaque morphologies represent encapsulated strains 
expressing capsular polysaccharide (CPS), whereas translucent colonies represent 
non-encapsulated strains, or cells expressing decreased amounts of CPS [123]. The 
bacterium can vary between opaque and translucent, with single strains capable of 
expressing both colony types on one streak plate [38, 121, 124]. In a study by 
Simpson et al., (1987) 38 V. vulnificus strains were examined for their colony 
morphology. They found that all strains produced either a mixture of opaque and 
translucent or translucent only colony types [124]. Mouse models of infection 
demonstrate that encapsulated strains show an increase in virulence and display 
resistance to serum activity, whereas translucent strains are reduced in virulence 
and sensitive to serum killing [121, 125]. The transition from an opaque to 
translucent colony morphology is based on phase variation in the group-1 CPS 
cluster. Phase variation is reported to be a consequence of multiple genetic 
alterations in the CPS operon [126].  
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Although capsules have long been used successfully in vaccines against pathogenic 
bacteria [127], the production of a capsule based vaccine is unlikely for V. vulnificus, 
due to the significant heterogeneity of the capsule between strains [12].  
1.8.2 Iron uptake mechanisms of V. vulnificus  
Many organisms require iron for a variety of cellular process, therefore the ability of 
pathogenic bacteria to scavenge iron from their host is important [9]. Iron in human 
hosts is generally unavailable to invading bacteria, as it is bound to transferrin [92]. 
Therefore pathogenic bacteria have evolved mechanisms to overcome this 
challenge. This is achieved by producing iron chelators known as siderophores, 
which are able to bind iron and return it to the bacterial cell. V. vulnificus has been 
shown to produce two types of siderophores, vulnibactin and hydroxymate-type 
[128].  
The transport of siderophores across bacterial membranes is generally driven by the 
TonB system, in an energy dependent process [129]. Many pathogenic Vibrios have 
been shown to contain two TonB systems [129], TonB1 and TonB2. Both TonB1 and 
TonB2 are present in V. vulnificus and have been shown to be involved in the uptake 
of exogenous iron-bound siderophores [130]. In addition to the uptake of V. vulnificus 
siderophores, the TonB1 and TonB2 systems of V. vulnificus are also able to uptake 
siderophores which have been produced by other bacteria [130].  
Unlike many other pathogenic Vibrios, V. vulnificus has been shown to encode an 
additional TonB system, TonB3 [9].  TonB3 is induced when V. vulnificus is grown in 
human serum and in minimal media containing glycerol. The leucine responsive 
protein and the cyclic AMP receptor protein, have been identified as factors that 
affect the regulation of the TonB3 system [131]. These are two global regulators that 
are able to regulate the TonB3 system in response to different environmental 
signals. Although the regulation of the TonB3 system has been elucidated for V. 
vulnificus, a direct role in virulence for this third system has yet to be established 
[131].  
As previously mentioned, V. vulnificus produces two types of siderophores, 
vulnibactin and hydroxymate-type [128]. In addition to siderophores, it was 
suggested that V. vulnificus could also scavenge iron from the human host, through 
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the use of the metalloprotease, VvpE. It was believed that the proteolytic ability of 
VvpE could cleave heme proteins from host transferrins and lactoferrins [132, 133]. 
The ability of VvpE to aid in the accumulation of iron was demonstrated 
experimentally by the addition of exogenous VvpE to V. vulnificus cultures, 
demonstrating that the metalloprotease could digest heme proteins [133].  
However, it was later shown by two different research groups, that the siderophore 
vulnibactin, is required for the uptake of iron from the human host, and not VvpE 
[132, 134]. This was demonstrated through the use of mutagenesis studies which 
showed that a deletion to either venB or vuuA, removed the ability of V. vulnificus to 
accumulate iron [132]. venB encodes for an enzyme required for vulnibactin 
synthesis, where as vuuA encodes a vulnibactin receptor protein. A deletion to the 
vvpE gene however, did not affect vulnibactin production or the assimilation of iron. 
These results therefore suggest that vulnibactin is required for the assimilation of 
iron, whereas VvpE is not [132]. Recent work understanding how vulnibactin is 
secreted from the cytoplasm to the extracellular environment, has suggested that 
vulnibactin is secreted via a type 1 secretory pathway, employing a resistance-
nodulation division (RND) efflux system. This study also identified TolC as an 
essential protein involved with the export of vulnibactin  [135].   
As documented earlier, fatal V. vulnificus infections often occur in individuals with 
predisposing liver conditions, or high iron serum levels [36, 68]. Accordingly, in vivo 
studies which investigated iron levels and V. vulnificus pathogenicity, showed that an 
increase in iron levels, caused a decrease in the amount of bacteria required to 
cause an infection from 106 to 1 bacterial cells. The study concluded that mice with 
liver damage were more susceptible to V. vulnificus infection [136].   
1.8.3 Motility and attachment 
In order to establish an infection, many bacteria will often move from the initial site of 
infection to another location within a host [137]. This motility is often achieved by the 
presence of flagella and as such flagella is often regarded as an important virulence 
factor for many pathogenic bacteria [138]. For example, V. vulnificus infection is 
commonly associated with sepsis, therefore depending on the route of infection, the 
bacterium will have to migrate from the initial site of infection to the bloodstream [14, 
139]. Accordingly, genetic mutagenesis studies have demonstrated that the flagellum 
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is a virulence factor for V. vulnificus [140, 141]. Attachment of bacterial cells to a host 
surface is also important for the establishment of an infection [142]. This is 
particularly true for V. vulnificus cells when invading via the gastrointestinal route, as 
cells will need to attach and destroy the intestinal cell wall, allowing the bacterium to 
enter the bloodstream [12]. 
1.8.3.1 Flagellum  
The basic flagellum structure is made up of the basal body, hook and filament [143]. 
In V. vulnificus the following genes encode for hook associated proteins (HAP), flgK 
(HAP1), flgL (HAP2) and flgH (HAP3), whereas flgK and flgH form a junction 
between the hook and filament, with flgL forming a capping structure at the end of 
the flagellum. To understand the role of the flagellum in V. vulnificus virulence, 
mutagenesis studies were performed. The study found that flgK and flgL mutants, 
both produced a flagellum which was identifiable by Western blotting, however the 
flagellum was not attached to the bacteria and was secreted out in to the 
supernatant [144]. Conversely, the flgH mutant produced a very loosely attached 
flagellum. Investigation into the motility of these mutants showed that both flgK and 
flgH were non motile, and all 3 mutants were reduced in their cytotoxicity and 
adherence to cell culture lines [144]. In a mouse model of infection, flgL and flgH 
were attenuated [145]. A mutant containing a deletion in the flgE gene is also non-
motile, attenuated in an in vivo infection model and reduced in adherence and biofilm 
formation [141].  Similarly disruption to the flgC gene leads to a significant decrease 
in motility, adhesion and cytotoxicity, with the mutant displaying an attenuation in a 
mouse model of infection [140].  
1.8.3.2 Pili 
Pili structures on V. vulnificus can be imaged using electron microscopy, and have 
been found to be important for adherence of the bacterium to epithelial cell lines 
[146]. Furthermore, deletion of the V. vulnificus vvpD gene, a homologue of the pilD 
gene in Pseudomonas aeruginosa, has been shown to effect surface expression of 
pili [92]. Indicating that V. vulnificus surface expressed pili are from the type 4 class, 
which are involved in attachment and motility [147]. PilD is a peptidase which 
cleaves the pre-pilin signal on PilA proteins, which are involved with pili generation. 
Furthermore, mutations to pilD in bacteria such as, P. aeruginosa, Aeromonas 
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hydrophila and Legionella pneumophila, have caused disruption to proteins secreted 
via the GSP. Similarly for V. vulnificus, mutations to the pilD gene led to a disruption 
in the secretion of several extracellular enzymes. For example, one extracellular 
enzyme was found to localise to the periplasmic space, therefore suggesting the 
protein is normally secreted via the GSP. The vvpD mutant was also attenuated for 
cytotoxicity to epithelial cell lines, adherence to Hep-2 cells lines and was attenuated 
in an iron-over loaded mouse model [147].   
1.8.4 Bacterial endotoxin 
Lipopolysaccharide (LPS), also known as endotoxin, is a molecule made up of a lipid 
and a polysaccharide region [148]. Molecules of LPS are not secreted but are found 
situated on the outside of Gram negative bacteria [149]. Due to the LPS molecule 
making up the outer leaflet of the outer membrane of Gram negative bacteria, LPS is 
easily accessible to the host immune system, and is a prudent activator of host pro-
inflammatory cytokines [148]. In addition to the activation of immune cytokines, LPS 
can also activate both the innate and adaptive immune response, this can lead to 
fever, organ failure and ultimately death from septic shock [148, 149]. 
1.8.4.1 V. vulnificus  endotoxin 
 In agreement with what is known about bacterial LPS, exposure of humans to V. 
vulnificus LPS is reported to result in septic shock [150]. Additionally, experimental 
injection of V. vulnificus LPS into rats via the intraperitoneal route has been shown to 
cause death in as little as 30 minutes [151]. In vitro studies of V. vulnificus LPS have 
also shown activation of rat microglia resulting in the release of inflammatory 
cytokines [150].  
A phenomenon associated with V. vulnificus infection is why a disproportionate 
number of males succumb to V. vulnificus sepsis compared to females [12, 43, 70]. 
This un-answered question was investigated by a study carried out in 2001, which 
looked at the protective mechanisms of oestrogen to sepsis induced by V. vulnificus 
LPS. The study used an in vivo mouse model to demonstrate the ability of the female 
hormone oestrogen to protect against the toxic effects of LPS. The study therefore 
hypothesised that the female hormone, oestrogen may account for why there are 
more V. vulnificus infections associated with males than with females [70]. Although 
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the study demonstrated that oestrogen can protect against the endotoxic shock 
induced by LPS, the exact mechanisms of the protection is yet to be established.  
In addition to oestrogen, low density lipoproteins (LDL), are also believed to help 
protect host organisms from V. vulnificus induced sepsis, as it has been shown that 
the levels of LDL in a patient’s serum can affect V. vulnificus infection outcome [152]. 
Although the study demonstrated that serum LDL levels can affect infection 
outcome, the exact methods by which LDL protect against V. vulnificus sepsis is 
currently undetermined [152]. A more recent study looking at the innate immune 
response to V. vulnificus LPS, demonstrated that the secondary metabolite, Cyclo 
(Phe-Pro) produced by V. vulnificus is able to suppress inflammatory cytokines in 
vitro. The study suggested that Cyclo(Phe-Pro) enables the pathogen to survive in 
the host by supressing the inflammatory immune response [153].  
1.8.5 Bacterial exotoxins 
During bacterial pathogenesis, bacteria employ a range of secreted virulence factors, 
these virulence factors can be used for both damaging host cells, as well as 
protecting the invading bacterium from the host’s immune response [92, 154]. 
Likewise, in addition to the virulence factor LPS, described in the above section, V. 
vulnificus also produces an array of secreted virulence factors to aid in the disease 
process [38, 43].  
Toxins secreted by pathogenic bacteria can be divided into three different sub-
classes, type I toxins, type II toxins and type III toxins [154]. Type I toxins exert their 
effect at the cell surface and do not require entry into the host cell [92, 154]. The 
second class of toxins is the type II toxins, these are classified as  toxins which 
cause damage to the integrity of host cell membranes [154], an example of a type II 
toxin is the Rtx class of toxins [92, 154, 155]. Finally, type III toxins are a group of 
toxins that are composed of two molecules and are therefore sometimes referred to 
as A/B toxins [154]. An example of a type III toxin is the well-studied cholera toxin 
[154]. The B subunit of the toxin generally binds to receptors of the surface of host 
cells, whereas the A subunit, which contains the enzymatic activity enters the host 
cell where it causes its deleterious effects [154].   
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 1.8.5.1 V. vulnificus Rtx toxin   
Although V. vulnificus is known to produce a range of secreted virulence factors, the 
most extensively studied toxin is the Rtx toxin [154, 156]. The Rtx or “repeats in 
toxin” is a class of toxin which is found extensively in Gram negative bacteria and 
can cause a range of biological effects [156]. Bacterial Rtx toxins often contain 
glycine and aspartate amino acid repeats and are usually secreted via the type 1 
secretion system [156].  
The RtxA toxin from V. vulnificus was first identified as a virulence factor for this 
pathogen in 2007 [155, 157]; and although the toxin shares significant homology to 
the Rtx toxin of V. cholerae, the RtxA toxin from V. vulnificus differs in its mode of 
action. For example, V. vulnificus RtxA has been shown to  cause disruption to the 
cellular membrane of mammalian cells [155], as well as causing cytoskeleton 
rearrangement and blebbing of cells, ultimately leading to the necrotic cell death of 
mammalian cells [158]. This is in contrast to the V. cholerae Rtx toxin, which has 
been shown not to disrupt the cellular membrane, but instead causes 
depolymerisation of actin leading to the rounding up of mammalian cells [155].  
The RtxA toxin of V. vulnificus is secreted via the T1SS which contains an RtxE 
ATPase. This was identified following in vitro experiments which demonstrated that 
RtxA could be identified in the supernatant of wild-type V. vulnificus, but not in the 
supernatant of an rtxE mutant [159, 160]. The rtxE is described as a virulence factor 
for V. vulnificus as the mutant is attenuated in a mouse model of infection. 
Additionally, the rtxE mutant was shown to be more attenuated than a rtxA mutant in 
vivo, suggesting that RtxE is involved with the secretion of additional virulence 
factors other than solely RtxA [159]. Following secretion of the RtxA toxin into host 
cells, the toxin has been shown to then be processed into two parts. In vitro studies 
have demonstrated that the larger N-terminal region localises to the host cell 
membrane, whereas the smaller C-terminal region can be detected inside the host 
cell [161]. The pore produced by the N-terminal fragment has been shown to cause 
an imbalance of calcium, whereby there is an influx of calcium into host cells leading 
to an increase in intracellular calcium levels. The study showed that the increase in 
calcium levels led to mitochondrial dysfunction and ultimately programmed necrotic 
cell death [161].  
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A study which monitored the infection process of V. vulnificus, by following 
intragastric inoculation of mice, found that deleting the rtxA gene caused a delay in 
bacterial growth in vivo, reduced colonisation of the small intestines and reduced 
dissemination of the bacteria to other organs such as the liver and spleen. The 
bacteria were monitored in vivo by imaging infected mice and tracking bacteria using 
luminescence. Overall the study found that the RtxA toxin aids in establishment of an 
infection and dissemination to other tissues, a loss of the RtxA toxin caused a delay 
in the establishment of infection and in general, a less severe infection [162].   
The majority of the studies which have examined the role of the RtxA toxin from V. 
vulnificus, have used the reference strains, CMCP6, MO6-24/O or YJ016. However, 
a recent bioinformatic study which assessed the variation in domains associated with 
the RtxA toxin from 40 V. vulnificus isolates found there to be four different variations 
of the toxin’s domain. This bioinformatic study found the most abundant RtxA toxin 
present in clinical isolates has reduced virulence in comparison to the toxin from 
environmental isolates. It is believed that the variation in the toxin effector domain 
arose from recombination events, either with RtxA genes from plasmid DNA or from 
the Vibrio strain, V. anguillarum. The authors suggested that strains of V. vulnificus 
are undergoing genetic rearrangement which may ultimately lead to selection of 
strains that exhibit reduced virulence in humans [163]. 
1.8.5.2 Extracellular cytolysin/haemolysin  
As well as producing a well-studied RtxA toxin, V. vulnificus is also known to secrete 
a 56kDa cytolysin/haemolysin, which is encoded by the vvhA gene [43, 164, 165]. 
Although homologous to the vvhA gene of V. cholerae [166], the vvhA gene from V. 
vulnificus is often used as a V. vulnificus species specific housekeeping gene that is 
commonly used to identify the provenance of isolates [167, 168].  
In 1985 the VvhA toxin was purified and characterised in several in vitro and in vivo 
experiments [164]. The studies demonstrated that the toxin was heat-labile, 
hydrophobic and able to cause lysis of red blood cells. Further characterisation of the 
toxin indicated that the protein was toxic to CHO cells in vitro, and lethal in an in vivo 
mouse model of infection [164]. As such VvhA is thought to be a potent V. vulnificus 
toxin due to the disease symptoms generated in mice at very low inoculation levels 
[164, 169].  
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To further understand the role of VvhA in V. vulnificus virulence, a deletion mutant 
was made and tested in vivo, with mice subsequently challenged via the 
intraperitoneal and intradermal infection route. Conversely to previous data, the 
study found that the vvhA mutant was not attenuated in vivo and virulence of the 
mutant was comparable to the wild-type strain [170]. This led researchers to believe 
that the VvhA toxin may not be as important in V. vulnificus infection as once 
believed. To determine whether VvhA was produced in vivo during infection, RNA 
was extracted from the infected mice. The study demonstrated that vvhA was indeed 
expressed during in vivo infection, as RT-PCR performed on cDNA generated from 
the RNA extractions, demonstrated expression of the vvhA gene [169]. Several 
years after the confusion of understanding the role of VvhA in V. vulnificus virulence, 
a study carried out an infection of mice with a vvhA mutant via the intra-gastric route, 
instead of the previously used intra-peritoneal or intra-dermal route [162]. The study 
found that the vvhA mutant was attenuated compared to the wild-type strain, and 
that VvhA in conjunction with RtxA, is required for gut pathogenesis. Demonstrating 
that both RtxA and VvhA are required for in vivo growth, establishment of an 
infection and dissemination from the gut to other organs [162]. This study 
demonstrates the importance of using appropriate models of infection as well as 
identifying suitable methods of inoculation when studying mutants in vivo.  
Although there has been much focus on the role of VvhA in V. vulnificus 
pathogenicity, there have been a couple of studies which have attempted to 
understand the delivery route of VvhA during infection; with one study suggesting 
outer membrane vesicles (OMV) as a potential secretion route [167]. It is understood 
that OMV are used by various Gram negative bacteria for the delivery of toxins to 
host cells and may present as a stress response by bacteria in response to changes 
in their environment [171]. This may explain why OMV are activated when bacteria 
enter a human host [171]. An experimental study using immunoblotting 
demonstrated that V. vulnificus produces OMV containing VvhA during in vitro 
infection which mediates apoptosis in epithelial cells [167]. It was shown that the 
toxin delivered by OMV is VvhA as VvhA null mutants are unable to cause 
cytotoxicity to cells. The study also observed that OMV interact with cholesterol on 
host cells to deliver the toxin, as treatment of epithelial cells with a cholesterol 
sequester inhibits the cytotoxic effects of OMV containing VvhA [167]. This is in 
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accordance with an additional study that showed cholesterol is required for the 
binding of VvhA to plasma cell membranes, and as such, removal of cholesterol 
inhibited VvhA binding to membranes [172]. 
 1.8.5.3 Extracellular proteases produced by V. vulnificus  
An additional secreted protein by V. vulnificus is the extracellular metalloprotease, 
VvpE [43]. In 1985, this 50.5 kDa protein was shown to function optimally at pH 7-8 
and was produced maximally during the late exponential growth phase. As well as 
being growth phase dependent, VvpE has also been shown to be effected by factors 
such as temperature, iron levels, oxygen and osmolality [173].   
In contrary to original findings described above, recent research has demonstrated 
that the VvpE protein is 45 kDa, not 50.5kDa and upon secretion is cleaved into two 
fragments, a 34 kDa protein and a C-terminal pro-peptide that is 11 kDa in length 
[174]. The original 45 kDa protein is thought to be cleaved into two fragments by 
extracellular autoprotolysis. During the early growth phase of V. vulnificus cells, both 
the 34 kDa protein and the 45 kDa protein can be found in the supernatant, however 
it was found that the 34 kDa protein predominates over the 45 kDa protein. Both 
sized proteins contain proteolytic capabilities. However the 34 kDa protein is more 
efficient at degrading soluble proteins than insoluble proteins. The 45 kDa protein 
however is sufficient at maintaining a proteolytic ability that is similar for both 
insoluble and soluble proteins [174].    
After the identification of VvpE, studies aiming to characterise the protease 
subsequently ensued. Early studies achieved this by carrying out injection of the 
purified protein into mice [175]. These studies proposed that VvpE was a virulence 
factor, as mice challenged with the enzyme manifested with disease symptoms such 
as dermonecrosis and swelling, symptoms commonly seen in wound infected 
patients [176, 177]. To further validate the claims that VvpE was a virulence factor, 
research groups synthesised vvpE mutants which were assayed in an iron over-
loaded mouse model of infection, mice were challenged via the subcutaneous route, 
inter-peritoneal route and by force feeding. However, the vvpE mutants did not show 
any signs of attenuation compared to the wild-type strain [178, 179]. This led authors 
to concluded that VvpE may not be as an important virulence factor as once 
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hypothesised [179], or that alternative virulence factor may be able to compensate 
for the loss of VvpE [178].   
Although vvpE mutants do not display attenuation in a mouse model of infection, 
vvpE mutants are attenuated in several invertebrate infection models [17]. For 
example, a vvpE mutant fails to cause melanisation in a Tenebrio moliter infection 
model, and additionally a vvpE mutant is also attenuated compared to the wild-type 
strain in Caenorhabditis elegans and Artemia salina infection models. Demonstrating 
a possible role for VvpE in invertebrate infection [17].   
Even though the involvement of VvpE in mammalian infection is controversial, 
analysis of vvpE mutants in vitro demonstrates that the mutants are attenuated 
compared to the wild-type. For example, a vvpE mutant is unable to swarm in vitro, 
this however can be restored by complementing the vvpE gene. It has also been 
further demonstrated that VvpE is able to degrade immunity proteins such as IgA 
and lactoferrins, suggesting that VvpE may play a role in establishment of infection 
by aiding V. vulnificus in adherence and colonisation, as well as carrying out removal 
of immunity proteins such as IgA [180]. Furthermore, an insertional knock out mutant 
of the vvpE gene causes a loss in elastase ability [175]. However, although a vvpE 
mutant displays a loss in elastase ability, residual protease activity is still detected, 
suggesting the presence of additional proteases. This was recently found to be true 
following the identification of a VvpE-homologue, which has been named VvpM 
[181]. The role of VvpM in V. vulnificus virulence was explored by generation of a 
recombinant form of the protease. The recombinant VvpM protease was shown to be 
virulent towards human tissue culture cell lines by inducing apoptosis of the cells, 
indicating a potential role of VvpM in pathogenesis [181].  
1.8.6 Gram negative secretion systems 
Given that the previous virulence factors described are predominantly extracellular 
toxins, there must be a way by which these bacterial toxins are released from the 
cell. In order to facilitate this interaction with the extracellular milieu many bacterial 
species employ mechanisms known as secretion systems [182]. Secretion systems 
can be used not only for the release of toxins, but also for the release of other 
compounds such as enzymes [183]. Currently there are 6 characterised secretion 
systems in Gram negative bacteria, named accordingly type 1-6 [182, 184]. 
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The six known secretion systems can be further categorised into either a one-step or 
two-step mechanism. Type 1, 3, 4, and 6 are all examples of one-step secretion 
systems, and as the name suggests, proteins are moved from inside the cell to the 
extracellular space by one continuous movement [185]. Unlike one-step secretion 
systems, two-step secretion systems secrete proteins that have first been 
transported from the cytoplasm to the periplasm by either the Sec or twin-argenine 
(Tat) apparatus [184]. Proteins are then moved from their short stay in the periplasm 
into the extracellular milieu, by either the type 2 or type 5 secretion system [183, 
184]. The Sec pathway is generally involved with the emission of both unfolded or 
partially folded proteins [186], while folded proteins are generally ejected via the Tat 
system. The Sec pathway is made up of Sec proteins, known as SecA and SecYEG. 
SecA is an ATPase and provides the energy for the movement of proteins, whereas 
SecYEG makes up the translocon apparatus. Sec proteins are trafficked to the 
periplasm by a N-terminal signal sequence, which is cleaved once proteins arrive in 
the periplasm [92, 183].  Like Sec-dependent proteins, Tat proteins also contain a 
signal sequence, however the sequence varies in length from the Sec signal [183], 
as well as containing a twin-arginine motif [184].  
1.8.6.1 V. vulnificus secretion systems 
Although there are currently six known secretion systems in Gram negative bacteria, 
the most extensively studied secretion system in V. vulnificus is the T2SS. It has 
previously been shown that the EspC protein is integral for connecting the inner and 
outer membrane regions of the T2SS [187, 188]. Furthermore deletion of the espC 
gene leads to a disruption in proteins secreted via the T2SS. For example, deletion 
of the espC gene in V. vulnificus resulted in diminished secretion of T2SS 
substrates, such as the VvhA toxin [189]. Accordingly, the epsC mutant strain was 
also defective in haemolytic ability associated with VvhA. The absences of the VvhA 
protein from the extra cellular milieu of the espC mutant strain was also further 
confirmed by Western blotting using a VvhA antibody which demonstrated that VvhA 
was not detected in the supernatant of the mutant strain, but was present in the 
supernatant of the wild-type strain, further validating the role of the T2SS in secretion 
of VvhA [189]. An in trans complementation of the epsC gene in the mutant was also 
able to restore the secretion of the VvhA toxin 
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In addition to VvhA, the protein VvpE has also been shown to be secreted via the 
T2SS, as deletion of the gene epsC led to a periplasmic accumulation of both VvpE 
and VvhA [189]. The study concluded that the T2SS is involved with the secretion of 
both the haemolysin/cytolysin, VvhA and the metalloprotease VvpE [189]. 
Although V. vulnificus is known to encode a T1SS which is believed to be involved 
with secretion of the well characterised RtxA toxin, the T1SS has not been 
extensively studied in V. vulnificus. However, it has been shown that disruption of the 
T1SS does not affect the secretion of either VvpE or VvhA, further suggesting that 
the secretion of VvpE and VvhA by V. vulnificus is T2SS dependent [189].  
Other than the secretion systems mentioned previously, no other secretion systems 
have been characterised in V. vulnificus. Bioinformatic analysis of V. vulnificus 
genomes has suggested the presence of a T4SS and T3SS due to the identification 
of virB and sopB, genes which are associated with the T4SS and T3SS respectively 
[190, 191]. However, there is a distinct lack of knowledge regarding the secretion 
systems that are functional in the V. vulnificus genome, representing an area which 
is particularly understudied for this pathogen. This thesis aims to contribute towards 
this understudied area with the identification of novel T6SSs, which are discussed in 
more detail in Chapters 4, 5 and 6. A schematic image in Figure 1 represents the 
secretion systems currently identified in V. vulnificus, including the T6SS1 and 
T6SS2 identified in V. vulnificus in the current study, also shown is the currently 
known effectors for the T1SS, T2SS and T6SS1.  
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Figure 1.1: Secretion systems in V. vulnificus. The image shows a schematic representation of a V. vulnificus 
cell. Included on the diagram is the single polar flagellum, the T1SS, which is believed to secrete the RtxA toxin, 
the T2SS which secretes the haemolysin, VvhA and protease VvpE. Additionally shown on the diagram is the 
T6SS1 which contain anti-bacterial properties. The T6SS2 is also shown; however the mode of action of this 
secretion system is currently undetermined. The T3SS and T4SS have not been included, as currently these two 
secretion systems have not been characterised beyond bioinformatic identification of one or two genes.  
1.9 Study objective  
V. vulnificus is a pathogenic bacterium which is known to vary in virulence potential. 
This has led to the hypothesis that not all strains are equal, with some strains better 
adapted to causing human infection than others. A possible reason for this may be 
due to differences in expression of virulence factors, such as those described above. 
Consequently, this study characterised a panel of strains from different isolation 
sources that had varying degrees of virulence by analysing their behaviour in several 
phenotypic assays based around known virulence determinants. The objective of this 
was to determine whether any of these assays could distinguish strains on the basis 
of their virulence potential or source of isolation.  
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Chapter 2 Phenotypic characterisation of V. 
vulnificus isolates 
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2.1 Introduction and aim 
 
The previous chapter introduced the diverse nature of V. vulnificus isolates in terms 
of virulence potential and genotype [19]. This observation of diversity between 
strains has led to the hypothesis that not all strains of V. vulnificus are equal in 
pathogenicity, with some strains better adapted to causing human infection than 
others [114]. This may be due to differences in expression of virulence factors. 
Therefore the aim of the current study was to determine whether such differences 
could be characterised through phenotypic assays. The phenotypic assays 
investigated the following known virulence factors, presence of capsule, protease 
production, motility and cytotoxicity towards the intestinal barrier model, CaCo-2 
cells. In addition, another aim was to identify whether any phenotypic assay findings 
could demonstrate correlation with, 1), the published in vivo mouse data on virulence 
groupings of these isolates, or 2), source of isolation.  
The graph in Figure 2.1 shows the virulence grouping of ten strains selected for 
study in this thesis as well as the three reference strains, YJ016, MO6-24/O and 
CMCP6 [13]. The data shown in Figure 2.1 is extracted from a study which 
investigated the virulence of 69 strains in an iron overloaded mouse model. 
Virulence was assessed by characterising the infected mice from the following 
measurements, cfu/g of bacteria in the skin, cfu/g of bacteria in the liver and a 
decrease in body temperature (<33oC was presumptive of death) [13]. Using these 
indicators of virulence, strains were grouped from one to five, whereby group one 
was the least virulent and group five the most virulent. The virulence groups 
contained the following characteristics; group 1 very low levels of skin infection with 
almost undetectable liver infection; group 2 low levels of skin infection with 
undetectable to low levels of liver infection; group 3 high levels of skin infection with 
undetectable to low levels of liver infection; group 4 high levels of skin infection with 
moderate to high levels of liver infection; group 5 very high skin infection and very 
high liver infection.  
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Figure 2.1: Virulence groupings of V. vulnificus isolates. Data shown is adapted from Thiaville et al., (2011) 
for the 10 V. vulnificus isolates used in the current study, including the three reference strains, YJ016, CMCP6 
and MO6-24/O. Strains were assigned into virulence groupings from one to five depending on the severity of 
disease symptoms and bacterial load in the skin, liver and spleen.  
Therefore, using the data in Figure 2.1, this study aimed to address whether any of 
the phenotypic assays performed on the ten strains, were able to predict virulence 
(as determined from the data in Figure 2.1) or source of isolation of a strain.  
2.2 Results  
2.2.1 Confirmation of V. vulnificus strains 
Prior to commencing phenotypic characterisation assays the panel of V. vulnificus 
strains were streaked onto Vibrio TCBS selective agar to ensure all strains were V. 
vulnificus. The majority of the strains produced characteristic green colonies. One 
strain however, 99-743, consistently produced yellow colonies. This is not 
uncommon as it is documented in the literature that a sub-group, ~3-15% of V. 
vulnificus strains are able to ferment sucrose and therefore appear yellow on TCBS 
agar [74]. To further confirm the provenance of the strains as V. vulnificus, a PCR 
was carried out to identify the presence of vvhA, a V. vulnificus specific gene which 
encodes the haemolysin/cytolysin [74]. Figure 2.2 demonstrates that all of the strains 
are positive for the vvhA gene as they produced the expected 520bp PCR product. 
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Figure 2.2: PCR confirmation of vvhA positive V. vulnificus isolates. Gel electrophoresis image of a PCR 
carried out on genomic DNA from the ten V. vulnificus strains using primers vvhA_F and vvhA_R, to amplify the 
vvhA gene, a  marker used to the current study demonstrating that all strains are V. vulnificus. The marker 
indicated with “M” represents a 1kb plus ladder for sizing of DNA fragments. Lanes 1-10 is a 5µl sample of the 
vvhA PCR run for each of the tested strains, lane 11 is a negative control.  
2.2.2 Growth characteristics of clinical and environmental V. vulnificus isolates  
The first phenotypic test analysed the growth of each V. vulnificus strain by the 
construction of growth curves, as it was hypothesised that the ability of some V. 
vulnificus strains to cause a rapid and fulminating disease may be linked to 
differences in growth. The current study hypothesised that the hyper virulent strains 
may grow faster than the lesser virulent strains. Additionally growth curves were also 
determined for each strain to aid in latter characterisation assays, where knowing the 
average cfu/mL and corresponding OD reading would be required. Figure 2.3(A) 
shows the growth curves for each strain. Overnight cultures were re-adjusted to an 
OD590nm of 0.03 and readings were taken every two hours at T0, T2, T4 and T6. 
Figure 2.3(B) demonstrates the cfu/mL viable counts for the corresponding OD 
readings at T2, T4 and T6. Viable cell counts were determined by carrying out a 
Miles and Misra serial dilution. 
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Figure 2.3: Growth characteristic of clinical and environmental V. vulnificus isolates. (A) OD590nm readings 
for V. vulnificus growth curves at two hourly intervals, T0, T2, T4, T6 and T8. (B) OD590nm corresponding Miles 
and Misra serial dilutions, cfu/mL. Clinical isolates are shown in red and environmental isolates are shown in 
green. The absorbency reading graph shown in (A) was repeated 3 times, the recorded cfu/mL was performed 
three times in triplicate. Error bars on the graph represent standard error of the mean. Growth curves were 
performed at 37
o
C in 2% LB media.       
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Figure 2.4: Scatter plot of V. vulnificus doubling time versus virulence groupings of the strains. The 
doubling time of the V. vulnificus strains were calculated and plotted against each strain’s corresponding 
virulence grouping. Green represents environmental isolates and clinical isolates are shown in red. Each point is 
labelled with the strains name. The data point for strain DAL-79087 which is a clinical strain is located behind the 
data point for 99-743.  The R-value for the scatter graph is, 0.1832 when analysed using a Pearson correlation.  
The results of a two-way ANOVA followed by a post-hoc Tukey test for the growth 
OD graph shown in Figure 2.3A is shown in Appendix A1. These statistical tests 
showed that at T0 and T2 there is no statistical significance between the mean 
values between the strains. This is an expected result as when observing the optical 
density graph, there is little difference between the strains at time T0 and T2. 
However, when analysing the later time points, T4 and T6, when the majority of 
strains are in the exponential phase, there are differences seen between the strains. 
The significant differences between several of the strains at T4 and T6 are 
highlighted in yellow, in Appendix A1.  
When comparing the strains which have a statistically significant greater mean OD 
reading at T4, there is no obvious pattern emerging where clinical strains have a 
higher OD reading than the environmental strains. For example, DAL-79087 and 
ATL-9824, which are clinical strains, have a higher OD reading than S3-16 which is 
an environmental strain. Furthermore, the clinical strains, DAL-79040, DAL-79087 
and ATL-9824, have a greater OD reading than the environmental strain, 106-2A. 
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Additionally, DAL-79087 and ATL-9824 have a significantly different OD reading to 
S3-16. However, other than these differences, there are no other significant 
differences between the clinical and environmental strains at T4. Demonstrating that 
not all clinical strains have a higher OD reading than environmental strains. When 
comparing the OD readings at T6, although there are more significant differences 
between the strains than at T4, similar results are obtained, in that not all clinical 
strains produce a significantly greater OD reading compared to environmental 
strains.  
When the growth data is compared to the in vivo virulence data for the strains, there 
is no obvious correlation of hyper virulent strains producing a statistically significant 
higher OD reading compared to the lesser virulent strains, this is true for both T4 and 
T6. For example, strain ORL-1506 is a hyper virulent strain, and this strain does not 
produce a significantly greater OD reading at either T4 or T6 than the least virulent 
strain, S3-16. Furthermore as shown in Figure 2.4 when the doubling time of each 
stain is plotted against the virulence data for the strains, the data shows there is a 
very weak positive correlation, with an R-value equal to 0.1832 when analysed using 
a Pearson correlation. This data therefore demonstrates that strains producing a 
higher OD reading are not necessarily more virulent than those producing a lower 
OD reading and source of isolation does not affect OD readings. 
2.2.3 Imaging of capsule on clinical and environmental V. vulnificus isolates  
The presence of a capsule has been shown to correlate with virulence for V. 
vulnificus strains and through the use of mutagenesis studies the capsule has been 
identified as a major virulence factor for this pathogen [121, 124]. Although the 
capsule has been shown to be a virulence factor for this pathogen [120-122, 192], 
the capsule is not a marker for V. vulnificus strains that are hazardous to human 
health. This has been demonstrated in the published in vivo mouse virulence data 
available for V. vulnificus isolates, which shows that both hyper and lesser virulent 
strains both contain a capsule [13].  
Previous capsule studies have shown that there is a difference in capsule production 
between strains. For instance, there have been reports of  some strains possessing 
a capsule, where as other strains do not [120, 121, 124]. This difference in capsular 
phenotype has been attributed to deletions in genes involved in capsule production 
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[123]. Therefore the aim of the capsule phenotypic study was to assess if all the V. 
vulnificus strains used in the current study, possessed a capsule.  
 
Two methods were used to identify the presence or absence of capsule in the 
current study; they were as follows, colony morphology on 2% NaCl LB-agar streak 
plates and India ink staining. Colony morphology was used to assess capsule 
production as it is reported in the literature to be an indicator of encapsulated and 
non-encapsulated strains, with the former being opaque and the latter translucent 
[120, 122-125, 193-195]. An additional India ink staining method was also used to 
assess capsule presence on each strain, as it allows capsule to be imaged using a 
light microscope.  
Streak plates were performed routinely prior to making overnight cultures and the 
colony morphologies displayed for each strain was opaque, suggesting that all the 
strains tested were encapsulated. None of the strains displayed the non-
encapsulated, translucent phenotype. Figure 2.5 demonstrates representative 
images of the opaque colony morphology displayed for the ten V. vulnificus strains 
used in the current study.  
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Figure 2.5: Capsule colony morphology of V. vulnificus strain on 2% NaCl LB agar plates. (A) Strain S2-22 
translucent and opaque colony morphology (colony PCR ensured translucent colonies were V. vulnificus). (B) 
The white arrows indicate translucent colonies. The translucent S2-22 colony variant identified in (A) was re-
streaked on to 2% NaCl LB agar alongside the encapsulated version of S2-22, which clearly shows the difference 
in encapsulated and non-encapsulated colony morphology. (C) Demonstrates streak plates of the ten V. 
vulnificus strains streaked onto 2% NaCl LB agar from freezer stocks. All 10 strains produced the encapsulated 
phenotype shown (A) ORL-1506, (B) S2-22, (C) DAL-79040, (D) S3-16, (E) 106-2A (F) 99-743, (G) ATL-9824, 
(H) 99-796, (I) DAL-79087, (J) NSV-5830.  
The colonies produced at 37oC on 2% NaCl LB-agar, were highly reminiscent of the 
encapsulated strain images reported in the literature [124]. Both the clinical and 
environmental strains produced similar colonies that were circular in shape, raised 
and with a dense shiny surface that was opaque. There was no difference seen in 
the colony morphology for either the clinical or environmental strains. The image in 
Figure 2.5 also contains a V. vulnificus strain that is translucent. This strain serves 
as a translucent control to compare to the opaque strains. The translucent strain is 
V. vulnificus S2-22 and was generated following passage through the infection 
model, Galleria mellonella. The translucent S2-22 colony which was produced 
following passage through G. mellonella was picked and re-streaked as shown in 
Figure 2.5A. The images in Figure 2.5A demonstrate the difference in colony 
morphology between translucent and opaque colony variants. Following on from 
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colony morphology on 2% NaCl LB-agar plates, India ink staining and imaging by 
microscopy of mid-log culture cells was performed. 
India ink is a qualitative, negative staining procedure used for imaging bacterial 
capsule. The presence of a capsule is indicated by a white halo surrounding cells 
when they are imaged under a light microscope. The white halo produced around the 
cells is due to India ink being unable to penetrate the capsule or cell body and 
therefore provides a dark, negative background when imaging cells using a light 
microscope. Therefore, to further validate the results seen in Figure 2.5, India ink 
staining was performed on all of the strains. Figure 2.6 A-J shows the results gained 
when V. vulnificus strains are grown to mid-log phase, in 2% NaCl LB broth at 37oC 
and stained with India ink. All of the strains analysed, both environmental and clinical 
contain a capsule, as all strains contain a white halo around the body of the cells. 
None of the strains appear without a capsule and the images shown are 
representative of a number of cells analysed.  
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Figure 2.6: Capsule imaging using India ink staining of V. vulnificus isolates from clinical and 
environmental origin. Images A-J are representative images, the yellow arrow on image (A) indicates the 
capsule and red arrow cell body. (A) V. vulnificus 106-2A environmental isolate (B) V. vulnificus 99-743 
environmental isolate, (C) V. vulnificus 99-796 environmental isolate, (D) V. vulnificus S3-16 environmental 
isolate, (E) V. vulnificus S2-22 environmental isolate, (F) V. vulnificus ATL-9824 clinical isolate, (G) V. vulnificus 
NSV-5830 clinical isolate, (H) V. vulnificus ORL-1506 clinical isolate, (I) V. vulnificus DAL-79040 clinical isolate, 
(J) V. vulnificus DAL-79087 clinical isolate.  
2.2.4 Protease production by clinical and environmental V. vulnificus isolates 
It has previously been shown that injection of purified VvpE from V. vulnificus into 
mice causes the following manifestations, edema, haemorrhagic damage, 
dermonecrosis, and an increase in vascular permeability. All of which are disease 
symptoms often associated with V. vulnificus infection. [176, 196-198]. However, the 
exact role of VvpE in V. vulnificus infection is still unclear as although injection of 
purified VvpE into mice causes disease symptoms commonly associated with V. 
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vulnificus infection, mutagenesis studies have shown that a vvpE deletion mutant is 
not attenuated compared to the wild-type strain [178].   
To test the total extracellular protease production of the ten V. vulnificus isolates in 
the current study, a protease assay using azocasein was used. This assay is a 
quantitative assay which measures a change in absorption using a 
spectrophotometer. In the assay, azocasein acts as a non-specific substrate for 
proteases, resulting in hydrolysis and release of the azo dye, causing a colour 
change that can be quantitatively measured. Figure 2.7 demonstrates the results 
gained for the azocasein protease assay. To allow for normalisation of growth in the 
assay, the corresponding growth OD was also calculated for each strain at each time 
point. For each sample a negative/background control was also performed, this 
comprised of media being added in place of the bacterial suspension. To normalise 
for growth and to remove the negative/background the following calculation was 
performed, (protease OD - negative)/growth OD.  
 
 
 
 
 
39 
 
 
 
Figure 2.7: Total extracellular protease production from clinical and environmental V. vulnificus isolates. 
(A) Protease production for ten V. vulnificus strains using a qualitative azocasein assay. Results show total 
protease production assayed at the time points, T0, T4, T8 T24 and T30 which have been normalised for growth 
and negative background removed. Clinical isolates are shown in red and environmental isolates are shown in 
green. Experiments were performed three times in triplicate. Error bars represent standard error of the mean. (B) 
Data extracted from graph (A) at T24, which corresponds to maximal protease production for all the strains. 
Clinical strains are shown in red and environmental strains shown in green. Error bars represent standard error of 
the mean.   
40 
 
 
Figure 2.8: Scatter graph of total protease production for V. vulnificus strains versus virulence grouping: 
The graph shows total protease production at T30 for each V. vulnificus strain plotted against each strain’s 
corresponding virulence grouping. The R-value calculated following a Pearson correlation is equal to -0.2475. 
Environmental strains are shown in green and clinical strains shown in red.  
Although cells were washed three times at the beginning of the assay, the results 
show there is some residual protease activity still detected for the strains at T0. 
However, by the time the cells have reached T4 this has levelled off for all the 
strains. At T8, the cells begin to show a difference in protease activity, with the 
greatest difference seen between the strains at T24 and T30. Figure 2.6B represents 
data extracted from Figure 2.7A for the T24 hour time point. This time point was 
chosen as it shows maximal protease production for most of the strains.  
The data in Figure 2.7B shows that there is no clear grouping of either clinical or 
environmental strains, which are shown in red and green respectively. Additionally, 
when this data is compared to the in vivo mouse data there is no clear clustering of 
hyper and lesser virulent strains. Statistical analysis using a one-way ANOVA 
followed by a post-hoc Tukey test on the results shown in Figure 2.7B showed that 
the strain ORL-1506, which is a group 5 hyper virulent strain, produces statistically 
significantly less protease than S2-22, which is a virulence group three strain, but 
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significantly more protease compared to the strains, 106-2A, 99-743, S3-16, NSV-
5830, DAL-79087 and 99-796, where P <0.05. The strains 106-2A, 99-743, S3-16, 
NSV-5830, DAL-79087 and 99-796 are grouped as virulence groups three, three, 
one, five, three and four respectively according to the published in vivo mouse 
virulence data, demonstrating that although ORL-1506 is a virulence group five 
strain, which produces statistically significantly more protease than some virulence 
group one, three and five strains, it doesn’t produce statistically significantly more 
protease than some other lesser virulent strains, as shown with the example, S2-22 
(P<0.05). Additionally it cannot be said that lesser virulent strains produce more 
protease, as the least virulent group one strain, S3-16, produces significantly less 
protease than ORL-1506 (P<0.05). Furthermore, the strain 99-796, which is a hyper 
virulent group four strain, produces significantly less protease compared to all of the 
strains tested, further indicating that hyper virulent strains do not always produce 
more protease than lesser virulent strains. In addition to presenting the total protease 
production, the graph shown in Figure 2.8 demonstrates that there is a very weak 
correlation of total protease production for the V. vulnificus strains when plotted 
against each strain’s corresponding virulence grouping. A Pearson correlation 
performed on the graph in Figure 2.8 produces an R-value of -0.2475, further 
demonstrating that there is no significant correlation between a strain’s virulence 
grouping and total protease production. 
This data therefore suggests that protease production is not a clear indicator of 
hyper or lesser virulent V. vulnificus strains, and additionally protease production is 
not a clear indicator of source of isolation. This therefore suggests that there are 
other factors other than protease which are causing the difference in virulence 
between V. vulnificus strains. 
2.2.5 Comparison of motility between clinical and environmental V. vulnificus 
isolates 
Motility is an important virulence factor for V. vulnificus, as the bacterium must be 
able to move from the initial site of infection in order to cause the fulminating 
systemic disease symptoms often associated with this pathogen [13]. The motility of 
this bacterium is documented as being attributed to a single polar flagellum that 
allows the organism to be highly motile [141, 199, 200].  
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To assess the motility of the ten V. vulnificus isolates in the current study a motility 
assay which looked at the swimming ability of each organism was performed. 2 µl of 
mid-log phase cultures were inoculated into the centre of 0.3% motility agar plates 
and incubated statically for 24 hours at 37oC. The motility assay was performed 
three times in triplicate, to reduce error between replicates and ensure the protocol 
was standardised, For each assay motility agar was melted, cooled to ~50oC and 25 
mL poured into each agar plate and allowed to dry in a laminar flow hood for 40 
minutes prior to inoculation. Following 24 hour incubation of the inoculated plates, 
the diameter of the colony for each strain was measured and recorded. Figure 2.9 
represents the data gained from the motility assay.  
 
 
Figure 2.9: Motility of V. vulnificus clinical and environmental isolates. Swimming ability of ten V. vulnificus 
cells assayed using motility agar following 24 hour incubation at 37
o
C. Error bars represent standard error of the 
mean, experiments were performed at least three times in triplicate for each strain.  
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Figure 2.10: Motility of V. vulnificus isolates plotted against virulence groupings. The scatter graph shows 
the motility of clinical and environmental V. vulnificus strains plotted against each strain’s corresponding virulence 
grouping. Clinical strains are shown in red and environmental strains shown in green. A Pearson analysis of the 
correlation between the two groups gives an R-value equal to 0.1547.  
 
On initial inspection of the graph in Figure 2.9 it would appear that the clinical 
isolates are almost uniform in their motility ability. The environmental strains appear 
to have more variation between each other, with V. vulnificus 106-2A being as motile 
as the clinical strains, whereas V. vulnificus S2-22 is a lot more reduced in its 
motility. The general trend from the graph is that clinical isolates are more motile 
than the environmental isolates. However, there is one anomaly which is the 
environmental strain, 106-2A which is  most motile of all the environmental isolates, 
and appears to be as motile as the clinical isolates. When applying a one-way 
ANOVA followed a post hoc Tukey test to compare each strain against each other, 
the results indicate that the clinical strains are not significantly more motile than the 
environmental strains. The only significant difference between the strains is that 
ORL-1506, NSV-5830, ATL-9824, DAL-79087 and 106-2A are significantly more 
motile than S2-22, (P < 0.05).  
The data does however demonstrate that all of the V. vulnificus strains are motile. In 
comparison to the mouse virulence data the results shows that hyper virulent strains 
are not necessarily more motile than lesser virulent strains, as hyper virulent strains 
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are not always significantly more motile than the lesser virulent strains. For example, 
there is no significant difference between the hyper virulent strain, ORL-1506 and the 
least virulent strain, S3-16. Furthermore the scatter graph shown in Figure 2.10 
demonstrates that there is a very weak positive correlation between motility and 
strain’s virulence grouping, which when analysed using a Pearson correlation gives 
an R-value equal to 0.1547. This data would therefore suggest that there are other 
virulence factors, other than motility that play a role in infection.  
2.2.6 LDH release from CaCo-2 cells infected with clinical and environmental V. 
vulnificus isolates 
The aim of the cytotoxicity assay was to determine if clinical isolates were more 
cytotoxic than environmental isolates. The results would be used to see if there was 
a correlation between the LDH cytotoxicity assay and the in vivo mouse data on 
virulence. The hypothesis being that hyper virulent strains, would be more cytotoxic 
than the lesser virulent strains.  
V. vulnificus has been reported in a number of literature articles to be cytotoxic 
towards in vitro cell culture lines [10, 155, 162, 199, 201]. The majority of reports use 
the following cell lines when investigating V. vulnificus cytotoxicity; HeLa cells which 
is a cell line that was originally established in 1951 from a cervical tumour biopsy 
[202], Hep-2 cell lines which are often used as a model for a human epithelial cell 
[203] and are thought to be derived from a larynx cancer [203], and finally the CaCo-
2 cell line. The CaCo-2 cell line is often used as a model of the intestinal barrier 
which was originally isolated from a human colon adenocarcinoma [204]. Therefore 
the current study chose to assess cytotoxicity using CaCo-2 cells as they present a 
good model for V. vulnificus gastrointestinal infection. 
Briefly, CaCo-2 Cells were routinely cultured in DMEM supplemented with 10% 
foetal calf serum. The CaCo-2 cells were cultured until 70% confluent, at which point 
cells were passaged into new media or seeded into wells and incubated overnight to 
allow cells to attach. Following overnight incubation, cells were infected with V. 
vulnificus cells at a MOI of 100 for six hours, as preliminary data indicated that a six 
hours infection period showed the greatest difference in LDH release between 
strains. 
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An initial experiment, shown in Figure 2.11A, comparing the clinical isolate, ORL-
1506 and environmental isolate, S2-22, showed that the clinical strain was 
significantly more cytotoxic towards CaCo-2 cells than the environmental isolate, P < 
0.0001, when analysed using an unpaired two-tailed student’s t-test. The results 
from this initial experiment demonstrated that a hyper virulent clinical isolate (as 
denoted from the mouse virulence data), is more cytotoxicity that a lesser virulent 
environmental isolate. 
 
Figure 2.11: LDH cytotoxicity assay on V. vulnificus clinical and environmental isolates following 
incubation with CaCo-2 cells. LDH release from CaCo-2 cells infected with the hyper virulent clinical isolate, 
ORL-1506 shown in red and the lesser virulent environmental isolate, S2-22 at MOI of 100 for six hours. 
Experiments were performed three times in triplicate; error bars represent standard error of the meant. Statistical 
analysis performed using a two-tailed unpaired student’s t-test, *** P < 0.0001. (B) LDH release from CaCo-2 
cells infected with a panel of V. vulnificus isolates from clinical and environment isolation, shown in red and green 
respectively. CaCo-2 cells were infected with a MOI of 100 for six hours at 37
o
C. Experiments were repeated in 
at least three times in triplicate and statistical analysis performed using a one-way ANOVA followed by a post hoc 
Tukey test.  
However, when analysing a larger panel of V. vulnificus strains, as shown in Figure 
2.11B, the results do not follow the initial trend seen in Figure 2.8A. For example, 
although the 3 clinical strains, ORL-1506, ATL-9824 and DAL-79087 all cluster 
together as strains that are more cytotoxic towards the CaCo-2 cells, an additional 2 
clinical strains, DAL-79040 and NSV-5830 appear less cytotoxic than the 
environmental strains, 99-743, 99-796 and 106-2A. When compared using a 1-way 
ANOVA followed by a post-hoc Tukey test, environmental strains, 99-743 and 99-
796 are significantly more cytotoxic than the clinical strains, DAL-79040 and NSV-
5830. This data demonstrates that clinical strains are not necessarily more cytotoxic 
than environmental strains, as the assay shows that environmental strains can also 
be significantly more cytotoxic than clinical strains.   
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When comparing the LDH assay data to the in vivo mouse virulence data, there is no 
correlation between the two studies. For example, although strain ORL-1506 is 
highly cytotoxic in the LDH assay, and was grouped as a virulence group five in the 
mouse study data, when comparing ORL-1506 to NSV-5830, also a virulence group 
five strain NSV-5830 appears significantly less cytotoxic than ORL-1506 in the LDH 
assay, P < 0.0001, (analysis based on an unpaired two-tailed student’s t-test).  
Additionally NSV-5830, produces low levels of cytotoxicity when compared with the 
all of the strains tested. Only strain S2-22 produced levels of LDH release lower, but 
these were not significantly different to strain NSV-5830. In the mouse virulence 
study, strain S2-22 is grouped as a virulence group three strain and NSV-5830 is 
grouped as a hyper virulent group five strain. Therefore, as S2-22 is not significantly 
less cytotoxic than NSV-5830, the results would suggest that the LDH assay is not 
an assay that can be reliably used to predict virulence. Additionally DAL-79087 also 
a virulence group three strain, produces significantly more LDH release than NSV-
5830, P < 0.0001 when compared using an unpaired two-tailed student’s t-test. 
Furthermore as shown in Figure 2.12, when the LDH absorbancy readings for each 
stain is plotted against each strain’s representative virulence group, the data shows 
there is no strong correlation between LDH release and virulence grouping of a 
strain. When using a Pearson correlation is applied to the data in Figure 2.12, the 
data demonstrates a very weak correlation with an R-value equal to 0.2454.  
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Figure 2.12: LDH release plotted against virulence grouping of each V. vulnificus strain. The scatter graph 
shows LDH absorbance plotted against each strain’s corresponding virulence grouping. Environmental strains 
are shown in green and clinical strains shown in red. A Pearson correlation gives an R-value of 0.2454. 
Therefore the data in Figure 2.11B suggests that although preliminary data (Figure 
2.11A) identified a clinical strain that was more cytotoxic than an environmental 
strain, when looking at a larger panel of strains, the trend does not hold true. 
Furthermore, the cytotoxicity assay is not able to mirror the mouse virulence data in 
terms of grouping hyper and lesser virulent strains; as the hyper virulent group five 
strains do not always produce significantly more LDH release from CaCo-2 cells.   
2.3 Discussion 
The initial aim of these phenotypic assays was to better understand the panel of ten 
V. vulnificus strains in terms of virulence. This was achieved by performing several 
phenotypic assays focusing on virulence factors that had previously been identified 
in V. vulnificus. The phenotypic assays employed assessed the growth 
characteristics, capsule, protease production, motility and cytotoxicity of each strain. 
Initially, the phenotypic data was used to determine whether source of isolation could 
predict the virulence potential of a strain. As it was hypothesised that clinical isolates 
maybe more virulent than the environmental isolates, as clinical isolates have 
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previously been passaged through a human host and therefore may be preselected 
as being more virulent. Analysis of the phenotypic data however indicated that 
source of isolation does not equate to virulence potential of a strain. This is in 
agreement with published data which reported that source of isolation is not an 
indicator of virulence for V. vulnificus strains [13]. Comparison of the phenotypic 
assay results with the published in vivo mouse virulence data demonstrated that 
none of the phenotypic assays were able to accurately mirror the results seen in the 
mouse virulence data. For example, hyper virulent strains in the mouse model did 
not necessarily equate to being more cytotoxic in an in vitro tissue culture model.     
The current study investigated growth characteristics of V. vulnificus strains as it was 
also hypothesised, that the ability of V. vulnificus to cause a rapid and fulminating 
disease, may be due to difference in growth characteristics between strains. The 
growth data however disproved this hypothesis. For example, comparison of the 
strains source of isolation with growth ODs, demonstrated that not all of the clinical 
strains produced a higher OD reading compared to the environmental strains and 
vice versa. Furthermore, when the growth curve data is compared with the in vivo 
mouse virulence data, it appears that growth characteristics do not necessarily 
equate with V. vulnificus’s virulence potential. For example, the strain ORL-1506 
which is a hyper virulent group five strain does not produce a significantly greater OD 
reading than S3-16, which is a lesser virulent group one strain. Therefore it can be 
concluded for this data that growth characteristics are unable to predict the virulence 
potential of a strain.  
Following on from growth characteristics, the study investigated the presence of the 
capsule on the ten V. vulnificus strains. This was carried out as capsule has been 
shown to be an important virulence factor for pathogenic bacteria, including V. 
vulnificus [120-123, 192]. A classic example of capsule as an essential virulence 
determinant is in Burkholderia mallei [205] and Streptococcus pneumoniae, with the 
latter expressing phase variable capsule production which produces two differing 
colony morphologies [206]. Similarly it has been reported in the literature that V. 
vulnificus strains are able to produce two types of colony morphology, opaque and 
translucent which corresponds to encapsulated and non-encapsulated strains 
respectively [120, 121, 207]. The bacterium is also reported to produce an 
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intermediate colony morphology which is strains expressing capsule, although at 
lower levels than opaque strains [123, 193].  
To determine if the V. vulnificus strains in the current study were encapsulated or 
non-encapsulated, two methods were employed. The first was by colony morphology 
and the second method was through the use of India ink staining to image the 
capsule by using light microscopy. The results from both sets of data indicated that 
the ten strains of V. vulnificus in the current study are all encapsulated.  
A possible explanation for the V. vulnificus strains in the current study not producing 
a mixture of opaque and translucent colonies as reported for other V. vulnificus 
strains in the literature [123, 193, 195] could be that the original colonies received by 
our laboratory were encapsulated and therefore preselected for capsule production.  
An alternative explanation may be due to the difference in methods used between 
laboratories, in particular the culture conditions used. In one study that identified 
three differing V. vulnificus colony morphologies, encapsulated, non-encapsulated 
and intermediate, cells were routinely cultured in HI-broth at 22oC [123]. Additionally, 
another study often cultured cells at temperatures lower than 37oC [195], or involved 
temperature shifts to induce the differing colony morphologies [194]. However, the 
culture conditions used in the current study, were LB broth supplemented with 2% 
NaCl, or LB-agar supplemented with 2% NaCl, and incubated at 37oC overnight. 
Therefore the culture conditions used is the current study maybe more supportive of 
the encapsulated phenotype rather than the non-encapsulated phenotype, which is 
more apparent at lower temperatures.  
The results also showed there was no difference seen between the clinical and 
environmental strains, in terms of presence or absence of capsule, as all strains from 
both isolation source produced capsule. This is similar to other observations seen in 
the literature where capsule production is observed for both clinical and 
environmental isolates [21, 124].  When the capsule data from this study is 
compared to the virulence grouping of V. vulnificus in the iron-dextran treated mouse 
model [13], it shows that both hyper virulent strains and lesser virulent strains 
contain a capsule. This data would therefore suggest that there are other virulence 
factors causing the difference in virulence potential seen between V. vulnificus 
isolates, and virulence potential is not attributed to capsule alone.  
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As neither capsule nor growth characteristics were able to identify strains based on 
virulence potential or source of isolation, the study investigated whether protease 
production was able to distinguish strains according to virulence potential or source 
of isolation. As previous research in P. aeruginosa has demonstrated that strains 
unable to produce protease are generally less virulent [208]. Furthermore, it has 
been shown that both Bacillus anthracis [209] and Clostridium botulinium produce 
pathogenic proteases during human infection [210]. The results from this study 
however, demonstrated that protease production by V. vulnificus is not a marker for 
virulence potential or source of isolation of a strain; as although all of the ten strains 
were able to produce protease, there was no clear trend between clinical and 
environmental strains or hyper and lesser virulent strains. This conclusion is 
unsurprising as the role of protease during V. vulnificus infection has not been 
completely elucidated. For example, it was initially reported that the protease, VvpE 
produced by V. vulnificus was a virulence factor, as when the purified protease was 
injected into mice, it caused the disease symptoms associated with V. vulnificus 
infection [176, 198]. However, several years later it was shown that a vvpE mutant 
was not attenuated in vivo [178]. Whether there are other virulence factors that are 
able to compensate for the loss of VvpE, allowing the bacterium to cause disease 
symptoms associated with V. vulnificus remains to be identified, as does the exact 
role of VvpE in V. vulnificus pathogenicity. Therefore, the finding that total protease 
production is unable to predict virulence or source of isolation of a strain in 
unsurprising.  
V. vulnificus motility was also assayed as it was hypothesised that the pathogen’s 
ability to cause a systemic disease may be due to motility, with hyper virulent or 
clinical strains being more motile than the lesser virulent environmental isolates. 
Furthermore, early V. cholerae studies demonstrated that non-motile V. cholerae 
strains were defective in intestinal colonisation compared to motile strains [211, 212]. 
To test the motility hypothesis, the strains were assayed using 0.3% motility agar. All 
of the ten strains tested were motile and able to swim across the agar plate. This 
was an expected result as V. vulnificus is documented as being a highly motile 
bacterium due to the single polar flagellum [199]. Initial motility results appeared 
promising with a general trend that clinical isolates were more motile than 
environmental isolates. However, when statistical analysis was performed, the 
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results indicated that not all clinical isolates were more motile than environmental 
isolates. Further comparison of the results with the mouse virulence data 
demonstrated that there was no correlation between virulence potential and motility. 
Motility, like capsule, is a virulence factor as demonstrated in mutagenesis studies 
for V. vulnificus [141, 199]. However, it would appear from the results in the current 
study, that motility on its own is not a marker for strains hazardous to human health, 
as both hyper and lesser virulent V. vulnificus strains are motile, with no statistically 
significant pattern between hyper and lesser virulent strains and motility. These 
findings are similar to a study performed on Bacillus cereus, which found that motility 
was not an exclusive marker for distinguishing between virulent and non-virulent 
strains [213]  
The final phenotypic assay to be tested was a cytotoxicity assay using CaCo-2 cells. 
Cytotoxicity was assessed using an LDH assay which measured the amount of LDH 
released from the CaCo-2 cells. The amount of LDH released is quantified using a 
colour change and the LDH released is directly proportional to the number of CaCo-2 
cells lysed. Preliminary data from the LDH cytotoxicity assay suggested that there 
was a correlation between LDH release, and source of isolation, as well as LDH 
release and virulence potential. For example, the clinical hyper virulent strain, ORL-
1506, produced statistically significantly greater LDH release from CaCo-2 cells than 
S2-22, an environmental lesser virulent strain. However, when a more 
comprehensive panel of strains was analysed, the results did not follow the same 
pattern. 
In terms of source of isolation, clinical strains did not consistently produce higher 
absorbancy readings than the environmental strains. This was expected as previous 
in vivo virulence data has shown than source of isolation does not necessarily 
correlate with the virulence potential [13]. Furthermore, when the LDH assay 
absorbency readings were compared with the in vivo mouse virulence data, there 
was no similarity between the virulence study and the current study. For example, 
hyper virulent strains did not consistently produce more LDH release than the lesser 
virulent strains. One drawback of comparing the cytotoxicity study with the in vivo 
mouse data, may be that the CaCo-2 cells are a model for intestinal physiology, 
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whereas the mouse data is based on a wound infection model. This may provide a 
possible explanation as why there is no similarity between the two studies.  
2.4 Conclusion 
Analysis of all the phenotypic assays performed in the current study, demonstrated 
that the testing of just one virulence factor is unable to accurately distinguish 
between hyper and lesser virulent V. vulnificus strains. Furthermore, scatter graphs 
which plotted the phenotypic data against the virulence groupings of each strain and 
were analysed using a Pearson correlation demonstrated that the correlations seen 
between the phenotypic studies and the virulence data available for each strain were 
very weak. Virulence of a strain was determined based on published results from an 
in vivo virulence model [13]. Furthermore, it was also shown that source of isolation 
is not an accurate predictor of a strain’s virulence potential. For example, clinical 
isolates are not necessarily more cytotoxic than environmental isolates.    
Although previous research has identified numerous virulence factors in V. vulnificus, 
currently not one virulence factor is able to accurately distinguish a hyper virulent 
strain from a lesser virulent strain. In addition to this, several research groups have 
compared the genomes of several V. vulnificus strains bioinformatically to identify 
differences in strains and potential virulence markers [214, 215]. Although the 
comparative genomics research has led to lists of comparative virulence genes 
being established, the work has not been followed up with laboratory assays to 
phenotypically characterise the difference between the strains.   
Furthermore, the results from the current study’s phenotypic assays, which assessed 
V. vulnificus strains for known virulence factors; demonstrated that not one virulence 
factor could be used to distinguish hyper virulent strains from lesser virulent strains. 
This demonstrated the need for novel virulence factors to be identified in V. vulnificus 
strains. Therefore the current study postulated that there was a need for a whole 
genome sequencing (WGS) comparison study to identify novel genetic differences 
between hyper and lesser virulent strains, which could ultimately be used to 
distinguish between strains that are hazardous to human health from those that are 
not. The study aimed in particular to identify differences in genetic regions between 
the strains, to try and understand the difference in virulence potential between V. 
vulnificus strains. In order to acknowledge this gap in V. vulnificus knowledge, it 
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seemed plausible to perform WGS analysis on the 10 V. vulnificus strains with the 
aim of identifying novel genetic differences.   
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Chapter 3 Bioinformatic analysis of V. 
vulnificus strains 
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3.1 Introduction and aim 
WGS of a bacterial genome was first carried out in 2005 using Sanger Sequencing 
[216]. Since then the cost of carrying out WGS has decreased significantly, allowing 
many research laboratories to carry out WGS of bacterial strains. The use of WGS 
has led to an eruption in the number of bacterial genomes sequenced, there are 
currently >6,500 bacterial genomes available on Genbank, with several genomes still 
in contig formats [217]. Bacterial WGS data has many uses, which can include, 
mapping of virulence factors, antibiotic resistance surveillance, infection control and 
drug development [218-220]. Illumina, Ion Torrent, Roche 454 and SOLiD, are 
several examples of next-generation sequencing (NGS) instruments that can be 
used to generate WGS data.  
The current study used Illumina sequencing to sequence the genomes of the ten V. 
vulnificus isolates described in chapter two. This was done with the aim of identifying 
genetic differences between the strains, which may account for the difference in 
virulence between the strains.  
3.2 Results 
3.2.1 Preparation and sequencing of genomic DNA (gDNA)   
Illumina sequencing was carried out on the following V. vulnificus strains, ORL-1506, 
99-796, 99-743, DAL-79087 and DAL-79040, by Exeter Sequencing Service, 
University of Exeter, using 250bp paired end reads on the Illumina MiSeq. The 
sequencing data for the remaining five V. vulnificus strains, S2-22, S3-16, 106-2A, 
ATL-9824 and NSV-5830 was supplied by CEFAS.  
Genomic DNA (gDNA) was extracted from V. vulnificus isolates using the Promega 
Wizard® Genomic DNA Purification Kit according to the manufacturer’s instructions. 
In brief two to three colonies of each bacterial strain were picked from an overnight 
streak plate, sub-cultured into 2% NaCl LB broth and incubated overnight at 37oC at 
200rpm. The following morning a 1 mL sample was taken from the overnight culture 
and gDNA extracted. Once the gDNA had been extracted, a 3 µl sample was 
electrophoresed through a 1% agarose gel to check the gDNA quality. Quality was 
checked by ensuring the sample produced a high molecular weight band with no 
fragmentation. The gDNA sample was then sent to Exeter Sequencing Service 
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where the necessary library preparation of the sample was carried out, including 
quantification of DNA using Qubit® Fluorometric Quantitation.  
3.2.2 Assembly of V. vulnificus raw sequencing reads  
The assembly of the raw sequencing data was achieved by using the de novo 
automated assembler, a5 [221]. The a5 pipeline does not require a reference 
genome to assemble sequencing reads, instead overlapping sequencing reads are 
built into contiguous reads (contigs), which are then further assembled into scaffolds 
[221]. The a5 pipeline builds scaffolds using the following five stages, stage one, low 
quality reads and adapter sequences are removed from the data, stage two, contigs 
are built using a de Brujin graph based algorithm, stage three, the contigs are then 
scaffolded and extended, stage four, the unmapped reads are mapped back to the 
assembled scaffolds, the miss-assembled reads are detected and broken, finally 
stage five, broken scaffolds are re-scaffolded. Once the raw sequencing reads had 
been assembled, the assembly was reviewed using the contigstat programme, which 
produces statistical data on raw sequencing read assemblies. The data presented in 
Table 3.1 shows the statistical analysis on the a5 assemblies using the contigstat 
programme, data presented includes data on the number of scaffolds and the length 
of the longest scaffold. Once the WGS data had been assembled, scaffolds were 
then used for downstream analysis such as gene annotation, phylogenetic tree 
construction and genotyping of strains. 
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Table 3.1: Statistics on assembly of raw sequencing reads using a5 pipeline. The table shows the basic 
statistics calculated for the a5 assembly of each bacterial strain. L50 is the length of the smallest scaffold which is 
equal to or greater than the 50% value. The 50% value is calculated by ordering in the scaffolds, in length from 
smallest to largest and the length totalled divided by two.  
Bacterial 
Strain 
Number of 
scaffolds 
Total length 
of scaffolds 
(bps) 
Length of 
longest 
scaffold 
(bps) 
L50 (bps) 
V. vulnificus 
DAL-79040 
46 4,866,902 1,310,740 553,895 
V. vulnificus 
DAL-79087 
99 4,891,124 371, 595 171,786 
V. vulnificus 
99-743 
81 4,874,281 777,312 204,495 
V. vulnificus 
99-796 
124 4,953,985 541,160 162,757 
V. vulnificus 
S3-16 
80 4,982,280 841,250 219,189 
V. vulnificus 
S2-22 
81 4,905,980 810,776 202,306 
V. vulnificus 
NSV-5830 
105 4,888,328 631,804 274,590 
V. vulnificus 
ATL-9824 
77 4,921,179 1,114,370 297,891 
V. vulnificus 
ORL-1506 
74 4,866,455 892,373 829,112 
V. vulnificus 
106-2A 
97 4,971,929 1,090,137 223,665 
V. vulnificus 
106-2A 
∆icmF 
T6SS1 
97 4,956,646 642,096 143,161 
V. vulnificus 
106-2A 
∆icmF 
T6SS2 
52 4,766,254 606,991 280,075 
V. fluvialis 
NCTC 
11327 
53 4,947,586 873,156 378,052 
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3.2.3 Bioinformatic genotyping of V. vulnificus strains 
As mentioned in chapter one, V. vulnificus strains can be sub-categorised based on 
genotype, one such protocol is the vcg  typing method [30]. This method is based on 
the finding that clinical strains contained a region of DNA ~200bp in length, that is 
generally, but not always, absent from environmental isolates [21]. To further 
characterise this ~200bp region, surrounding DNA of approximately 700bp was 
amplified [30]. Following DNA alignment against a reference genome, the authors 
found that this ~700bp region corresponded to the 3’ end of the VV0401 gene, as 
well as downstream non-coding sequence. From this alignment, typing primers P1, 
P2 and P3 were designed to distinguish between C and E genotypes [30]. PCRs 
employing the primers P1 and P3 amplify a region indicative of C-genotypes, 
commonly associated with clinical isolates.  Conversely, primers P2 and P3 amplify a 
region common to most environmental strains, E-genotypes. This specificity is due to 
a difference of sequence at the binding region of P1 and P2, which is shown in 
Figure 3.1.  
  
 
Figure 3.1. Primer binding sites of vcg genotyping primers, P1 and P2. V. vulnificus C and E-genotypes can 
be distinguished using PCR, this method is based on the differences in the primer binding sites of the primers P1 
and P2. The primer binding site of P2 is boxed in green and binds to E-genotype strains, which is distinguishable 
from C-genotype strains that bind primer P1, shown boxed in red. The differences in the DNA base sequence 
between the C and E-genotypes are also highlighted in red, further demonstrating the difference in DNA 
sequence between the C and E-genotypes.  
 
Using this information, the current study used a local BLAST search to identify the 
scaffolds on which the VV0401 gene was located for all of the 10 strains. The 
scaffolds were then used to generate in silico PCRs with the primers P1 and P3, or 
P2 and P3. Figure 3.2 shows the alignment of the primer binding sites for each of the 
strains investigated. In addition, each strain’s information, in terms of isolation 
source, virulence potential and vcg-type is also tabulated in Table 3.2. Out of the ten 
strains analysed, the following three strains were omitted, ORL-1506, NSV-5830 and 
ATL-9824. ORL-1506 and NSV-5830 were omitted as the sequence alignment of 
these strains was too diverse and did not produce accurate alignments, on the other 
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hand, the strain ATL-9824 failed to produce a PCR product due to the inability of the 
P3 primer to bind in silico.  
Figure 3.2 Sequence alignment of the 
vcg primer binding sites. Shown in the 
top half of the image is the sequence 
alignment for the C-genotype strains, 
boxed in red is the P1 primer binding site 
for the reference strain, YJ016. In 
comparison the E-genotype strain, 
JY1306 is also shown, highlighted in red 
are the base pair changes, indicating the 
difference in DNA sequence between 
the E-genotype and C-genotype strains. 
Conversely the E-genotypes are shown 
in the bottom half of the image. Boxed in 
green is the P2 site for the reference 
strain, JY1306. In comparison the 
YJ016, C-genotype reference strain is 
also shown. The red bases indicate the 
difference in base pairs between the C 
and E-genotype strains. In both images 
the universal reverse primer P3 is also 
shown, boxed in blue.  
 
 
Table 3.2: V. vulnificus strain information. The table shows each strain’s isolation source, vcg type and 
virulence grouping according to the published virulence mouse data for each strain. Strains, ORL-1506, NSV-
5830 and ATL-9824 were unable to be typed in silico.   
Strain Isolation source vcg type Virulence group 
ORL-1506 Clinical Unable to type  5 
NSV-5830 Clinical Unable to type 5 
99-796 Environmental  C-type 4 
106-2A Environmental C-type 3 
S2-22 Environmental C-type 3 
99-743 Environmental E-type 3 
DAL-79087 Clinical E-type 3 
DAL-79040 Clinical C-type 2 
ATL-9824 Clinical Unable to type 2 
S3-16 Environmental C-type 1 
 
The binding site of the C-genotype primer, P1 is boxed in red in Figure 3.2. This 
primer bound to the strains S3-16, S2-22, DAL-79040, 106-2A and 99-796, indicating 
that these strains are of C-genotype. Conversely, the E-genotype primer, P2 is 
boxed in green, this primer bound to the strains 99-743 and DAL-79087, identifying 
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these strains as E-genotype. Although the vcg typing method was established to 
distinguish between strains based on isolation source and provide an indicator of 
virulence potential [30], the data presented here demonstrates that this method is 
unable to accurately identify strains based on isolation source or virulence potential. 
For example, as demonstrated in Table 3.2, strain S3-16 is an environmental strain, 
yet this is grouped as a C-genotype, furthermore according to the virulence data [13], 
this strain is a lesser virulent group one strain, demonstrating that the vcg genotyping 
method is unable to accurately predict source of isolation or virulence potential of a 
strain.  
Following on from genotypic characterisation of strains, the bioinformatic data was 
used to construct phylogenetic trees for the ten V. vulnificus strains. This was done 
to identify if phylogenetic analysis could distinguish strains based on isolation source 
or virulence potential.   
3.2.4 Phylogenetic tree construction for V. vulnificus strains from clinical and 
environmental origin 
Phylogenetic trees are often used to study the genetic evolution of organisms. With 
the advent of WGS producing large amounts of data, generating phylogenetic trees 
based on single nucleotide polymorphisms (SNPs) has become increasingly popular 
[222-224]. SNPs are a change in a single nucleotide position in a DNA sequence 
[92] and are often associated with low mutation rates and evolutionary stability, 
making them good candidates for studying the evolution of organisms [224]. Studies 
looking at Escherichia coli outbreaks in Europe and antibiotic resistance in 
Staphylococcus aureus are a couple of examples of where SNP analysis has been 
used for evolutionary analysis [219, 225]. SNP analysis has also recently been used 
to understand the evolution of the V. vulnificus biotype 3 sub-species [226]. 
Therefore the current study aimed at using SNP analysis to construct phylogenetic 
trees of V. vulnificus biotype 1 strains, with the aim of identifying clusters of strains 
based on either virulence or source of isolation. Phylogentic trees were constructed 
based on SNP profiles, using the pipeline, SNPhylo [223].  
In order for the programme SNPhylo to generate phylogenetic trees, the data must 
be inputted into the pipeline in Variant Call Format (VCF). To achieve this the raw 
sequencing reads were first trimmed against the reference genome, YJ016 using 
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“Trim Galore!” listed in the Materials and Methods. Following trimming of adapter 
sequences using Trim Galore! the reads were converted from SAM to BAM and 
finally into vcf format, the data was then uploaded to SNPhylo [223], which 
constructed phylogenetic trees for the ten strains. The assembled trees are shown in 
Figures 3.3, 3.4 and 3.5. The SNP analysis was carried out on data from 
chromosome 1 and 2 separately as well as both chromosomes combined. This was 
done to identify if strains clustered differently depending on the chromosome 
analysed. Figure 3.3 shows the phylogenetic tree constructed when both 
chromosomes are combined, whereas Figure 3.4 and 3.5 show the phylogenetic 
trees constructed when SNPs from either chromosome 1 or chromosome 2 are 
analysed separately. The length of the branches on the trees corresponds to the 
amount of change between strains. For example, the longer the branch the larger the 
amount of difference, the number at the bottom of the figures shows the scale of this 
change. 
 
 
Figure 3.3: Phylogenetic tree constructed from chromosomes one and two for V. vulnificus.  
The phylogenetic tree constructed when analysing SNPs from chromosomes one and two using SNPhylo. Five 
clusters are generated for the ten V. vulnificus strains analysed, the clusters include strains with varying degrees 
of virulence potentials, with clinical and environmental isolates, shown in red and green respectively interspersed 
throughout the clusters. The length of the branches on the trees corresponds to the amount of change, for 
example the longer the bar the larger the amount of difference between the strains.   
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Figure 3.4: Chromosome one constructed phylogenetic tree. SNP analysis of chromosome one for ten V. 
vulnificus strains shows there is no clustering of either clinical or environmental strains, which are shown boxed in 
red and green respectively. The SNP analysis of chromosome one also shows there is no clustering of hyper and 
lesser virulent strains. The scale bar shown at the bottom of the images corresponds to the scale of change, 
which is 0.1.  
 
Figure 3.5: Phylogenetic tree constructed based on SNP analysis for chromosome two. Analysis of SNPs 
in chromosome two for ten V. vulnificus strains using SNPhylo demonstrated that there is no clear clustering of 
either clinical or environmental strains, which are shown in red and green respectively, as both isolates are 
interspersed through the tree demonstrating that there is no clear clustering of either clinical or environmental 
strains. Additionally there is also no clear clustering of either hyper or lesser virulent strains, which are also 
interspersed throughout the tree. Shown at the bottom of the image is the scale bar, which shows the amount of 
change between each strain.  
 
Comparison of the phylogenetic trees presented in Figures 3.3, 3.4 and 3.5 
demonstrates that the SNP analysis produces different results depending on the 
chromosomes being analysed, in addition to the differences there are also 
similarities. For example, all of the phylogenetic trees shown produce five groupings 
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of the strains, however the strains that make up these five groupings differ.  Figure 
3.3, which illustrates the phylogenetic tree produced when both chromosomes are 
analysed, shows that the strains split into the following five groups; strains S2-22, 
ATL-9824 and 106-2A appear as three separate out-groups, whereas DAL-79040, 
99-796 and S3-16 make up group four, with DAL-79087, 99-743, NSV-5830 and 
ORL-1506 making up group five.  Analysis of the phylogenetic tree produced for 
chromosome one in Figure 3.4 suggests that S2-22 is not an out-group as seen in 
Figure 3.3 and instead clusters with the strain, DAL-79040 in a single clade sharing a 
common ancestor, making up group one. However, the strain ATL-9824 consistently 
appears as an out-group, making up group two. Group three is made up of the two 
strains, S3-16 and 99-796. The largest group, group four is made up of 99-743, DAL-
79087, ORL-1506 and NSV-5830. Finally, the strain 106-2A does not appear to 
cluster with any other strains and appears as an outgroup making the final group, 
group five. Finally Figure 3.5 which represents the phylogenetic tree constructed for 
chromosome two, shows the following 5 groups; groups one to four are constructed 
from the following four outgroup strains, S2-22, DAL-79040, 106-2A and ATL-9824, 
the remaining strains make up the final fifth group, 99-743, DAL-79087, ORL-1506, 
NSV-5830, 99-796 and S3-16.  
All three phylogenetic analyses produce similar groupings of strains, except for the 
following strains, S2-22, DAL-79040, S3-16 and 99-796 which are changeable 
depending on the tree that is analysed. The strain S2-22 appears as an outgroup in 
Figures 3.3 and 3.5, however in Figure 3.4, the chromosome one analysis, the 
position of strain S2-22 changes. Instead of appearing as an out-group, it now 
clusters with DAL-79040. A possible explanation for the changeable positon of strain 
S2-22 maybe due to the chromosome two of DAL-79040 and S2-22 being more 
divergent, hence why the two strains cluster separately when chromosome two is 
analysed, but not when chromosome one is analysed. Conversely, S3-16 and 99-
796 appear to have a more divergent chromosome one than the strains NSV-5830, 
ORL-1506, DAL-79087 and 99-743, as when chromosome one, shown in Figure 3.4, 
is analysed, S3-16 and 99-796 cluster in a group of their own, separate from the 
strains, NSV-5830, ORL-1506, DAL-79087 and 99-743. However, when 
chromosome two is analysed S3-16 and 99-796 cluster with the strains NSV-5830, 
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ORL-1506, DAL-79087 and 99-743, suggesting that the strains are similar in regards 
to chromosome two, but more divergent with regards to chromosome one.  
When comparing the phylogenetic results to the strains’ source of isolation, there is 
no clear clustering of either clinical strains or environmental strains. For example the 
clinical isolate, ORL-1506 clusters with environmental isolate, 99-743 in each tree 
analysed. These results are not to dissimilar to the results gained by another 
research group which demonstrated that V. vulnificus strains from both clinical and 
environmental origin were interspersed throughout a constructed phylogenetic tree, 
with no cluster being made up of all clinical or all environmental isolates [55]. 
Comparison of the current study’s phylogenetic tree data with the available in vivo 
virulence data [13], indicates that there is no clear clustering of hyper and lesser 
virulent strains. For example, the virulence group one strain, S3-16 consistently 
groups with 99-796, a virulence group four strain. Additionally DAL-79087 which is a 
virulence group three strain is found in a cluster with NSV-5830 and ORL-1506, 
which are virulence group five strains.  
The results presented here demonstrate that V. vulnificus phylogenetic tree analysis 
does not produce clear groupings of strains based on virulence potential, or source 
of isolation. Therefore the study utilised the WGS data to carry out WGS comparison 
and gene annotation, to identify genetic differences between the strains. This was 
performed with the aim of identifying genetic differences that can discriminate 
between strains of differing virulence potential. 
3.2.5 WGS comparison of V. vulnificus strains  
WGS comparison is the process by which multiple genomes are aligned to a 
reference genome, allowing for differences and similarities between the genomes to 
be observed. WGS comparison is becoming increasingly common in the field of 
microbiology allowing for differences in virulence genes or antibiotic resistance 
markers to be identified between different strains of bacteria. The current study 
therefore employed WGS comparison to identify genetic differences between the ten 
V. vulnificus strains used in the current study. WGS comparison was achieved by 
using the bioinformatic software programmes, MUMmer [227] and Circos [228]. 
MUMmer was used to align the a5 assembled scaffolds against the reference 
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genome YJ016, this alignment was visualised using circos [228], and is shown in 
Figure 3.6.  
 
Figure 3.6: Circos visualisation of assembled scaffolds from V. vulnificus isolates compared to the 
reference strain, YJ016. The blocked regions on the diagram indicated regions of DNA in the assembled 
scaffolds from clinical isolates, shown in red and environmental isolates shown in green that have less than 80% 
sequence identity compared to the reference strain, YJ016. The reference strain YJ016, is shown on the outside 
in black, with the red and blue tracks representing the forward and reverse CDS features respectively. 
Highlighted in blue on the outside is the location of T6SS2 on chromosome two. From the inner circle working out 
the strains are as follows, 99-743, 99-796, S3-16, S2-22, 106-2A, DAL-79087, DAL-79040, ATL-9824, MO6-
24/O, NSV-5830 and ORL-1506 
 
The black outer circle in Figure 3.6 represents the reference strain, YJ016 with the 
CDSs’ on the forward and reverse strands shown in red and blue respectively. The 
blocked sections of red and green in the inner circles signify the ten clinical and 
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environmental strains repetitively, as well as an additional reference strain, MO6-
24/O also shown. These red and green areas indicate regions of DNA in the 
assembled scaffolds that have less than 80% sequence identity compared to the 
reference strain. The data was presented in this way to highlight dissimilarities 
between the ten query sequences compared to YJ016.  
Analysis of Figure 3.6 demonstrates that there are numerous differences in the query 
sequences compared to the reference strain, as highlighted by the blocked regions 
of red and green. On the other hand there are also similarities, as there are regions 
on the diagram that have no blocking of colour, indicating that the regions of DNA 
are >80% similar when compared to the reference strain. In particular there is a 
region of no colour which corresponds to the plasmid region of YJ016, this would 
suggest that the query sequences contain a plasmid. However when this was 
checked by aligning the trimmed sequencing reads from the ten strains against the 
plasmid sequence from YJ016, using Bowtie2. The alignment statistics presented in 
Table 3.3 indicates that there is no alignment between the ten strains and the 
plasmid from YJ016. This is not to say that the ten strains do not contain a plasmid, 
as the laboratory preparation used a gDNA extraction kit, listed in the Materials and 
Methods which is for the extraction of primarily gDNA and not plasmid DNA.   
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Table 3.3: Alignment rate of V. vulnificus strains against the plasmid of YJ016. The table shows the overall 
alignment rate of trimmed raw sequencing reads from the ten V. vulnificus strains against the reference genome, 
YJ016. Bioinformatic alignment was achieved using the software, Bowtie2.   
V. vulnificus strain Overall alignment against the 
plasmid of YJ016 (%) 
ORL-1506 0 
NSV-5830 0 
ATL-9824 0 
DAL-79087 0 
DAL-79040 0 
99-796 0 
99-743 0 
106-2A 0 
S3-16 0 
S2-22 0 
 
Although the WGS comparison presented in Figure 3.6 demonstrates there are 
many differences and similarities between the query strains and the reference strain, 
there is a drawback with this method. The disadvantage of using the WGS 
comparison method presented in Figure 3.6 is that the data will only show what is 
not present in the query data compared to the reference data. Therefore if there are 
additional genes in the query data, these will not be identified, as the unmapped 
scaffolds will not be mapped. Consequently, if a strain such as ORL-1506 contains 
genes that YJ016 does not, these genes would not be identified using the presented 
WGS comparison method and would be grouped into unmapped data. Therefore in 
order to identify genes that maybe encoded on the unmapped data, an assembly of 
the un-aligned scaffolds would also need to be performed, making WGS comparison 
a lengthy task when there are several different query strains being analysed. The 
current study therefore carried out WGS gene annotation of the assembled scaffolds 
to identify differences in genes between the strains. 
3.2.6 Gene annotation of WGS data 
Annotation of WGS data in the current study was achieved by utilising the automated 
server, RAST [229]. RAST works by blasting predictive ORFs against groups of 
proteins known as FIGfams, which are families of homologous proteins that share a 
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common function [230]. Once RAST completes its annotation the data can be 
downloaded in several different formats [229]. The current study chose to extract the 
RAST annotation into Excel and manually scrutinise the spreadsheets. This led to 
the identification of a novel secretion system, known as the type 6 secretion system 
(T6SS), the genomic location of which is shown in Figure 3.6. A literature search on 
secretion systems and V. vulnificus highlighted that the T6SS had not been 
previously described in this organism. Further interrogation into the prevalence of 
this secretion system among the ten strains, identified a difference in the number of 
T6SSs. All of the sequenced strains contained a T6SS, herein referred to as T6SS2 
(annotated in Figure 3.6), whereas three strains, 99-796, S3-16 and 106-2A 
contained an additional T6SS, herein referred to at T6SS1. Further bioinformatic 
analysis of the reference genomes, YJ016, MO6-24/O and CMCP6 demonstrated 
that these strains too contained a T6SS, T6SS2; however they were negative for 
T6SS1.  
The initial aim of this bioinformatic study was to identify differences in genetic 
regions that could account for the varying virulence potentials between V. vulnificus 
strains. However, due to the discovery of the T6SS, the study chose to halt further 
bioinformatic research into investigating genetic differences, and instead focus 
attention on the T6SS. In particular the study was interested in understanding the 
role of the additional T6SS, T6SS1 which was only present in a sub-set of strains 
(99-796, 106-2A and S3-16).  
3.2.7 Bioinformatic analysis of the T6SS gene clusters in sequenced V. 
vulnificus strains 
Originally identified and characterised in V. cholerae, [231] the T6SS has since been 
described in numerous Gram negative proteobacteria, including Pseudomonas 
aeruginosa [232] Burkholderia mallei [233], Serratia marcescens [234] and 
Campylobacter  jejuni [235]. The minimum set of core proteins required to assemble 
a functional T6SS [236] are depicted in Figure 3.7A. Supplementary to these core 
proteins, several bacterial species also contain additional proteins, known as 
accessory proteins, which are shown in Figure 3.7B. Accessory proteins can include 
phosphatases and kinases which are involved in the T6SS regulation [232, 237]. The 
majority of the proteins encoded within the T6SS cluster shown in Figure 3.7 are 
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named according to historical naming nomenclature. However, to avoid confusion, a 
new T6SS terminology has arisen, the type six secretion “Tss” nomenclature. Both 
terminologies are shown in Figure 3.7. However, for the remainder of the study, 
proteins and genes are generally referred to in accordance with the original 
nomenclature, except for recently identified T6SS proteins such as the tssK, which 
do not have a common historical name are referred to in accordance with the Tss 
naming nomenclature. 
 
 
Figure 3.7: The core T6SS proteins and accessory proteins. A) A schematic diagram showing the 13 
conserved proteins required for a functional T6SS as determined by Bingle et al (2008). B) The image shows a 
schematic representation of the accessory proteins often associated with the T6SS in some but not all strains 
harbouring the T6SS(s). Both images have included the COG identity as well as the Tss naming nomenclature 
for the T6SS proteins, additionally the common name is also indicated for genes which have been either 
phenotypically investigated or the name commonly referred to in the literature. Image adapted from Coulthurst SJ 
(2013).  
 
In an attempt to putatively understand the functionality of T6SS1 and T6SS2 in V. 
vulnificus, the secretion systems were examined for the presence of 13 core 
components. Analysis of the gene organisation demonstrated that both secretion 
systems contained the 13 genes required for a functional T6SS, as well as several 
accessory genes. The genetic organisation of T6SS1 is shown in Figure 3.8 and 
shown in 3.9 is the genetic organisation of T6SS2.  
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Figure 3.8: Genetic organisation of V. vulnificus T6SS1. The schematic gene organisation of T6SS1 form V. 
vulnificus 106-2A, S3-16 and 99-796 is shown. For comparison the genetic organisation of T6SS2 from 106-2A is 
also shown. T6SS1 contains all of the genes required for a functional T6SS shown outlined in black as well as 
accessory genes such as fha which are outlined in red. The colour coding of the genes corresponds to the colour 
coding shown in Figure 3.7, the gene organisation shown is taken from the RAST annotation server coupled with 
BLAST searches to identify COG identities.  
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Figure 3.9: The genetic arrangement of V. vulnificus T6SS2. The image shows the genetic organisation of the 
T6SS2 in the ten V. vulnificus strains sequenced as well as the reference strains, YJ016, MO6-24/O and CMCP6. 
T6SS2 contains all of the 13 genes required for a functional T6SS which are outlined in black, as well as several 
accessory proteins outlined in red. The gene organisation shown is taken from the RAST annotation server 
coupled with BLAST searches to identify COG identities.  
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Initial inspection of the V. vulnificus reference genome YJ016, found all of the T6SS2 
genes to be unannotated. Furthermore, the reference strains MO6-24/O and CMCP6 
also contained inaccurate and incomplete annotation, with the majority of the T6SS 
genes annotated as hypothetical or uncharacterised. In order to identify the T6SS2 in 
the reference strains, alignment was performed using the sequence of icmF from 
T6SS2. The DNA sequence surrounding this gene was then searched for ORFs 
using Clone Manager. Each ORF was then subjected to a BLAST search using NCBI 
to annotate these genes which is shown in boxed region in Figure 3.9. The original 
mis-annotation of the reference strains may provide a possible explanation as to why 
this secretion system has not been previously identified in V. vulnificus.  
Comparison of T6SS1 and T6SS2 in V. vulnificus, demonstrates that there are 
several genetic differences. For example, T6SS2 harbours more accessory 
components than T6SS1. Additionally the location of genes such as vipA and vipB 
differ between the two clusters; T6SS1 encodes vipA and vipB genes at the distal 
end of the secretion system locus, whereas T6SS2 harbours vipA and vipB genes in 
the middle of the locus. In addition to the differences, there are also similarities, as 
exemplified by the hcp and vgrG genes, both of which are located next to each other 
and at the distal end of the T6SS clusters. The gene organisation of T6SS1 from V. 
vulnificus also shares synteny with the T6SS of V. cholerae, as shown in Figure 
3.10. In addition to the similarities however, there are also several differences, for 
example, V. cholerae, contains three vgrG genes and two hcp genes, whereas V. 
vulnificus contains only one of each gene. Additionally, although the majority of the 
V. cholerae T6SS genes are located contiguously on chromosome one, there are 
copies of the hcp gene and vgrG gene located on chromosome two, which are distal 
from the main T6SS locus (as exemplified in Figure 3.10) [238, 239]. An extensive 
search of the ten V. vulnificus genomes highlighted that there were no distal hcp or 
vgrG genes.  
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Figure 3.10: Gene organisation of V. vulnificus T6SS1 compared to the T6SS gene organisation in V. 
cholerae. The image shows the similarity in gene organisation of the T6SS1 from V. vulnificus 106-2A with V. 
cholerae O1 El Tor N16961. There are however several differences such as the number and location of the hcp 
and vgrG genes.  
Comparison of the strains that harbour T6SS1 with those that are T6SS1 negative, 
found that all T6SS1 positive strains are environmental isolates, whereas the strains 
that harbour T6SS2 are from both clinical and environmental origin. In comparison to 
the in vivo virulence data it was found that the majority of the strains that harbour 
T6SS1, were lesser virulent strains, for example S3-16 and 106-2A are lesser 
virulent group one and three strains. However, the strain 99-796 which is also T6SS1 
positive is a hyper virulent group four strain [13]. Table 3.4 demonstrates the 
prevalence of both T6SS1 and T6SS2 among the 10 clinical strains, T6SS1 is found 
only in the environmental strains analysed whereas T6SS2 is present in both clinical 
and environmental isolates.  
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Table 3.4: Prevalence of T6SS1 and T6SS among the 10 V. vulnificus strains analysed. The diagram shows 
the distribution of T6SSs among the 10 V. vulnificus strains. Y indicates the presents of the indicated T6SS, 
whereas a N indicates the absences of the indicated T6SS. Also shown is the virulence group of a strain and 
isolation source, E indicates an environmental strain, whereas C indicates a clinical strain.   
Strain Source Virulence Group  T6SS1 T6SS2 
106-2A E 3 Y Y 
S3-16 E 1 Y Y 
99-796 E 4 Y Y 
99-743 E 3 N Y 
S2-22 E 3 N Y 
DAL-79087 C 3 N Y 
DAL-79040 C 2 N Y 
ATL-9824 C 2 N Y 
NSV-5830 C 5 N Y 
ORL-1506 C 5 N Y 
3.3 Discussion  
V. vulnificus biotype 1 strains are opportunistic human pathogens that are known to 
vary in virulence [13, 36, 43]. The current study hypothesised that this difference in 
virulence potential maybe due to genetic variations between the strains. Using a 
WGS approach the study aimed to identify these differences bioinformatically. A total 
of ten biotype 1 strains were sequenced, which generated WGS data that was then 
utilised in several downstream analyses, such as phylogenetic tree analysis, WGS 
comparison and gene annotation. The output data from these downstream analyses 
was compared to the strains source of isolation and virulence potential.  
In order to understand the evolutionary relatedness of the ten V. vulnificus strains, 
phylogenetic trees were constructed based on SNP analysis. The constructed 
phylogenetic trees were then examined to investigate whether strains produced 
groups relating to either source of isolation or virulence potential. The phylogenetic 
trees demonstrated that there was no clear clustering of strains based on either 
source of isolation or virulence potential. A recent study by Bier et al., [10] generated 
phylogenetic trees for 53 V. vulnificus strains based on multi-locus sequence typing 
(MLST), with the aim of identifying virulence markers for risk assessment of 
subsequently identified V. vulnificus strains. The study suggested that the V. 
vulnificus strains grouped into two clusters which were based on isolation source. 
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Cluster I was reported to be made up of predominantly environmental isolates, 
whereas cluster II was made up of mainly clinical isolates [10]. However, analysis of 
the phylogenetic tree from this study, which is shown in Figure 3.11, demonstrates 
that this grouping of strains based on isolation source is not exclusive.  
 
 
Figure 3.11: Phylogenetic tree generated for V. vulnificus strains based on MLST analysis. The image is 
adapted from Bier et al., (2013), which shows V. vulnificus strains group into two clusters, cluster I is associated 
with environmental isolates, whereas cluster II is made up of clinical isolates. Highlighted in red are clinical 
isolates that appear in the environmental cluster and highlighted in green are environmental isolates that appear 
in the clinical cluster. Demonstrating the clusters are not exclusive for grouping either environmental strains or 
clinical strains. 
For example, clinical strains can be observed in the environmental cluster I, as well 
as environmental isolates appearing in the clinical cluster II. Highlighted in red in 
Figure 3.11 are the clinical strains that appear in the environmental lineage and 
highlighted in green are the environmental isolates that cluster in the clinical group, 
demonstrating that the phylogenetic tree analysis is unable to accurately predict 
source of isolation of the strains. The phylogenetic trees constructed in the current 
study were also unable to produce groupings of strains that were exclusively clinical 
or environmental, as clinical and environmental strains were interspersed throughout 
the trees. In terms of virulence potential, the phylogenetic trees from the current 
study were also unable to generate groupings of strains based on virulence potential. 
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Virulence of the strains was assessed according to the in vivo virulence data 
generated by Thiaville et al., (2011) [13]. 
As the phylogenetic tree analysis was unable to group V. vulnificus strains based on 
source of isolation or virulence potential, the study utilised the WGS data to perform 
WGS comparison and gene annotation. This was done with the aim of identifying 
genetic differences between strains that could account for the varying virulence 
potentials or isolation source. A similar WGS comparison approach was utilised 
recently to compare pathogenic and non-pathogenic strains of Clavibacter, to better 
understand the genetic basis of virulence displayed between the strains [240]. WGS 
comparison of four V. vulnificus strains was also been performed by Gulig et 
al.,(2010) [215], with the aim of identifying differences in virulence factors between 
strains [215]. Prior to bioinformatic analysis the study grouped strains according to 
clades, based on MLST analysis [31]. The MLST data was also coupled with 
virulence data for the strains, which was assessed by using an in vivo mouse model 
of virulence [13, 215]. This bioinformatic study identified 80 genes that were specific 
to the hyper virulent strains and absent from lesser virulent strains. The study 
suggested that these genes maybe virulence factors that enable the hyper virulent 
strains to cause systemic infection and death in a mouse model of infection [215]. 
However, this study was only in two virulent and two non-virulent strains [215].  
Similarly, the current study performed WGS comparison of the ten V. vulnificus 
strains with the aim of identifying genetic differences between the strains that may 
account for the disparity in virulence potentials between the strains. WGS 
comparison was performed using the bioinformatic software programmes Mummer 
and Circos, this allowed for the assembled scaffolds for the query strains to be 
aligned and visualised against the reference genome, YJ016. The alignment 
demonstrated that there were several differences and similarities between YJ016 
and the query sequences. However, the WGS comparison differences were not fully 
elucidated in the current study as simultaneously to WGS comparison, gene 
annotation of the WGS data was also performed. This latter method led to the 
discovery T6SSs, novel secretion systems that had not been previously described in 
V. vulnificus.   
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The current study chose to carry out gene annotation in parallel with the WGS 
comparison, as the WGS comparison method utilised in the study has its 
weaknesses. For example, if the reference strain is negative for genes that are 
present in the query scaffolds, then these regions will not be mapped to the 
reference strain, resulting in unmapped regions. One way of identifying these 
unmapped genomic regions is to carry out a BLAST search of the unaligned regions 
against the genomes of other organisms in order to identify unmapped genes, a 
method that Gulig et al., (2010) carried out [215]. However, when several genomes 
are being analysed this can be a lengthy task, hence the current study carried out 
whole genome annotation on all strains to examine the differences in genes between 
the strains. Genetic annotation proved successful for identifying gene differences, as 
the current study successfully identified two previously unidentified secretion 
systems, termed T6SS1 and T6SS2. It is possible that if WGS comparison alone 
was utilised, the T6SS1 may not have been identified, as the reference strain, YJ016 
contains only T6SS2 and is negative for T6SS1.  
Although the current study aimed to identify genetic differences between the strains, 
following the identification of the novel T6SSs, the study focused on characterising 
the secretion systems, in particular T6SS1, as the secretion system shared synteny 
with genetic organisation of the T6SS in V. cholerae. Furthermore, T6SS1 was only 
present in environmental isolates with a predominance to be associated with lesser 
virulent V. vulnificus strains. Investigation into the genetic organisation of T6SS1 
demonstrated that the secretion system contained all of the 13 conserved proteins 
required for a functional T6SS [236, 237].  
Previous phenotypic studies have shown that the T6SS contains anti-prokaryotic 
capabilities, whereby bacterial strains that harbour a T6SS have a competitive 
advantage over bacterial strains that do not harbour a cognate T6SS [234, 241-248]. 
Therefore it was hypothesised that T6SS1 positive V. vulnificus strains may have a 
competitive advantage over the T6SS1 negative strains. To test this hypothesis the 
study aimed to phenotypically characterise T6SS1 through the use of mutagenesis 
studies coupled with in vitro assays.   
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3.4 Conclusion 
In conclusion to the bioinformatics study, it was found that although the phylogenetic 
tree analysis of V. vulnificus strains did not show any clustering of strains in terms of 
source of isolation or virulence potential, the gene annotation of WGS data identified 
novel T6SSs, termed T6SS1 and T6SS2. Although the WGS comparison method 
showed several genetic differences between the V. vulnificus strains analysed, the 
current study did not investigate these further as attention was focused on 
understanding the role of the novel T6SSs.   
T6SS1 was chosen for further study as it shared synteny with the previously 
identified and functional T6SS in V. cholerae as well as the finding that T6SS1 was 
only present in a sub-set of strains, with a predominance to be associated with lesser 
virulent environmental isolates.  
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Chapter 4 The type 6 Secretion System (T6SS) 
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4.1 History of the T6SS 
4.1.1 The T6SS discovery 
Prior to the identification of the T6SS as a bona-fide secretion system [231], there 
had been much research surrounding the T6SS genes and locus [249-252]. 
However, despite suggestions of a novel secretion system [253], it wasn’t until 2006 
that Mekalanos and colleagues carried out a transposon mutagenesis study in V. 
cholerae which ultimately led to the discovery of the novel T6SS [231]. Since then, 
the T6SS has been identified and characterised in various Gram negative bacteria 
[234, 235, 248, 254], with in silico analysis suggesting that the T6SS is present in 
25% of all sequenced Gram negative bacterial genomes [236].  
4.1.2 Naming of T6SS components 
As briefly mentioned in the Chapter three, 13 core proteins have been identified 
which are required for the proper assembly of the T6SS [236], these 13 proteins are 
listed in Table 4.1. Additionally, several species of bacteria have also been shown to 
encode additional T6SS proteins which are referred to as accessory proteins [237]. 
Many of the accessory proteins have been shown to be involved with regulation of 
the T6SS as exemplified by the phosphatase and kinases encoded within the P. 
aeruginosa T6SS cluster [242]. 
It has also been reported in the literature that the 13 core proteins can be separated 
into two groups, the membrane associated complex proteins and phage related 
complex proteins [255, 256]. The membrane associated complex is made up of 
TssJ/VasD, TssK, TssL/DotU and TssM/IcmF and the phage related complex is 
made up of proteins which share homology to the bacteriophage tail structure, 
TssB/VipA, TssC/VipB, TssD/Hcp, TssE/VCA0109, TssF, TssG, TssH/ClpV and 
TssI/Vgrg.  
In an attempt to standardise the T6SS naming nomenclature, the terminology “Tss” 
arose, which is an acronym for “type six secretion” [237, 256]. However, as shown in 
Table 4.1, several T6SS components are referred to in accordance with historical 
names. For example, IcmF and Hcp are still used interchangeably with the Tss 
terminology. However, to avoid confusion this thesis will refer to T6SS components 
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in accordance with the common/historical nomenclature, with the exception of TssA, 
TssF, TssG and TssK, which do not have commonly associated names.  
Table 4.1: The 13 core proteins required for a functional T6SS 
Protein Name 
(Tss 
nomenclature/common 
name) 
COG Identity Function 
TssA 3515 Unknown function 
TssB / VipA 3516 Similar to the bacteriophage T4 contractile sheath. 
Interacts with VipB to form sheath around the Hcp 
[257]. 
TssC / VipB 3517 Similar to the bacteriophage T4 contractile sheath. 
Interacts with VipA to form sheath around the Hcp 
[257]. 
TssD / Hcp 3157 Forms hexameric rings that stack up on top of each 
other, hypothesised to form the needle structure of 
the T6SS [258]. 
TssE / VCA0109 3518 Believed to be involved with forming the base plate 
of the T6SS with similarity to the gp25 protein of the 
T4 bacteriophage [256].  
TssF 3519 Unknown function 
TssG 3520 Unknown function 
TssH / ClpV 0542 Provides the energy for the disassembly of the VipA 
and VipB sheath [259].  
TssI / VgrG 3501 Found at the distal end of the T6SS it forms the 
puncturing device capped onto the tip of the Hcp 
protein. Shares homology with the gp27 and gp5 
proteins of the T4 bacteriophage [260].  
TssJ / VasD 3521 A lipoprotein which is hypothesised to anchor the 
T6SS to the membrane by inetracting with the 
proteins DotU and IcmF [261].  
TssK  3522 A cytoplasmic protein that is hypothesised to form 
part of the baseplate structure connecting the tail of 
the T6SS structure to VasD, DotU and IcmF. TssK 
has also been shown to interact with the sheath 
protein, VipB [256]. 
TssL / DotU 3455 DotU shares homology to the type IVb secretion 
system DotU/IcmH proteins. It is believed that DotU 
interacts with vasD and IcmF, forming a 
membrance complex that anchors the T6SS to the 
cell envelope [262] 
TssM / IcmF 3523 Core scaffolding protein of the T6SS [231] and is 
also believed to be an ATPase and supply energy 
for the assembly of the T6SS [263].  
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4.2 The T6SS structure 
4.2.1 The phage related complex 
The T6SS is a cell puncturing device which as previously mentioned is believed to 
form an inverted bacteriophage like structure, a schematic diagram of the T6SS 
structure is depicted in Figure 4.1 [238].  
 
Figure 4.1: Schematic diagram of the T6SS in 
its contracted form. Shown in blue are the VipA 
and VipB proteins which form contractile tubes that 
are structurally similar to the T4 bacteriophage 
sheath that wrap around the Hcp tube. Upon 
contraction of the VipA and vipB proteins, the Hcp 
needle (yellow) is forced up out of the cell. On top 
of the Hcp needle is the VgrG protein (green), 
which is the cell puncturing protein. The puncturing 
action of VgrG is further aided by the PAAR protein 
(orange), which is sharpens the tip of VgrG. The 
whole T6SS structure is anchored in place by the 
membrane associated complex consisting of IcmF 
(purple), DotU (red), VasD (black) and the 
baseplate structure (brown).  
 
 
 
Based on homology studies, the Hcp protein shares similarity to the gp5 tail protein 
of phage λ [264], and is hypothesised to form the needle structure of the T6SS [258, 
265, 266]. More recently experimental evidence has shown that the Hcp protein 
forms hexameric rings that stack on top of each other in a head to tail manner [258], 
further suggesting that the Hcp protein forms the needle structure of the T6SS. In 
addition to being a structural element, Hcp is also believed to be involved with 
chaperoning T6SS effector proteins [267]. At the distal end of the Hcp needle 
structure is the VgrG protein. The VgrG protein has been shown to share homology 
with the gp5 and gp27 proteins of the T4 bacteriophage [260] and is hypothesised to 
form the puncturing device of the secretion system. It has also recently been shown 
that several VgrG proteins are partnered to PAAR (Pro-Ala-Ala-Arg) regions. These 
PAAR regions have been shown to interact with the VgrG protein and are believed to 
improve the puncturing action of VgrG [268]. In addition to VgrG’s structural 
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capabilities, several VgrG proteins have been shown to contain effector functions. 
These VgrGs are termed, “evolved VgrGs”, and are distinguishable from structural 
VgrGs based on the addition of a C-terminal extension [269]. An example of an 
evolved VgrG is VgrG-1 of V. cholerae. This evolved protein has been shown to 
contain an actin cross-linking domain which is used in virulence towards 
macrophages [269, 270].  
In agreement with the analogy of the T6SS as an inverted bacteriophage structure 
[238], the T6SS has also been shown to display two differing morphologies. An 
elongated extended morphology, as well as a shorter contracted morphology (the 
contracted morphology is shown in Figure 4.1) [271]. Experimental work with V. 
cholerae has demonstrated that the two differing morphologies are due to the VipA 
and VipB proteins [259]. These proteins are hypothesised to form a sheath like 
structure that wraps around the Hcp proteins which propel the Hcp needle out of the 
cell and into neighbouring cells [259]. Time-lapse microscopy on V. cholerae cells 
using green-florescent protein labelled VipA demonstrated that the T6SS sheath 
goes through cycles of assembly, contraction, disassembly and re-assembly. 
Although ClpV is not necessarily part of the phage-related complex, the involvement 
of ClpV is mentioned here briefly as recent research has shown that disassembly of 
the VipA/VipB sheath is dependent on the ClpV protein, which provides energy for 
the disassembly [259].   
4.2.2 The membrane associated complex, anchoring the T6SS 
The tail-sheath like complex of the T6SS secretion system described above, is 
anchored to the bacterial cell by the VasD, IcmF and DotU complex [256]. DotU and 
IcmF (Figure 4.1 red and purple) are so named due their homology to the T4SSb, 
however the VasD protein (Figure 4.1 black) currently has no homology to other 
identified secretion system proteins [272].  
The outer membrane lipoprotein, VasD is anchored in place by association with the 
outer membrane, it also contains a region that extends into the periplasm which 
allows for contact with the IcmF protein [273]. Although IcmF can be found residing 
in the inner membrane, a large proportion of the protein is also found located in the 
periplasm where it contacts VasD [256]. IcmF is a T6SS scaffolding protein [274] that 
has also been shown to contain ATPase activity [275]. IcmF is stabilised by 
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interaction with the DotU protein, [276] a protein that resides mainly in the cytoplasm. 
However, DotU also contains a C-terminus peptidoglycan binding motif that allows 
the protein to bind peptidoglycan which further aids in anchoring the T6SS complex 
to the bacterial membrane [256]. DotU proteins that lack a C-terminal peptidoglycan 
binding motif, contain the accessory protein, TagL. TagL also contains peptidoglycan 
binding abilities and therefore in the absence of the DotU motif, TagL anchors the 
T6SS structure to the cell [277]. A schematic representation of the location of the 
VasD, IcmF and DotU proteins is shown in Figure 4.1.  
Until recently it was unclear how the phage-related portion of the T6SS structure was 
connected to the trans-membrane spanning complex made up of, VasD, IcmF and 
DotU. However, recent research has suggested that a baseplate structure made up 
of TssAEFGK may be involved with connecting the two structures. Recently it has 
been shown that TssK may play a role in connecting the phage related portion of the 
T6SS to the membrane associated complex; as TssK has been shown to interact 
with both IcmF and DotU.  [259, 278]. In addition to a connective function, TssK has 
also been shown to interact with the protein of unknown function, TssA [278]. An 
additional understudied T6SS protein is VCA0109 (shown in brown in Figure 4.1), 
the exact role of this protein is still relatively unclear. However, homology studies 
have indicated that this protein maybe involved with baseplate formation as it is 
homologous to the protein, gp25 from the T4 bacteriophage [259, 265].  
4.3 Anti-eukaryotic properties of the T6SS   
Through the use of transposon mutagenesis studies in V. cholerae, it was found that 
a T6SS transposon mutant was attenuated in Dictyostelium, a eukaryotic model of 
infection [231]. This finding was later complemented with in vitro studies that 
demonstrated the T6SS of V. cholerae was also involved in virulence towards 
macrophages. In particular the evolved VgrG, VgrG-1 was shown to prevent 
phagocytosis by cross-linking actin [270]. The authors also demonstrated that 
internalisation of V. cholerae cells by macrophages activated the T6SS and caused 
the release of the effector, VgrG-1 [270]. The researchers of this study therefore 
hypothesised that the T6SS is a mechanism by which internalised V. cholerae can 
prevent macrophages from further phagocytosis and therefore protects the 
extracellular bacteria. This is turn allows for the dissemination of V. cholerae 
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throughout the human host as internalised V. cholerae cells would render the 
infected macrophages inactive [269]. A schematic representation of this working 
model proposed by the authors is shown in Figure 4.2. In vivo experimentation has 
also revealed that VgrG-1 causes cross-linking of actin in vivo, which is believed to 
contribute to the inflammatory diarrhoea symptoms commonly associated with V. 
cholerae infection [274].  In addition to VgrG-1, V. cholerae also encodes a pore 
forming T6SS effector, VasX. This effector has been shown to contain anti-
prokaryotic properties and is used by V. cholerae to target and kill D. discoideum 
[279].  
 
Figure 4.2: Schematic diagram of the anti-
eukaryotic properties of the T6SS from V. 
cholerae. The internalisation of V. cholerae by 
macrophages (A) leads to packaging of V. 
cholerae into V. cholerae containing vesicles (B), 
this causes the activation of the T6SS and the 
release of VgrG-1 (green) into the cytosol of the 
macrophage. VgrG-1 causes actin cross-linking 
in the macrophage (C). This renders the 
macrophage incapable of further phagocytosis, 
therefore the extracellular V. cholerae cells (D) 
are protected from phagocytosis by the 
macrophage.  
 
 
Further examples of the T6SS’s anti-eukaryotic properties are exemplified in bacteria 
from the Burkholderia species. For example, many of the T6SS genes in B. 
pseudomallei have been shown to be expressed during in vivo infection [280]. In 
particular, the T6SS-1 of B. pseudomallei has been shown to be essential for 
virulence in a mouse model of infection, as well as playing a role in the formation of 
mononucleated giant cells (MNGC), a characteristic phenotype associated with B. 
pseudomallei infection [281]. Until recently the T6SS effector responsible for the 
formation of MNGC was unknown. However, it has been demonstrated in the closely 
related B. thailandensis, that T6SS-5 is essential for mammalian virulence and the 
protein VgrG-5 is an “evolved VgrG” which is believed to be the key effector involved 
in the formation of MGNC [282].   
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Other anti-eukaryotic T6SSs include the T6SS recently identified in C. jejeni. This 
T6SS has been shown to play a role in colonisation in vivo as well as the 
involvement with adherence and invasion in vitro [235]. Studies with P. aeruginosa 
also provide evidence that the T6SS is expressed and functional during human 
infection as the sputum of cystic fibrosis patients infected with P. aeruginosa 
contains Hcp protein. In addition to this finding, Hcp antibodies were also identified in 
the serum of infected patients [182].  
More recently however, the versatility of the T6SS has been demonstrated. As in 
addition to targeting eukaryotic cells, the T6SS can also target prokaryotic cells. 
Since this discovery, there has been an explosion in T6SS research and it’s anti-
prokaryotic properties which are discussed in more detail in the sections below.   
4.4 An introduction to anti-prokaryotic T6SS effectors and immunity proteins   
The idea that the T6SS was involved with targeting bacterial species was first 
conceived following the identification of a T6SS protein in P. aeruginosa [242, 246]. 
The Type Six Effector, Tse2, secreted by P. aeruginosa was found to specifically 
target prokaryotic cells in a T6SS contact dependent manner, causing an inhibitory 
effect on the growth of targeted cells [242]. The inhibitory growth effects of Tse2 
were found to be neutralised by the expression of the protein, Tsi2 (Type 6 Secretion 
System Immunity Protein) [242] and further co-immunoprecipitation experiments 
demonstrated that both Tse2 and Tsi2 are able to interact with one another [242].  
Since the discovery of Tse2 in P. aeruginosa, there has been much research aimed 
at understanding the secretome of anti-prokaryotic T6SSs, and as such knowledge 
in this field has expanded. It is now widely accepted that in addition to the T6SS 
encoding anti-bacterial effectors/toxins, the T6SS also encode cognate immunity 
proteins. These proteins are able to neutralise the deleterious effects of the T6SS 
toxins, and as such confer protection from the effects of an attacking daughter cell 
[246, 283, 284].  
As a result of the increasing research and knowledge surrounding T6SS anti-
prokaryotic toxins, it has become apparent that the toxins can be divided into 3 
different classes. An overview of these differing T6SS toxins is discussed in the 
sections below. 
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4.5 The differing classes of anti-prokaryotic T6SS toxins        
The three different classes of T6SS toxins are divided up as follows, toxins that 
target the cell wall, toxins that target the cell membrane and toxins that target 
cytoplasmic nucleic acids [237, 247]. A schematic diagram in Figure 4.3 represents a 
hypothesised delivery mechanism of T6SS effectors, it should be noted however that 
although there has been much research into understanding independent effectors of 
the T6SS, the exact delivery mechanism of these identified T6SS effectors remains 
unknown [285]. The current hypothesis is that effectors are either fused to structural 
elements such as the VgrG or PAAR and transported out of an attacker cell and into 
a prey cell as “specialised effectors”, or translocated as “cargo effectors”, whereby 
effectors interact directly with structural elements such as the Hcp (as shown in 
Figure 4.3) [285].  
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Figure 4.3: Schematic diagram representing T6SS effector transport. The image shows a cross section of 
the T6SS Hcp needled with effectors being translocated within the Hcp needled from an attacker strain into a 
prey strain as “cargo effectors”. Upon injection of the T6SS needle into the prey strain, effectors/toxins are 
released. Toxins can cause damage to integral bacterial components such as the membrane, peptidoglycan layer 
or DNA of the prey strain. The attacker strain however is protected from the deleterious effects of the toxins by 
immunity proteins.  
4.5.1 Cell wall targeting effectors 
Due to the ever expanding field of identified T6SS toxins and immunity proteins, a 
new nomenclature has been proposed, whereby identified toxins and immunity pairs 
are named according to the toxin’s target. For example, peptidoglycan amidase 
T6SS toxins are now named, “Tae”, an acronym for type 6 secretion amidase 
effector and corresponding cognate immunity proteins are named “Tai”, type 6 
secretion amidase immunity [285]. As the name implies, Tae toxins contain amidase 
activity which allows the toxins to cleave peptidoglycan cross-bridges.  
To identify novel Tae/Tai toxin-immunity pairs in T6SS harbouring organisms, a 
bioinformatic analysis was performed on 193 organisms [286]. This analysis 
identified 51 putative Tae/Tai pairs which were analysed to compare their 
evolutionary relatedness. Phylogenetic trees demonstrated that the toxins separated 
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into four evolutionary distinct clades, designated Tae1-4 [286]. The study 
characterised each clade in vitro by analysing a Tae toxin from each. This 
demonstrated that the Tae protein contained amidase activity and was toxic when 
targeted to the periplasm of E. coli [286]. An example of a previously identified Tae 
toxin is Tse1 from P. aeruginosa. This toxin was found to  cluster in the group one 
clade of Tae toxins [246], and as such was renamed Tae1PA [286]. Clade two 
includes BTH_10068 from B. thailandensis, also known as Tae2BT, clade three 
includes PFL_5498 from P. fluorescens known as Tae3PF[286], and clade four 
includes Ssp1 and Ssp2 from S. marcescens also known as Tae4.1SM and Tae4.2SM 
[283].  
As well as the Tae proteins, another class of cell wall degrading toxins have been 
identified. These are known as type 6 secretion glycoside hydrolase effectors, “Tge”, 
and these effectors can be divided into 3 classes, Tge1-3. Like the Tae toxins, Tge 
toxins also target bacterial peptidoglycan. However, unlike Tae proteins which cleave 
peptidoglycan cross-bridges, Tge proteins are able to target the glycan backbone of 
peptidoglycan, thereby causing damage to the cell [246, 287].    
As previously mentioned, T6SS structural elements can also act as effectors, such 
as the case for the V. cholerae evolved VgrG, VgrG-1. Similarly to VgrG-1, V. 
cholerae encodes an additional evolved VgrG protein, VgrG-3. This latter evolved 
VgrG has been shown to contain a C-terminal domain with peptidoglycan degrading 
properties and through the use of in vitro assays, VgrG-3 has been shown to target 
bacterial cells in an antagonistic manner [288].  
4.5.2 Cell membrane targeting effectors 
In addition to targeting the peptidoglycan layer, T6SS toxins are also known to attack 
the cell membrane. T6SS toxins that attack cell membrane lipids are known as the 
type 6 secretion lipase effectors “Tle” [289]. Tle effectors are often encoded in 
genomes adjacent to the VgrG proteins, along with a downstream open-reading 
frame, which is believed to be the immunity protein [289]. The Tle cognate immunity 
proteins are known as Tli, type 6 secretion lipase immunity, which are able to 
neutralise the toxic effects of the Tle proteins [289, 290]. It has been suggested that 
the Tle proteins exert their effect on the cell membrane from within the periplasmic 
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space, this is because the cognate immunity proteins, Tli localise to the periplasmic 
space [289].  
A bioinformatic approach demonstrated that there are 5 families of Tle proteins, 
named Tle1-5. Tle1, Tle2 and Tle5 have been experimentally examined in B. 
thailandensis [289], V. cholerae [289, 290] and P. aeruginosa [289] respectively and 
it has been demonstrated that all are able to act as antibacterial effectors [289]. The 
Tle effector present in V. cholerae was identified as a T6SS secreted protein 
following comparative secretome analysis of a wild-type strain with a T6SS 
transposon mutant. This identified the Tle effector was named TseL and was 
bioinformatically shown to contain a lipase domain. In vitro assays demonstrated that 
TseL in conjunction with the other T6SS effectors, VasX and VgrG-3 was required 
for bacterial targeting [290].   
4.5.3 DNA targeting effectors 
Recent studies have also shown that the T6SS can produce toxins that are able to 
target cellular DNA. Recombinant hot spot (Rhs) proteins in Dickya dadanti have 
been shown to damage DNA as the Rhs proteins carry nuclease domains that have 
been shown to degrade cellular DNA. In particular, the Rhs proteins, RhsA and RhsB 
were shown to be involved with intracellular bacterial competition in D. dadanti [291]. 
It was found that the Rhs elements were found either linked to vgrG or hcp genes or 
next to other T6SS genes. In accordance with T6SS toxins, RhsA and RhsB were 
also found to have corresponding immunity proteins [291].    
4.6 The role of the T6SS in bacterial communities 
Due to the T6SS toxins capabilities to disrupt major bacterial cell components, it is 
hypothesised that a role of the T6SS is bacterial competition. The identification of 
immunity proteins co-occurring with toxins to protect kin cells, further adds to this 
evidence. Additionally, T6SSs harbouring anti-prokaryotic capabilities are not 
generally found in bacteria that are often found in isolation [248]. Furthermore it has 
also been demonstrated that several bacterial species activate their T6SS in 
response to differing environmental cues. For example, at low cell densities P. 
aeruginosa [292], V. cholerae [293] and V. parahaemolyticus [254] activate certain 
T6SSs. This has led researchers to suggest that the T6SS may be used to set up a 
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niche, whereby at low cell densities the T6SS is activated in order to displace other 
competing bacteria. Alternatively, environmental cues such as temperature, salinity 
and pH can cause activation of the T6SS, which bacteria may use as signals to 
detect that they have entered a host or certain environment that may contain 
competing bacteria [243, 254, 294].  
In addition to the hypothesis that bacteria harbouring a T6SS engage in inter-species 
targeting, it has also been shown for V. cholerae [295] and S. marcescens [234], that 
the T6SS is used in intra-species targeting. This can be achieved when there is a 
difference in toxin and immunity pairs between competing strains. It is unsurprising 
that the T6SS may be used in this way as strains occupying the same niche will be in 
competition with each other for nutrients and space. Therefore having a mechanism 
by which strains of a certain genotype can predominate will give a fitness advantage 
to the competing genotype. It is often seen in both the laboratory setting and in the 
natural environment that one genotype of a species will often dominate [247] which, 
among other factors, may be due to the T6SS.  
4.7 Monitoring T6SS functionality  
One of the most commonly cited ways of identifying a functional T6SS in vitro is to 
monitor the secretion of the well-known T6SS associated protein, Hcp. Hcp is 
reported as being the most abundant protein of the T6SS [258] and can often be 
detected in culture filtrates. It is believed that the Hcp is detected in the supernatant 
due to shearing off from the cells [234] which is often detected by methods such as 
Western blotting and mass spectrometry [231, 234, 263, 296]. Indeed, the initial key 
experiment used to identify the T6SS as a bona fide secretion system was a 
Western blot, which demonstrated detection of Hcp in both the cell lysate and culture 
filtrate of the wild-type V. cholerae strain, V52. However, following disruption to the 
T6SS scaffolding protein, IcmF, the Hcp was unable to be secreted. As such Hcp 
was only detected in the cell lysate and not in the culture filtrate.  
4.8 Monitoring T6SS killing in vitro 
In addition to monitoring the functionality of the T6SS, the associated bacterial killing 
phenotype can also be monitored in vitro. A set of experiments designed by 
Mekalanos and colleagues using time-lapse fluorescent microscopy demonstrated 
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the killing abilities of the P. aeruginosa T6SS when cultured in the presence V. 
cholerae, a T6SS positive organism [297].  Intriguingly these experiments showed 
that the T6SS in P. aeruginosa is not always constitutively expressed [298], and 
moreover, the T6SS of P. aeruginosa is able to locate where an attack is being 
presented, and assemble the T6SS in a specific location within the cell to mount a 
counter attack [297]. Often, P. aeruginosa sister cells can be seen attacking each 
other when monitored using time lapse fluorescent microscopy, a phenomenon 
which was termed “T6SS duelling” by the authors  [297]. The same study 
demonstrated that the detection of an attack and the mounting of a counter attack is 
not distinguishable in V. cholerae cells, as it is believed that V. cholerae cells exhibit 
much higher T6SS activity, whereby cells are continually firing the T6SS, and firing 
of the T6SS is not specific as seen in P. aeruginosa [297]. P. aeruginosa only 
exhibits T6SS activity in certain regions of the cell, suggesting that the activity is due 
to cells detecting a stimulus, and reacting.  
Time-lapse fluorescence microscopy has also been used to demonstrate that P. 
aeruginosa will preferentially target cells that first mount an attack on P. aeruginosa 
[299]. For example, when bacterial cultures of V. cholerae harbouring an intact T6SS 
are mixed with P. aeruginosa cultures, V. cholerae will spontaneously fire the T6SS, 
when the T6SS contacts P. aeruginosa, P. aeruginosa will mount a counter attack by 
detecting where it has been targeted and assemble the T6SS in the location to target 
the V. cholerae cells [298]. V. cholerae cells that have been targeted by P. 
aeruginosa then display a morphological rounding shape and die. However, it was 
shown when V. cholerae cells that were deficient in T6SS assembly were mixed with 
P. aeruginosa, P. aeruginosa did not target these cells. This phenomenon of a T6SS 
attack only being mounted once an attack had already been made was termed “tit-
for-tat” [298].  
In order to assess the anti-prokaryotic properties of the T6SS in a more simplified 
manner than using time lapse fluorescent microscopy, a co-culturing method has 
been established [234, 245, 254]. This is a method by which a T6SS attacker strain 
is cultured statically on an agar plate in the presence of a susceptible or T6SS 
negative strain, designated prey [245]. Co-culturing of the prey strain with either the 
wild-type attacker strain, or a T6SS mutant attacker strain with a dysfunctional T6SS, 
allows analysis of the prey strains survival. A prey strain that is targeted by the T6SS 
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will survive significantly better when co-cultured with a T6SS mutant strain than 
when co-cultured with a wild-type attacker strain [234, 245, 248, 254, 295].  Prey and 
attacker strains are cultured in unison on agar plates as T6SS killing has been 
shown to be contact dependent, whereby the addition of filter paper between prey 
and attacker cells on agar plates is known to abrogate T6SS killing [245]. So far the 
T6SS has only been shown to be toxic to Gram negative bacterial species [241, 244, 
254, 285]. This is due to the finding that the T6SS is ineffective at targeting Gram 
positive organisms and yeasts such as, Candida albicans or Sacchoromyces 
cerevisiae [245]. 
4.9 Study objectives 
WGS data demonstrated that V. vulnificus contains two T6SS, termed T6SS1 and 
T6SS2. The study chose to investigate T6SS1 further as it shared synteny with the 
previously described and functional T6SS of V. cholerae. Furthermore, this secretion 
system was found exclusively in environmental strains, with a predominance to be 
associate with the lesser virulent strains. The study aimed to assess T6SS1 
functionality by Western blotting, to monitor secretion of the T6SS1 associated 
protein, Hcp.  
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Chapter 5 Phenotypic characteristics of T6SS1 
from V. vulnificus 106-2A 
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5.1 Introduction and aim 
WGS analysis carried out in the current study identified novel T6SSs in V. vulnificus 
strains. The data showed that all of the ten strains sequenced contained a T6SS 
termed T6SS2. However, three strains, 106-2A, S3-16 and 99-796 contained an 
additional T6SS, termed T6SS1. A literature search on V. vulnificus and secretion 
systems confirmed that the T6SS had not been previously described in this species.  
This recently discovered bacterial secretion system has been shown to have 
numerous functions, including the secretion of both anti-eukaryotic and anti-
prokaryotic effectors. Analysis of the T6SS1 genetic organisation described in 
Chapter three, demonstrated that T6SS1 had synteny with the well characterised 
T6SS of V. cholerae. In addition, T6SS1 appeared to be more prevalent in strains of 
environmental origin and as such may be more ubiquitous in V. vulnificus strains. 
Therefore the T6SS1 was chosen for further investigation.  
5.2 Results  
5.2.1 The T6SS1 is functional in V. vulnificus 106-2A. 
Secretion of the T6SS hallmark protein Hcp is generally accepted as the gold-
standard method for assessing T6SS functionality. Hcp secretion can be assessed 
by using methods such as Western blotting and mass spectrometry  [234, 236, 254, 
270, 300]. Detection of Hcp in culture filtrate is believed to be due to shearing off of 
the protein from cells [234, 269, 301]. The current study performed Western blotting, 
using an antibody against the Hcp protein to determine the functionality of T6SS1 in 
V. vulnificus. The Hcp antibody was supplied by Dr. Stefan Pukatzki, from the 
University of Alberta, Canada. The antibody was originally raised against the peptide 
region, AGTSGSDDWRKPIEA, from Hcp in V. cholerae [269]. This same sequence 
was present in Hcp from V. vulnificus T6SS1 and therefore allows for cross reactivity 
with V. vulnificus.  
In order to study this novel secretion system, the biotype 1 strain 106-2A was 
selected.  This strain is an environmental isolate, originally cultured from the Gulf of 
Mexico, and has been shown to exhibit medium virulence in a mouse model of 
infection [13].   To assess functionality of T6SS1, V. vulnificus 106-2A cells were 
grown at 23oC, 30oC and 37oC in LB or LB supplemented with 3% NaCl. These 
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conditions were investigated as previous V. parahaemolyticus T6SS research 
demonstrated that temperature and salinity effects T6SS functionality. Proteins were 
extracted as detailed in the Materials and Methods from cells grown under the 
differing conditions. In brief, 25 mL cultures were grown to an OD590 of 1.5. A 20 mL 
sample of the cells was then centrifuged and the supernatant filtered and 
precipitated using TCA to obtain the culture filtrate proteins. Precipitated proteins 
were quantified using a BCA assay and along with whole cell lysate, subjected to 
SDS-PAGE. Proteins were then transferred to a nitrocellulose membrane which was 
Ponceau S stained to ensure proteins had been transferred and that protein loadings 
were equal.  The stain was then removed and the membrane subjected to Western 
blotting using the Hcp antibody.  
Figure 5.1 shows the temperature dependent secretion of the T6SS1 associated Hcp 
protein at approximately 23kDa on the Western blots. Hcp can be detected in the 
culture filtrate at 23oC and 30oC (lane 2, Figure 5.1A and B), but not at 37oC (lane 6 
Figure 5.1B). Furthermore, supplementation of LB broth with 3% NaCl causes a 
decrease in the Hcp band intensities at 23oC and 30oC (lane 3 and 4, Figure 5.1A 
and B), suggesting that salinity may have an inhibitory effect on Hcp secretion from 
T6SS1. At 37oC in LB-only (lane 5, Figure 5.1A) there is a substantial amount of Hcp 
detected in the cell lysate, suggesting that the hcp gene is being expressed, 
however, Hcp cannot be detected in the supernatant (lane 6, Figure 5.1A), 
suggesting that at 37oC the T6SS1 is not fully functional. Furthermore, cells grown at 
37oC, in LB supplemented with 3% NaCl (lanes 7, Figure 5.1A), exhibit a significant 
decrease in the amount of Hcp in the cell lysate, further suggesting that increasing 
NaCl levels may have an inhibitory effect on hcp expression. Control samples run on 
the Western blot shown in Figure 5.1 include the wild-type V. cholerae V52 strain 
(provided by Dr. Stefan Pukatzki), against which the Hcp antibody was raised. A 
negative control is provided by the V. cholerae V52 mutant strain, with hcp1 and 
hcp2 deleted (provided by Dr. Stefan Pukatzki). A further negative control was also 
included, C. difficile, as the antibody does not bind to any of the C. difficile proteins, 
this negative control demonstrates the specificity of the Hcp antibody.  
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Figure 5.1: Western blot images demonstrating expression and secretion of Hcp. (A) V. vulnificus cells 
lysate (C) and culture filtrates (S) from cells grown at 23
o
C and 37
o
C in LB with and without 3% NaCl. Hcp 
detection at ~23 kDa, corresponding Ponceau S stains shown in Appendix A2. (B) Cell lysate (C) and 
supernatant (S) from V. vulnificus cells grown as 30
o
C in LB and LB supplemented with 3% NaCl, Hcp detected 
at ~23 kDa. V. cholerae V52 cell lysate run as a positive control (V. cholerae WT), showing detection of Hcp at 
~23 kDa (lane 7). Negative controls provided by V. cholerae ∆hcp1∆hcp2 (V. cholerae ∆hcp, lane 8), and C. 
difficile (lanes 6 and 6). Protein samples loaded equalled 14 µg of protein/lane Protein marker is represented with 
(M). Indicated above each lane are the temperature and media conditions. Both images are representative 
images of Western blots carried out on protein extractions from three independent experiments.  
 
In conclusion, these results suggest that the T6SS1 is active at 23oC and 30oC but 
inactive at 37oC; with increasing NaCl concentrations causing an inhibitory effect on 
both the expression and secretion of Hcp. Following on from these functionality 
experiments, a T6SS1 mutant was generated in 106-2A in order to confirm the 
molecular basis of this phenotype.  
5.2.2 Production and confirmation of ∆icmF1 and ∆icmF2 mutants in V. 
vulnificus 106-2A 
Direct and random mutagenesis are two examples of reverse genetic analysis 
commonly used to characterise novel microbial genes [302]. A directed mutagenesis 
study usually involves an initial hypothesis being made about a certain gene, this 
gene is then mutated either by insertion, or deletion, allowing for the gene of interest 
to be characterised. It was hypothesised that the expression and secretion of Hcp by 
V. vulnificus is due to a functional T6SS1. To test this hypothesis an in-frame 
deletion mutant of icmF in strain 106-2A was constructed (In addition to generating a 
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T6SS1 icmF mutant a similar mutant in T6SS2 was also synthesised 
simultaneously to act a control in downstream phenotypic assays).  
The icmF gene was chosen for deletion as it encodes a core scaffolding protein 
which is required for the correct assembly of the T6SS [231, 236]. Studies have 
shown targeted disruption of icmF renders the T6SS non-functional, as assessed by 
the inability of the secretion system to translocate Hcp [231]. Therefore, the current 
study used Western blotting to assess T6SS functionality by monitoring the relative 
amounts of Hcp in culture filtrate of the wild-type strain and of the ∆icmF mutant. 
Construction of unmarked in-frame mutants of icmF in T6SS1 and T6SS2 was 
achieved by utilising the counter-selectable suicide vector, pDM4 [115, 131, 162, 
179, 199, 303-306]. The strategy used to construct pDM4 deletion vectors is outlined 
in Figure 5.2. 
 
 
Figure 5.2: Construction of suicide vector pSRC11. Flanking regions either side of icmF were PCR amplified 
using the primers indicated. These regions were then ligated into holding vectors to generate pSRC8 and 
pSRC9. The cloned regions were excised and ligated into pDM4, creating pSRC11. The resultant mutant 
essentially had ~ 3000bp of the central portion of the icmF gene deleted. A similar construct, pSRC10 was 
generated in a comparable way.  
 
The intermediate constructs pSRC8 and pSRC9 shown in Figure 5.2 were generated 
by PCR amplification of left and right flanks from icmF (primers used are listed in the 
materials and methods, in addition the gene sequence of icmF is available in 
Appendix A3 and A4 for T6SS1 and T6SS2 respectively). These plasmids were then 
sent for sequencing to ensure the fidelity of the PCR. Correctly sequenced upstream 
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and downstream fragments were then digested with SmaI and NdeI and NdeI and 
ApaI respectively and ligated into SmaI and ApaI digested pDM4. This produced 
pSRC11, which contained the icmF flanking regions from T6SS1. A similar plasmid, 
pSRC10 was made with in-frame deletion of icmF from T6SS2. 
Both pSRC10 and pSRC11 were then introduced separately into V. vulnificus 106-
2A by tri-parental mating. Confirmation of the integration of each plasmid into the 
genome to generate first cross-over integrants was confirmed by selecting 
chloramphenicol resistant clones. The mechanism of production of a first cross-over 
integrant is depicted in Figure 5.3.  
 
 
Figure 5.3: Schematic representation of the integration of a suicide vector into the V. vulnificus genome. 
Integration of the deletion construct into the V. vulnificus genome by homologous recombination of the left 
flanking region is shown. Black arrows indicate binding regions of MutScreen Forward and CmR. LF= left flanking 
region of target gene, RF = right flanking region of target gene, purple line = middle of target gene, cm = 
chloramphenicol resistance cassette, SacB = sacB gene encoded on pDM4 for counter selection. Thick black line 
= pDM4 back bone, thin black line = bacterial genome, arrows indicate binding of exemplified primers. Image 
adapted from Reyrat et al., (1998).    
 
First cross-over integrants were checked by PCR using the primers MutScreen 
Forward and CmR or MutScreen Reverse and CmF, Figure 5.3. CmF and CmR were 
designed to bind within the suicide plasmid whereas MutScreen Forward and 
Reverse were designed to bind distal to the flanking regions. Generation of a PCR 
product could thus only be achieved following successful integration of the suicide 
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plasmid into the genome. The provenance of the first cross over integrants was 
further checked using the V. vulnificus specific primers, vvhA forward and reverse.  
Confirmed first cross over integrants were then plated onto LB agar plates containing 
5% sucrose. This was performed in order to select for second cross-over integrants 
which had successfully excised the suicide vector from the genome. This process is 
schematically represented in Figure 5.4.  
 
 
Figure 5.4: Schematic representation of the 2
nd
 homologous cross-over event. 2
nd
 crossover homologous 
recombination occurring at the right flank produces a mutant, recombination at the left flank produces a wild-type 
revertant. LF= left flanking region of target gene, RF = right flanking region of target gene, purple line = middle of 
target gene, cm = chloramphenicol resistance cassette, SacB = sacB gene encoded on pDM4 for counter 
selection. Thick black line = pDM4 back bone, thin black line = bacterial genome, thick arrows = MutScreen 
primers, * = Length of PCR product generated using MutScreen primers against icmF. Image adapted from 
Reyrat et al., (1998).    
 
During the second cross-over event the plasmid is excised from the genome and the 
integrant recombines to form either a mutant or a wild-type revertant. To ensure 
clones produced during the second cross over were negative for the plasmid, 
colonies were streaked onto both sucrose and chloramphenicol plates. 
Chloramphenicol sensitivity and an ability to grow in the presence of sucrose 
indicated that the suicide plasmid had been lost. In addition, clones were genetically 
checked using PCR to ensure the icmF gene had been replaced with a truncated 
version. PCRs were performed using the primers MutScreen Forward and Reverse 
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for the icmF gene in either T6SS1 or T6SS2. This allowed for the distinction between 
wild-type revertants and mutant clones based on PCR product sizes, revertants 
produce a product 4622bps in length, while mutants generated a smaller 1555bps 
fragment. The primers additionally ensured the excision of the plasmid from that 2nd 
crossover clones as the primers bound within the genome. Confirmed ∆icmF clones 
were referred to as either “∆T6SS1 mutant” or “∆T6SS2 mutant”, which refers to 
∆icmF in T6SS1 and T6SS2 accordingly. As such, from here on this thesis will refer 
to ∆icmF mutants as “∆T6SS1 mutant” or “∆T6SS2 mutant”. 
The gel electrophoresis image presented in Figure 5.5 confirms an icmF mutant in 
T6SS1, using the MutScreen primers. Lane one shows the PCR product generated 
when wild-type gDNA is used as template for the MutScreen primers, amplifying a 
band 4622bps in length. The same PCR using gDNA from 106-2A ∆T6SS1 produces 
a band 1555bp shown in lane two. A negative control using nuclease free water in 
place of gDNA is shown in lane three.  
 
 
 
Figure 5.5: Gel electrophoresis image of PCR to 
confirm an icmF mutant in V. vulnificus 106-2A 
T6SS1. PCR bands generated when using the 
MutScreen forward and revers primers. Lane one, 
wild-type icmF gene, 4622bps; lane two, mutated 
icmF gene, 1555bps; lane three, negative control; M, 
Fermentas 1kb plus ladder. Appendix A5 shows a 
similar gel electrophoresis image for the icmF deletion 
in T6SS2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
To further confirm the mutation of the icmF gene in T6SS1 and to ensure no other 
mutation had occurred in the genome, the mutant was sent for WGS. Figure 5.6A 
shows a WGS comparison of assembled scaffolds from the wild-type strain, V. 
vulnificus 106-2A, and the mutant strain, V. vulnificus 106-2A ∆T6SS1. 
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Figure 5.6: WGS comparison of V. vulnificus 106-2A and V. vulnificus 106-2A ∆T6SS1. Black outer 
fragments represent scaffolds from the wild-type strain, V. vulnificus 106-2A. Blocked inner red regions represent 
V. vulnificus 106-2A ∆T6SS1 scaffolds. Red blocks represent regions of DNA in the mutant sequence with >80% 
homology compared to regions of DNA in the wild-type sequence. Regions of DNA with <80% homology are 
represented with no colour. The hashed circle highlights a difference in the alignment between the wild-type and 
mutant scaffolds. This region corresponds to the deleted icmF gene. (B) Wild-type sequencing reads are 
represented with the grey shaded track lines, associated ARTEMIS annotation for sequencing reads are 
represented with blue arrows above the grey. Over-laid onto the wild-type sequencing reads is the mutants strain 
annotation highlighted in red boxes. This demonstrated that the missing region in the mutant strain, shown in the 
middle of the boxed red regions corresponds to the icmF gene in the wild-type strain. 
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MUMmer [227] and Circos [228] created the WGS comparison in Figure 5.6A. The 
image was generated using the wild-type and mutant scaffolds, denoted by black 
and red respectively. The blocked red regions represent DNA sequence in the 
mutant that is >80% homologous to the wild-type strain. Genetic sequences with 
<80% homology are shown with no colour and represent a “gapped” region. The 
hashed circle in Figure 5.6A shows a  region that is absent in the mutant strain yet is 
present in the wild-type strain. Characterisation of this deleted region was achieved 
by uploading the genetic co-ordinates from the wild-type strain and mutant strain to 
ARTEMIS, a gene annotation programme [307]. The co-ordinates corresponded to 
the icmF gene which was present in 106-2A wild-type, but absent in 106-2A 
∆T6SS1, as shown in Figure 5.6B.  
5.2.3 A ∆T6SS1 mutant of V. vulnificus is deficient for Hcp secretion 
Functionality of T6SS1 was phenotypically assessed by monitoring secretion of the 
Hcp protein in LB at 30oC, as Hcp was shown to be maximally expressed at this 
temperature, as seen in Figure 5.1. The Western blot in Figure 5.7 shows detection 
of the Hcp in the cell lysate and the supernatant (lanes one and two) for the wild-type 
strain. However, ∆T6SS1 cells grown under the same conditions are deficient for 
Hcp secretion as Hcp is only detected in the cell lysate (lane three) and not in the 
supernatant (lane four). This demonstrated that deletion of the icmF gene in T6SS1 
renders the secretion system non-functional.  Furthermore, Figure 5.7 acts as an 
internal control for Hcp secretion in the wild-type strain, as Hcp is not detected in the 
supernatant of ∆T6SS1, demonstrating that the Hcp identified in the culture filtrate of 
the wild-type strain is due to secretion and not cell lysis.  
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Figure 5.7: Assessment of Hcp secretion from V. vulnificus 106-2A wild-type and V. vulnificus 106-2A 
∆T6SS1. Cell lysate (C) and supernatant (S) for wild-type (WT) and ∆T6SS1 mutant (∆T6SS1) grown in LB at 
30
o
C. Hcp protein detected at ~23kDa in lanes 1 and 2, lane 4 is absent for Hcp secretion for the ∆T6SS1 
mutant. Protein marker (M), 16.00 µg protein/lane. The image is a representative image of Western blots carried 
out on protein extractions from three independent experiments.  
 
In conclusion, the Western blot demonstrates that secretion of Hcp in 106-2A is due 
to T6SS1. Disruption of this secretion by introduction of an in-frame deletion to icmF 
renders the system non-functional, as assessed by monitoring Hcp localisation using 
Western blotting.  
5.2.4. The hypothesised role of T6SS1 in V. vulnificus 106-2A  
As discussed in Chapter four, the T6SS was initially discovered as a virulence factor 
against eukaryotic cells [231, 270]. However, following the discovery of a T6SS anti-
bacterial effector in P. aeruginosa [242], many of the recent T6SS studies have 
focused on the system’s novel anti-prokaryotic properties [234, 236-238, 241, 242, 
244-248, 254, 269, 297, 298, 301, 308, 309]. Experimental study of the system’s 
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ability to target bacterial cells is generally evaluated using co-culture killing assays, 
as described in section 4.8.  
The current study hypothesised that the T6SS1 of V. vulnificus would contain anti-
prokaryotic properties, as functionality experiments shown in Figure 5.1 
demonstrated that the secretion system was active at environmental temperatures. 
Conversely the system is inactive at 37oC and as such the current study speculated 
that T6SS1 was unlikely to target eukaryotic cells. To test the hypothesised ability of 
T6SS1 to target bacterial cells, co-culture killing assays were performed. The prey 
strains chosen for investigation included a T6SS1 negative V. vulnificus strain, 99-
743, as it was hypothesised that T6SS1 positive V. vulnificus cells would have a 
competitive advantage over T6SS1 negative V. vulnificus strains. In addition to 99-
743, the prey strain, V. fluvialis NCTC 11327 was also chosen as it is likely that V. 
vulnificus would encounter V. fluvialis in the natural environment as they share 
similar environmental niches. Prior to commencing the co-culturing assays, growth 
curves were performed. This allowed for the assessment of growth for the prey and 
attacker strains before commencing downstream phenotypic assays.  
5.2.5 Growth characteristics of V. vulnificus 106-2A wild-type, 106-2A ∆T6SS1, 
106-2A ∆T6SS2, V. vulnificus 99-743 and V. fluvialis  
Growth curves for the followings strains, V. vulnificus 106-2A wild-type, 106-2A 
∆T6SS1, 106-2A ∆T6SS2, V. vulnificus 99-743 and V. fluvialis NCTC 11327 were 
performed in LB at 30oC. These conditions were selected as downstream co-
culturing assays would be performed at this temperature. 30oC was preferred over 
23oC as V. vulnificus cultures grew slower at the latter temperature. Supplementary 
to assessing the strains growth characteristics, the data also allowed for the ∆T6SS1 
and ∆T6SS2 mutants to be monitored to ensure the introduced genetic mutations did 
not cause any pleiotropic effects on growth. 
The graph in Figure 5.8 displays the growth data for each of the tested strains. 
Statistical analysis by means of a two-way ANOVA, followed by a post-hoc Tukey 
test was performed on the growth curves, the results of which are shown in Appendix 
A6. 
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Figure 5.8: Growth curves Vibrio strains. Growth curves were performed in LB at 30
o
C, shaking. The OD590nm 
reading for the time points, 0, 2, 4, 6, 8 and 24 hours is presented. Each growth curve was repeated three times 
in triplicate, error bars represent standard error of the mean. Statistical analysis of the growth curves was 
performed using a two-way ANOVA shown in Appendix A2.  
 
Statistical analysis on the growth curves demonstrated that there is no significant 
difference in the mean OD590nm values of 106-2A and the corresponding ∆T6SS1 
and ∆T6SS2 mutants, indicating that the introduced genetic mutations do not cause 
pleiotropic effects on growth. There is also no significant difference at T0 and T2 for 
any of the strains tested. However, at time points, T4, T6 and T8 V. fluvialis 
produces statistically significantly higher OD590nm readings compared to the other 
strains.  
In conclusion, the growth curves demonstrate that the genetic mutations to icmF of 
T6SS1 or T6SS2 does not cause any pleiotropic effects on growth. Furthermore, the 
growth curves show that the tested strains produce similar OD readings, information 
that was required for downstream phenotypic assays.   
5.2.6 T6SS1 positive V. vulnificus 106-2A can target T6SS1 negative V. 
vulnificus 99-743 
To test the hypothesis that T6SS1 positive V. vulnificus strains have a competitive 
advantage over T6SS1 negative strains, co-culture killing assays were performed, as 
previously described in section 4.8. The initial prey strain tested was the T6SS1 
negative V. vulnificus strain, 99-743. Killing assays were performed as documented 
in the Materials and Methods. In brief, the prey and attacker strains were grown to an 
OD590nm 1.0, and then adjusted to an OD590nm 0.8, and mixed at a 3:1 ratio of 
attacker to prey. The co-culture plates were incubated at 30oC for 5 hours. Following 
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incubation, the growth was scraped off and re-suspended in sterile PBS. Serial 
dilutions were then spotted onto TCBS plates. TCBS agar plates containing serial 
dilutions for T0 and T5 were then incubated at 37oC. The Vibrio selective agar, 
TCBS was used for enumeration as V. vulnificus 106-2A, ∆T6SS1 and ∆T6SS2 
colonies appear green, whereas V. vulnificus 99-743 colonies are yellow, therefore 
allowing for the quantification of both strains based on colony colour. Incubation of 
the enumeration plates was performed at 37oC as the T6SS1 is inactive at this 
temperature and therefore T6SS targeting between the strains should not occur. An 
illustrative image is shown in Figure 5.9, demonstrating the ability of yellow and 
green serial dilution colonies to be distinguished.  
 
Figure 5.9: Miles and Misra TCBS agar 
serial dilution plate. Green and yellow 
colonies produced from co-culture serial 
dilutions of V. vulnificus 106-2A and V. 
vulnificus 99-743 on TCBS agar. 
 
 
 
 
 
 
 
 
 
Data for the co-culture killing assays used to assess the anti-prokaryotic targeting 
properties of V. vulnificus 106-2A T6SS1 are shown in Figure 5.10. Assays were 
performed using the prey strain, 99-743 in co-culture with either 106-2A wild-type or 
∆T6SS1. In addition to assessing the targeting abilities of ∆T6SS1, ∆T6SS2 was also 
included as a control. This was done to establish whether T6SS2 played a role in 
targeting bacterial species. The raw data gained from the co-culturing killing assays 
is shown in in Figure 5.11, the raw data was used to calculate the fold change in 
survival of the prey and attacker strains using the equation, output (cfu/mL)/input 
(cfu/mL), which is shown in Figure 5.10.  
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Figure 5.10: The T6SS1 of V. vulnificus 106-2A can be utilised to target the T6SS1 negative V. vulnificus 
strain, 99-743. The fold change in cfu/ml of the T6SS1 negative prey strain, V. vulnificus 99-743 shown in yellow 
when co-cultured with the attacker strains, V. vulnificus 106-2A wild-type, ∆T6SS1 mutant or ∆T6SS2 mutant. 
Survival of the attacker strains are depicted in green on the graph. The x-axis represents the strains used in 
individual co-culture killing assay. Assays were performed three times in triplicate, each spot on the graph 
represents a co-culture killing assay and error bars show standard error of the mean. Statistics were performed 
using the unpaired two-way Student’s t-test, * P < 0.05.   
 
 
Figure 5.11: The T6SS1 of V. 
vulnificus 106-2A can target a T6SS1 
negative V. vulnificus strain.  The 
graph represents raw data gained from 
viable cfu/mL produced at T0 and at T5 
for the attacker strains V. vulnificus 106-
2A wild-type (106-2A WT), ∆T6SS1 
mutant (106-2A:IcmF1), ∆T6SS2 
mutant (106-2A:IcmF2) shown in green 
and the prey strain, V. vulnificus 99-743 
(99-743) shown in yellow following co-
culture assays. To the right of each 
attacker strain is the corresponding prey 
strain which were co-cultured together. 
Experiments were performed three 
times in triplicate, error bars show 
standard error of the mean. Statistics 
were performed using the unpaired 2-
way Student’s t-test, * P < 0.05. 
 
 
Assessment of the graph in Figure 5.10 shows the fold change in recovery of viable 
cells for the prey strain, 99-743 (depicted in yellow) is greatly increased when co-
cultured with the T6SS1 mutant. Recovery of 99-743 is almost three logs higher 
113 
 
when grown with the T6SS1 mutant compared to the wild-type strain. A statistical 
comparison using the student’s t-test demonstrates that this difference is significant 
where P < 0.05. To ensure that the observed killing of 99-743 was due to T6SS1 and 
not T6SS2, the T6SS2 mutant strain was also used in co-culture killing assays. As 
seen in Figure 5.10, there is no difference in the recovery of 99-743 when co-
cultured with ∆T6SS2 or with the wild-type strain. Analysis using the student’s-t-test 
further demonstrates that there is no significant difference in the survival of 99-743 
when co-cultured with either the wild-type strain or ∆T6SS2. Therefore the killing of 
99-743 is due to the functionality of T6SS1 and not T6SS2. 
Included on the graph is the survival of the attacker strains, 106-2A wild-type, 
∆T6SS1 and ∆T6SS2, shown in green. The recovery of the attacker strains is 
comparable to recovered 99-743 cells when co-cultured with ∆T6SS1. Statistical 
analysis demonstrates there is no significant difference in the recovery of either the 
wild-type, ∆T6SS1 or ∆T6SS2 mutants when co-cultured with 99-743, demonstrating 
that 99-743 does not target 106-2A strains. In conclusion, this data shows that a 
T6SS1 positive strain exhibits anti-prokaryotic properties against a T6SS1 negative 
V. vulnificus strain. This suggests that T6SS1 positive strains have a competitive 
advantage over strains that are T6SS1 negative. Furthermore, the killing of 99-743 
seen by V. vulnificus 106-2A wild-type is attributed to the T6SS1 as a deletion in 
T6SS2 has no effect.  
5.3 Discussion  
WGS annotation of ten V. vulnificus strains identified novel secretion systems termed 
T6SS1 and T6SS2. As these novel secretion systems had not been previously 
described in V. vulnificus, the T6SS was chosen for investigation. In particular 
T6SS1 was evaluated as the gene organisation of T6SS1 has synteny to the 
previously described and functional T6SS in V. cholerae V52 [231]. Furthermore, the 
T6SS1 was only present in a sub-set of environmental strains, with a predominance 
to be associated with lesser virulent strains.  
T6SS functionality can be assessed by monitoring the secretion of Hcp [231]. 
Therefore the functionality of T6SS1 was assessed by Western blotting to monitor 
Hcp secretion. This demonstrated that the T6SS1 was fully functional at 23oC and 
30oC, but not at 37oC. This is different to results gained in V. cholerae V52, which 
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contains a T6SS that is functional at 37oC as assessed by the secretion of Hcp [231]. 
This difference in temperature regulation of the T6SS between V. cholerae and V. 
vulnificus is unsurprising as other bacterial species also show differences in T6SS 
thermoregulation [254, 310]. For example, V. parahaemolyticus has been shown to 
contain two T6SSs which are differentially regulated by temperature [254] and 
Yersina pseudotuberculosis has four T6SS, which are differentially regulated by 
temperature [310] 
In addition to temperature, the current study investigated the effect on changing 
salinity levels on T6SS1 associated Hcp secretion, as previous studies in V. 
parahaemolyticus and V. cholerae [243] have demonstrated that differing salinity 
concentrations effect the secretion of T6SS proteins [254]. The results from the 
current study found that increasing salinity levels caused an inhibitory effect on the 
secretion of Hcp from T6SS1. 
Comparison of T6SS1 in V. vulnificus studied here, with the T6SSs in V. 
parahaemolyticus demonstrates that the expression and secretion of Hcp from 
T6SS1 of V. vulnificus is similar to the expression and secretion of Hcp from T6SS2 
in V. parahaemolyticus [254]. For example, V. parahaemolyticus T6SS2 associated 
Hcp was found to be expressed at 23oC, 30oC and 37oC. However, secretion was 
only detected in LB at 23oC and 30oC, but not at 37oC [254], akin to the results seen 
here for V. vulnificus for T6SS1. However, with the addition of NaCl to the media, V. 
parahaemolyticus does not secrete Hcp from T6SS2, which is different to V. 
vulnificus, which secretes Hcp from T6SS1 with the addition of NaCl, although at 
lower levels than when cells are grown in LB alone. Conversely the Hcp from T6SS1 
of V. parahaemolyticus is expressed only at 23oC and 30oC but not 37oC. The 
secretion of Hcp from T6SS1 in V. parahaemolyticus however, is only detected at 
30oC in high salt concentrations and to a lesser extent at 23oC in low salt conditions 
[254]. These results would suggest that T6SS1 from V. vulnificus 106-2A shares a 
similar secretion and expression pattern to T6SS2 from V. parahaemolyticus in terms 
of temperature regulation. However, the effect of salinity on the regulation on the 
T6SS differs between the two bacteria.  
An alternative example of T6SS salinity regulation is also exemplified in V. cholerae. 
For example, although the T6SS of non-O1 and non-O139 V. cholerae strains, such 
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as V52 is constitutively active in standard laboratory LB media [311], the T6SS of the 
V. cholerae O1 strain, A1552 is active in high salinity solutions. The finding that V. 
cholerae A1552 is active when in the presence of high salinity is unsurprising given 
that V. cholerae is often found in costal and estuarine environments. These findings 
in V. cholerae A1552 disagree with the findings presented here for V. vulnificus, 
where increasing salinity levels has an inhibitory effects on T6SS1. However, the in 
terms of thermoregulation regulation the T6SS1 of V. vulnificus and the T6SS of V. 
cholerae A1552 are similar as they are both functional at 23oC, but inactive at 37oC.  
In addition to temperature and osmolality regulation several T6SSs also show post 
translational regulation, as exemplified by the common nosocomial pathogen, P. 
aeruginosa. This pathogen encodes three T6SSs, named accordingly HSI-I to HS-I-
III. It has been shown that HS-I is regulated post-translationally by a serine-threonine 
phosphatase and a serine-threonine kinase, encoded by PppA and PpkA 
respectively [232]. In wild-type P. aeruginosa it has been shown that HSI-I does not 
secrete Hcp under normal laboratory conditions. However, deletion of pppA results in 
a constitutively active T6SS, whereby Hcp is secreted. Conversely, deletion of ppkA 
eliminates T6SS activation [232]. Deletion of pppA causes T6SS activation as in the 
wild-type strain, PppA antagonises PpkA. PpkA is activated by an unknown 
environmental signal which causes dimerization and autophosphorylation of PpkA. 
The autophosphorylation of PpkA leads to binding and phosphorylation of FHA (fork 
head association domain) which ultimately leads to the secretion of Hcp [232]. 
Recent research has also shown that TagR and TagF can promote and repress HSI-
I secretion of Hcp respectively [312, 313].  
Although the T6SS1 of V. vulnificus does not contain a serine-threonine 
phosphatase or a serine-threonine kinase, findings from this study show that T6SS2 
encodes genes for pppA, ppkA and fha. This may suggest that V. vulnificus T6SS2 
may display regulation similar to the HSI-I of P. aeruginosa. This may propose an 
area for further V. vulnificus research as the current study did not investigate the 
functionality of T6SS2.     
The secretion of Hcp was attributed to T6SS1 as an icmF deletion mutant in T6SS1 
was deficient for Hcp secretion. Other research groups have previously deleted the 
icmF gene in several other bacterial species which has successfully disrupted the 
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secretion system [182, 231, 296, 314]. Deletion of the icmF gene from T6SS1 in V. 
vulnificus rendered the secretion system non-functional, as assessed by Western 
blotting to monitor the secretion of the Hcp protein. The T6SS1 mutant also provided 
an internal control demonstrating that the Hcp detected in the supernatant of the 
wild-type strain was due to secretion and not cell lysis.  
The T6SS has previously been shown to target bacterial cells [234, 237, 238, 241, 
242, 245, 247, 297, 298, 301, 315]. It was therefore hypothesised that the T6SS1 of 
V. vulnificus 106-2A may contain anti-prokaryotic properties as it was active at lower 
temperatures such as 23oC and 30oC which are akin to those in the environment, but 
inactive at 37oC. Due to the inactivation of T6SS1 at 37oC, it was speculated that the 
T6SS was unlikely to be anti-eukaryotic. In order to test the ability of the T6SS1 to 
target bacterial cells, the T6SS1 mutant was compared to the wild-type strain in co-
culture assays. In addition to the T6SS1 mutant, a T6SS2 mutant was also assessed 
to understand whether the T6SS2 mutant had any effect on targeting bacterial cells. 
The co-culture assays were performed on agar surfaces as previous research had 
demonstrated that the T6SS is unable to target prey cells when cultured in broth 
[315, 316]. Additionally, preliminary data in the current study demonstrated that the 
T6SS1 is unable to target prey cells when co-cultured in broth but can when co-
cultured on a solid surface.  
The study hypothesised that T6SS1 positive V. vulnificus cells may have a 
competitive advantage over V. vulnificus cells that are T6SS1 negative. Therefore 
co-culture assays were performed using the V. vulnificus T6SS1 negative strain, 99-
743. The results from the co-culture killing assay demonstrated that 99-743 was able 
to survive significantly better when co-cultured with the T6SS1 mutant strain 
compared to the wild-type strain. However, when the co-culture killing assay was 
performed with the T6SS2 mutant there was no significant difference in the recovery 
of 99-743 compared to the wild-type strain, demonstrating that T6SS1 gives V. 
vulnificus 106-2A a competitive advantage over the T6SS1 negative stain, 99-743.  
The ability for the T6SS1 positive strains to target the T6SS1 negative strains, 
maybe due to the difference in toxin and immunity proteins encoded by the strains. A 
similar study carried out in V. cholerae demonstrated that V. cholerae displays intra-
species specific competition where it was postulated that certain strains contain 
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compatibility sets of toxins and immunity proteins. Therefore strains which express 
cognate toxins and immunity proteins are able to co-exist, whereas V. cholerae 
strains containing different toxin and immunity proteins are unable to co-exist. This is 
due to the ability of T6SS immunity proteins to neutralise cognate toxins [284]. The 
toxin and cognate immunity protein pairs allow V. cholerae cells to distinguish 
between self and non-self-cells as well as allowing the bacteria to  engage in 
competitive intra-species competition [295]. This work in V. cholerae was further 
followed up with bioinformatic analysis of toxin and immunity protein pairs which 
further supports the hypothesis that different strains of V. cholerae contain different 
compatibility pairs of toxins and immunity proteins, allowing for the competitive 
behaviour seen between strains in vitro [288]. In light of the findings regarding 
bacterial species containing differing classes of T6SS toxins and cognate immunity 
proteins allowing for bacterial cells to engage in intra and inter-species targeting, the 
current study hypothesised that V. vulnificus may too contain specific toxins and 
cognate immunity proteins that are specific to strains encoding T6SS1, which may 
allow T6SS1 positive strains to target T6SS1 negative strains. For example T6SS1 
positive V. vulnificus strains may contain compatible toxins and immunity proteins, 
enabling the strains to discriminate between self and non-self. However, the T6SS1 
negative strains may not encode cognate immunity proteins to the toxins encoded by 
T6SS1 positive strains, therefore T6SS1 positive strains can their cognate toxins to 
target the T6SS1 negative V. vulnificus strains in an antagonistic manner. However 
further research would need to be carried out in order to identify toxins and immunity 
pairs specific to T6SS1 to verify this hypothesis.  Figure 5.12 demonstrates the 
working hypothesis that T6SS1 of V. vulnificus is involved with intra-species 
targeting.  
Although this study did not investigate the secreted toxins of T6SS1 experimentally, 
it is likely that the effectors are Rhs elements. As the genes encoded adjacent to the 
vgrG of T6SS1 are rhs genes. Similarly, the T6SS rhs genes encoded by D. dadanti 
are found adjacent to vgrG genes. Furthermore, studies in D. dadanti demonstrated 
that the rhs genes were involved in bacterial completion and degradation of cellular 
DNA. Therefore, the current study speculates that the rhs genes found adjacent to 
the T6SS1 locus of V. vulnificus may have similar properties [291].  
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Figure 5.12: T6SS1 of V. vulnificus is involved with intra-species targeting. Image (A) represents a V. 
vulnificus cell encoding T6SS1 and T6SS2 targeting a T6SS1 negative cell with an assembled T6SS1. 
Translocation of the toxins represented in black renders the T6SS1 negative cells unable to survive (B). 
However, as seen in (B) the T6SS1 positive cell is not susceptible to the deleterious effects of the toxins as 
T6SS1 also encodes cognate immunity proteins, denoted by red circles which neutralises the toxins. (C) A non-
functional T6SS1 due to a deletion in the icmF gene shown in purple is no longer able to build a functional 
T6SS1, therefore the T6SS1 negative strain is not targeted and it able to survive.  
 
The current study also hypothesised that T6SS1 may play a role in understanding 
the bigger V. vulnificus research question which has plagued many scientists 
working on this organism for several years, the question of, “why are there relatively 
few serious cases of V. vulnificus human infection given the natural prevalence and 
virulence potential of this bacterium?” With this question in mind, the current study 
hypothesised that the lesser virulent T6SS1 positive V. vulnificus strains are able to 
target hyper virulent strains naturally in the marine environment, therefore there are 
less hyper virulent strains occurring naturally which may result in a decreased 
incidence of serious human infection. The current study poses this as a hypothesis 
as out of the ten strains analysed bioinformatically, all of the T6SS1 positive strains 
were of environmental origin. Furthermore analysis of the virulence potential of these 
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strains, as assessed by the virulence data from the in vivo mouse studies [13], 
demonstrated that T6SS1 is predominantly identified in lesser virulent strains. For 
example, the T6SS1 positive strain S3-16 is virulence group one and produces very 
low levels of skin infection with almost undetectable liver infection [13]. Furthermore, 
strain 106-2A is a low virulence group three strain, which although is associated with 
high levels of skin infection it produces undetectable to low levels of liver infection, 
demonstrating that these two strains are unable to produce a fatal systemic disease 
which is often associated with death in V. vulnificus infected patients. There was one 
strain however, 99-796 which was a hyper virulent group four strain producing high 
levels of skin infection with moderate to high levels of liver infection. Therefore 
further research understanding the prevalence of the T6SS1 in V. vulnificus strains 
from both clinical and environmental origin with varying virulence potentials would 
need to be undertaken to validate the hypothesis detailed above.  
5.4 Conclusion  
In conclusion, the current study identified that the T6SS1 of V. vulnificus 106-2A is 
functional at 23oC and 30oC in LB and LB supplemented with 3% NaCl. Functionality 
was assessed by monitoring the secretion of Hcp by Western blotting. It was also 
noted that although hcp is expressed at 37oC, the Hcp protein is not secreted, 
indicating that T6SS1 is not fully functional at 37oC. Hcp secretion was attributed to 
T6SS1 as a T6SS1 mutant containing an in-frame deletion of icmF was unable to 
secrete Hcp. The T6SS1 mutant was also used in a co-culture killing assays with the 
V. vulnificus T6SS1 negative prey strain, 99-743. These results demonstrated that 
T6SS1 positive V. vulnificus 106-2A has a competitive advantage over T6SS1 
negative, V. vulnificus 99-743, as 99-743 survives significantly better when co-
cultured with the T6SS1 mutant compared to the wild-type strain. Furthermore, 
assessment of the ∆T6SS2 mutant demonstrates that the competitive advantage of 
V. vulnificus 106-2A is due to T6SS1 and not T6SS2.  
The current study additionally found that T6SS1 may provide a possible explanation 
to one of the major question surrounding this bacterium, “Why are there so few 
serious V. vulnificus associated infections given the natural prevalence and 
abundance of this pathogen occurring naturally in the environment?” The current 
study found that the majority of the hyper virulent V. vulnificus strains are T6SS1 
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negative, whereas several of the lesser virulent strains are T6SS1 positive. 
Therefore, the current study has hypothesised that the limited number of serious 
human infection associated attributed to V. vulnificus may be due to the lesser 
virulent T6SS1 positive strains targeting the hyper virulent T6SS1 negative strains in 
the environment.  
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Chapter 6 The inter-species targeting abilities 
of V. vulnificus T6SS1 
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6.1 Introduction and aim 
The T6SS is documented in the literature to be involved with intra-species targeting 
[295]. Accordingly, it was shown in the previous chapter that V. vulnificus engages in 
intra-species targeting as evidenced by a T6SS1 positive strain killing a T6SS1 
negative strain, demonstrating that T6SS1 positive V. vulnificus cells have a 
competitive advantage over T6SS1 negative cells. In addition to intra-species 
targeting, the literature reports that the T6SS is also involved in inter-species 
competition [234, 241, 245, 254, 297, 298, 317]. Therefore, the current study 
hypothesised that T6SS1 of V. vulnificus may be involved in targeting bacterial 
species other than V. vulnificus. To test this hypothesis, the Vibrio species, V. 
fluvialis was used as a prey strain in co-culture assays. As well as testing an 
alternative Vibrio species, the study also tested a non-Vibrio species, B. 
thailandensis in co-culture assays. Furthermore, the study also investigated the 
virulence of T6SS2 towards the eukaryotic infection model, G. mellonella. As 
previously published research has demonstrated that the T6SS is involved in 
targeting eukaryotic cells [231, 233, 248, 269, 270, 274, 282].  
The study also used a ∆T6SS2 V. vulnificus strain in all of the assays, as it was 
hypothesised that T6SS1 may be specific to intra-species targeting and T6SS2 may 
be involved with inter-species competition or virulence towards eukaryotic cells.  
6.2 Results 
6.2.1 V. vulnificus can utilise T6SS1 to target an alternative Vibrio species 
To further investigate the specificity of T6SS1 to target other Vibrio species, the co-
culture killing assay was repeated with the prey strain, V. fluvialis NCTC 11327. 
Similarly to 99-743, V. fluvialis appears yellow on TCBS, allowing for V. fluvialis 
colonies to be distinguished from V. vulnificus colonies on enumeration plates. In 
addition to ∆T6SS1, ∆T6SS2 was also assayed to test whether T6SS2 was able to 
target V. fluvialis cells, as although T6SS2 was not involved with targeting T6SS1 
negative V. vulnificus strains, it was hypothesised that T6SS1 may be specific to 
targeting V. vulnificus species and T6SS2 may be involved in targeting other Vibrio 
species. 
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The co-culture results are shown in Figure 6.1 which demonstrates that the fold 
change in the recovery of V. fluvialis NCTC 11327 (shown in yellow) is significantly 
greater when co-cultured with ∆T6SS1 compared to when co-cultured with the wild-
type strain. Statistical analysis of this difference using a student’s t-test indicates that 
the difference is significant, where P < 0.005. Evaluation of V. fluvialis recovery when 
co-cultured with ∆T6SS2, demonstrates that there is no difference in the survival of 
V. fluvialis when co-cultured with either the ∆T6SS2 strain or the wild-type strain. 
These results therefore demonstrate that the killing seen by the wild-type strain is 
due to T6SS1 and not T6SS2, as a mutation to T6SS2 does not affect the survival of 
V. fluvialis in a co-culture assay. The raw data for the graph shown in Figure 6.1 is 
shown in Figure 6.2. 
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Figure 6.1: V. vulnificus 106-2A is able to utilise T6SS1 to target V. fluvialis during co-culture. Shown in 
yellow is the fold change in growth (cfu/mL) for the prey strain, V. fluvialis when co-cultured with the attacker 
strains V. vulnificus 106-2A wild-type, ∆T6SS1 mutant or ∆T6SS2 mutant, shown in green. Strains used in 
individual co-culture assays are shown on the x-axis. Assays were performed three times in triplicate, each spot 
on the graph represents a co-culture killing assay and error bars show standard error of the mean. Statistics were 
performed using the unpaired two-way Student’s t-test, ** P < 0.005.   
 
Figure 6.2: V. vulnificus 106-2A can target 
V. fluvialis in a T6SS1 dependent manner. 
Raw data gained following co-culture with the 
attacker strains, V. vulnificus 106-2A wild-type 
(106-2A WT), ∆T6SS1 mutant (106-2A:IcmF1), 
∆T6SS2 mutant (106-2A:IcmF2) shown in 
green and the prey strain, V. fluvialis (V. 
fluvialis) shown in yellow at 30
o
C for 5 hours. 
Shown in green are the results gained for the 
attacker strains at T0 and T5 and shown in 
yellow are the results for the prey strain at T0 
and T5. To the right of each attacker strain 
shown in green is the corresponding prey 
strain shown in yellow. V. fluvialis survives 
significantly better when co-cultured with 
∆T6SS1 mutant compared to co-culture with 
106-2A wild-type strain. There is no recovery 
of any ∆T6SS1 mutant colonies following co-
culture with V. fluvialis. Experiments were 
performed three times in triplicate, error bars 
show standard error of the mean. Statistics were performed using the unpaired 2-way Student’s t-test, *** P < 
0.0005.  
Conversely to the results gained in Figure 5.10, the ∆T6SS1 shown in green in 
Figure 6.1 is unable to survive in the presence of the prey strain, V. fluvialis. 
Furthermore, analysis of the recovery of the attacker strains, ∆T6SS2 and wild-type 
also show a decrease in growth when compared to Figure 5.10. For example, 
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∆T6SS2 and wild-type show a ~2-log and ~1-log increase respectively in growth 
when co-cultured with V. fluvialis, however when the same strains are co-cultured 
with 99-734, there is ~3-log increase in growth. Additionally the raw data shown in 
Figure 6.2 shows there is no recovery of any T6SS1 mutant cells following co-culture 
with V. fluvialis. This led to the hypothesis that V. fluvialis may contain a functional 
T6SS that was active at 37oC and was able to target V. vulnificus on the TCBS 
enumeration plates. This hypothesised targeting of V. fluvialis against V. vulnificus, 
would account for the inability to recover ∆T6SS1 cells, as these cells would be 
unable to mount an attack on V. fluvialis due to ∆T6SS1 being unable to assemble a 
functional T6SS.  
To test the hypothesis that V. fluvialis was killing V. vulnificus at 37oC on the TCBS 
enumeration plates, antibiotic resistant attacker and prey strains were generated. V. 
vulnificus 106-2A wild-type, ∆T6SS1 and ∆T6SS2 were engineered to harbour 
trimethoprim resistance encoded on the plasmid pSCrhaB3 (Figure 6.3) whereas V. 
fluvialis was made chloramphenicol resistant by introducing the plasmid, pBHR-RFP 
(Figure 6.3). The antibiotic resistance allowed for the prey and attackers strains to be 
enumerated separately on selective plates following the co-culture killing assay 
rather than in concurrence on TCBS plates, thereby removing the ability for the 
strains to target one another on the enumeration plates.  
 
Figure 6.3: Plasmid maps for pSCrhaB3 and pBHR-RFP. The plasmid maps represent the genes encoded on 
each plasmid. In particular, trimethoprim resistance is in encoded by dhfr on pSRrhaB3 and chloramphenicol 
resistance by cm on pBHR-RFP.  
126 
 
6.2.2 V. fluvialis NCTC 11327 can target V. vulnificus 106-2A ∆T6SS1 at 37oC 
The results of the co-culture killing assays using the antibiotic resistant strains are 
shown in Figure 6.4. Assessment of the graph demonstrates that the prey strain, V. 
fluvialis is able to survive significantly better when co-cultured with ∆T6SS1 then 
when co-cultured with the wild-type strain. The data from this co-culture assay, which 
uses antibiotic resistant strains, also shows that there is no significant difference in 
the survival of V. fluvialis when co-cultured with either ∆T6SS2 or the wild-type 
strain, demonstrating that the killing seen by the wild-type strain is due to T6SS1 and 
not T6SS2.  
 
 
Figure 6.4: Genetically engineered antibiotic resistant strains demonstrate that the T6SS1 of V. vulnificus 
106-2A can target V. fluvialis NCTC 11327 at 30
o
C. Fold change in growth (cfu/ml) of the prey and attacker 
strains when enumerated using antibiotic selective plates. Shown in yellow is the prey strain V. fluvialis and 
shown in green is the attacker strains, V. vulnificus 106-2A wild-type, ∆T6SS1 mutant or ∆T6SS2 mutant. Assays 
were performed three times in triplicate, each spot on the graph represents a co-culture killing assay and error 
bars show standard error of the mean. Statistics were performed using the unpaired two-way Student’s t-test, * P 
< 0.05.   
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Figure 6.5: Co-culture killing assay using 
genetically engineered antibiotic resistant 
prey and attacker strains. Co-culture assay 
using the attacker strains, V. vulnificus 106-2A 
wild-type (106-2A WT), ∆T6SS1 mutant (106-
2A:IcmF1), ∆T6SS2 mutant (106-2A:IcmF2) 
shown in green and the prey strain, V. fluvialis 
(V. fluvialis) shown in yellow, followed by 
enumeration of strains using antibiotic selection 
plates. Shown in green are the results gained for 
the attacker strains at T0 and T5 and shown in 
yellow are the results for the prey strain at T0 
and T5. To the right of each attacker strain 
shown in green is the corresponding prey strain 
shown in yellow. Results show V. fluvialis 
survives significantly better when cultured with 
∆T6SS1 mutant compared to 106-2A wild-type 
strain. Assays were performed 3 times in 
triplicate, each spot on the graph represents a 
co-culture killing assay and error bars show 
standard error of the mean. Statistics were 
performed using the unpaired 2-way Student’s t-test, * P < 0.05.   
Analysis of the survival of the attacker strains when enumerated separately using 
antibiotic selection plates, demonstrates that V. fluvialis can no longer target 
∆T6SS1, as survival of ∆T6SS1 is comparable to wild-type levels. This is due to the 
strains not being in contact on the enumeration plates. Furthermore, the raw data in 
Figure 6.5 demonstrates that following co-culture with V. fluvialis, ∆T6SS1 cells can 
be recovered when using the antibiotic enumeration plates, unlike the previous 
experiment in which ∆T6SS1 cells could not be recovered when enumerated on 
TCBS agar plates when V. fluvialis is present.     
The data presented in Figure 6.6 further highlights the difference in survival of V. 
vulnificus ∆T6SS1 when enumerated on TCBS agar compared to the antibiotic 
plates following co-culture with V. fluvialis the graph in Figure 6.4 was generated. 
Figure 6.6 shows the fold-change levels for the V. vulnificus attacker strains shown 
in green when enumerated on TCBS agar. Shown in red, is the V. vulnificus attacker 
strains survival when enumerated on antibiotic plates. The graph shows the fold 
change in ∆T6SS1 survival is significantly greater when enumerated on antibiotic 
selection plates compared to TCBS agar plates, where P < 0.05, when compared 
using the student’s t-test.  
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Figure 6.6: Survival of V. vulnificus strains when enumerated on either TCBS agar plates or antibiotic 
selection plates, following co-culture with V. fluvialis. Fold change in recovery of the attacker strains, V. 
vulnificus 106-2A wild-type, ∆T6SS1 mutant or ∆T6SS2 mutant when co-cultured with V. fluvialis. Shown in green 
is the fold change in recovery for V. vulnificus 106-2A wild-type, ∆T6SS1 mutant or ∆T6SS2 when enumerated on 
TCBS agar plates and shown in red is fold change in recovery for V. vulnificus 106-2A wild-type, ∆T6SS1 mutant 
or ∆T6SS2 when enumerated on antibiotic selection plates. Assays were performed three times in triplicate, each 
spot on the graph represents a co-culture killing assay and error bars show standard error of the mean. Statistics 
were performed using the unpaired two-way Student’s t-test, * P < 0.05.   
It was also noted that the fold change in V. fluvialis recovery was different between 
Figure 6.1 and Figure 6.4. It was therefore speculated that the difference could be 
due to the instability of the antibiotic resistance plasmid in V. fluvialis, which could 
lead to the antibiotic killing of V. fluvialis on antibiotic enumeration plates. To test this 
hypothesis a plasmid stability test was carried out. The graph in A7 of the Appendix 
illustrates the results gained for plasmid stability test in V. fluvialis, which was 
performed as detailed in the Materials and Methods. The results demonstrate that 
the plasmid is not stable during the five hour co-culture conditions when there is no 
selection pressure present, as there is a statistically significant difference in the 
cfu/mL counts between the TCBS agar plates and the antibiotic plates, where 
P<0.05, when analysed using the student’s t-test. In addition to the instability of the 
plasmid, the difference in V. fluvialis survival between Figure 6.1 and Figure 6.4 may 
also be due the antibiotic on the enumeration plates and the temperature shift from 
30oC to 37oC causing a stress on the cells, which may cause the cells to enter a 
viable but non-culturable state.  
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6.2.3 WGS sequencing of V. fluvialis NCTC 11327  
As the current study hypothesised that V. fluvialis NCTC 11327 contained a T6SS 
that was targeting V. vulnificus at 37oC, WGS was carried out on the V. fluvialis 
NCTC 11327 strain to identify a T6SS locus. The data generated from WGS was 
assembled using a5 and annotated using the RAST server. Using a combination of 
the RAST and NCBI BLAST searches of ORFs, two T6SSs were found in V. fluvialis, 
these T6SSs termed VF T6SS1 and VF T6SS2 are shown in Figure 6.7. 
 
 
Figure 6.7: The gene organisation of the 2 T6SSs from V. fluvialis NCTC 11327. Schematic gene 
organisation for the 2 T6SSs, denoted VF T6SS1 and VF T6SS2 identified in V. fluvialis NCTC 11327 by RAST 
annotation of assembled WGS scaffolds. For comparison the T6SS1 and T6SS2 from V. vulnificus 106-2A is also 
shown. 
 
The gene organisations of the T6SSs in V. fluvialis were compared to the genetic 
organisation of the T6SSs in V. vulnificus. This demonstrated a high degree of 
synteny between the two secretion systems. For example, V. fluvialis contains a 
T6SS, denoted VF T6SS1 (Figure 6.7) that was identical in gene organisation to 
T6SS1 of V. vulnificus. The second T6SS identified in V. fluvialis, denoted VF T6SS2 
(Figure 6.7) had synteny with the T6SS2 of V. vulnificus. However the icmF gene in 
the second secretion system identified in V. fluvialis contained an uncharacteristically 
short icmF gene.  
In conclusion, the current study has shown that V. vulnificus is able to target V. 
fluvialis at 30oC in a T6SS1 dependent manner. However, inactivation of the T6SS1 
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by way of an in frame deletion to the icmF gene renders the secretion system non-
functional, allowing for V. fluvialis to target V. vulnificus at 37oC. This was 
demonstrated as following co-incubation of TCBS enumeration plates at 37oC, the 
study was unable to recover V. vulnificus ∆T6SS1 cells. However, when the strains 
were engineered to harbour antibiotic resistance and enumerated separately on 
antibiotic selection plates, V. fluvialis was no longer able to target V. vulnificus 
∆T6SS1. In light of these findings the study performed WGS on V. fluvialis NCTC 
11327, as it was hypothesised that the targeting ability of V. fluvialis may be due to a 
T6SS. Analysis of WGS data demonstrated that V. fluvialis contained two T6SSs, 
termed VF T6SS1 and VF T6SS2. Although this study has demonstrated that V. 
fluvialis contains two T6SSs, further investigation is needed to determine whether 
they are functional. In addition, mutagenesis studies would need to be performed to 
determine whether the targeting of V. vulnificus by V. fluvialis is due to VF T6SS1, 
VF T6SS2, a combination of both, or an alternative factor.  
6.2.4 The T6SS1 of V. vulnificus 106-2A is involved in killing non-Vibrio species  
The demonstrated ability of T6SS1 from V. vulnificus to target a T6SS1 negative V. 
vulnificus strain and other Vibrio species, led to the hypothesis that the T6SS1 may 
also be able to target other non-Vibrio species. To test this hypothesis, co-culture 
killing assays were performed with B. thailandensis as prey. Enumeration of V. 
vulnificus was performed on TCBS agar plates. B. thailandensis was engineered to 
harbour chloramphenicol resistance by the introduction of the plasmid pBHR-RFP 
and was enumerated on chloramphenicol plates. This was done as TCBS does not 
support the growth of B. thailandensis and V. vulnificus cannot grow in the presence 
of chloramphenicol. Fold change in recovered viable cfu/mL for B. thailandensis 
following co-culture with either V. vulnificus 106-2A wild-type, ∆T6SS1 or ∆T6SS2 is 
presented in Figure 6.8.  
The results show that T6SS1 is able to successfully target B. thailandensis in T6SS1 
dependent manner. The results indicate that the killing is due to T6SS1 and not 
T6SS2 as there is no significant difference between the survival of B. thailandensis 
when it is co-cultured with either 106-2A wild-type of ∆T6SS2. Additionally shown in 
Figure 6.8 is the fold change in growth of V. vulnificus strains when co-cultured with 
B. thailandensis. The results show that V. vulnificus is able to survive in the presence 
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of B. thailandensis as there is an increase in the fold change of recovered viable 
cells for all the V. vulnificus strains tested. The raw date for Figure 6.8 is presented 
in Figure 6.9. 
 
Figure 6.8: The T6SS1 from V. vulnificus 106-2A is able to target B. thailandensis E264 during a co-
culture assay. The fold change in the recovery (cfu/ml) of the prey strain, B. thailandensis is shown in yellow 
when co-cultured with either V. vulnificus 106-2A wild-type, ∆T6SS1 mutant or ∆T6SS2 mutant, the x-axis 
displays strain used in a single co-culture assay. Shown in green is the fold change in recovery for the attacker 
strains, V. vulnificus 106-2A wild-type, ∆T6SS1 mutant or ∆T6SS2 mutant. Assays were performed three times in 
triplicate, each spot on the graph represents a co-culture killing assay and error bars show standard error of the 
mean. Statistics were performed using the unpaired two-way Student’s t-test, *** P < 0.0005.   
 
Figure 6.9: T6SS1 from V. vulnificus 106-2A 
is able to target B. thailandensis. Co-culture 
assay using the attacker strains, V. vulnificus 
106-2A wild-type (106-2A WT), ∆T6SS1 mutant 
(106-2A:IcmF1), ∆T6SS2 mutant (106-
2A:IcmF2) shown in green and the prey strain, 
B. thailandensis (B. thail) shown in yellow. 
Shown in green are the results gained for the 
attacker strains at T0 and T5 and shown in 
yellow are the results for the prey strain at T0 
and T5. To the right of each attacker strain 
shown in green is the corresponding prey strain 
shown in yellow. Results show B. thailandensis 
survives significantly better when cultured with 
∆T6SS1 mutant compared to 106-2A wild-type 
strain. Experiments were performed three times 
in triplicate, error bars show standard error of 
the mean. Statistics were performed using the 
unpaired 1-way Student’s t-test, * P < 0.0005.    
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6.2.5 V. vulnificus contains alternative mechanisms for attacking B. 
thailandensis other than T6SS1    
Although the results shown in section 6.2.4 demonstrate that V. vulnificus can target 
B. thailandensis in a T6SS1 dependent manner, it was noted that the fold-change in 
growth for B. thailandensis was much lower than for the fold change in growth of V. 
fluvialis as shown in Figure 6.1. Therefore the study hypothesised that V. vulnificus 
may produce effectors other than those secreted by T6SS1 that may target B. 
thailandensis. To test this hypothesis a negative control was also assayed, this was 
where B. thailandensis was mixed with LB in place of the attacker strain. The study 
did not include the ∆T6SS2 mutant in the assay as according to the data shown in 
Figure 6.6, targeting of B. thailandensis by V. vulnificus 106-2A is due to T6SS1 and 
not T6SS2. The graph in Figure 6.10 shows the fold change in recovered viable cells 
when B. thailandensis is co-cultured with either V. vulnificus 106-2A wild-type, 
∆T6SS1 and LB media (negative control). The raw data for the graph shown in 
Figure 6.10 is presented in Figure 6.11.   
 
 
Figure 6.10: Co-culture killing assay with V. vulnificus and B. thailandensis with a 24 hour incubation 
period. The fold change in recovery (cfu/ml) of the prey strain, B. thailandensis is shown in yellow when co-
cultured with either V. vulnificus 106-2A wild-type, ∆T6SS1 mutant or LB as a negative control. Shown in green is 
the fold change in recovery of the attacker strains, V. vulnificus 106-2A wild-type and ∆T6SS1 mutant. Assays 
were performed three times in triplicate, each spot on the graph represents a co-culture killing assay and error 
bars show standard error of the mean. Statistics were performed using the unpaired two-way Student’s t-test, ** 
P < 0.005, *** P < 0.0005.   
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Figure 6.11: Co-culture killing assay with V. 
vulnificus and B. thailandensis with a 24 
hour incubation period. Co-culture assay 
using the attacker strains, V. vulnificus 106-2A 
wild-type (106-2A WT) and ∆T6SS1 mutant 
(106-2A:IcmF1) shown in green and the prey 
strain, B. thailandensis (B. thail) shown in 
yellow were performed for 24 hours. Shown in 
green are the results gained for the attacker 
strains at T0 and T24 and shown in yellow are 
the results for the prey strain at T0 and T24. 
To the right of each attacker strain shown in 
green is the corresponding prey strain shown 
in yellow. Results show B. thailandensis 
survives significantly better when cultured with 
∆T6SS1 mutant compared to 106-2A wild-type 
strain, however residual prey B. thailandensis 
is still able to survive following a longer 
incubation period. Experiments were 
performed three times in triplicate, error bars 
show standard error of the mean. Statistics 
were performed using the unpaired 1-way 
Student’s t-test, * P < 0.0005.    
The results in Figure 6.10 show the survival of B. thailandensis is significantly 
greater when co-cultured with the T6SS1 mutant compared to the wild-type strain. 
Furthermore, comparison of the B. thailandensis negative control compared with B. 
thailandensis recovery when cultured with ∆T6SS1, shows that B. thailandensis is 
able to survive significantly better in the negative control. This suggests that V. 
vulnificus may produce other factors other than T6SS1 effectors that can target B. 
thailandensis; furthermore the negative control demonstrates that the reduction of B. 
thailandensis when co-cultured with the wild-type strain is due to V. vulnificus and 
not due to the assay conditions.  
Secondary to the negative control, the study increased the co-culture incubation 
period from five hours to 24 hours. This was done as it was noted that following co-
culture with V. vulnificus 106-2A wild-type there was residual B. thailandensis cells 
that were able to survive the co-culture period. A result which was seen in the 
majority of co-culture assays performed in this study. Therefore the current study 
hypothesised that a longer co-incubation may remove the ability of residual prey 
cells to survive. This hypothesis was tested by incubating the co-culture cells for 24 
hours instead of five hours. However, the image in Figure 6.10 shows that a longer 
incubation period does not improve the killing ability of V. vulnificus 106-2A wild-type 
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as residual B. thailandensis cells are still recovered, as seen in Figure 6.10 and 
Figure 6.11. 
In conclusion this study has shown that the T6SS1 of V. vulnificus can target both 
Vibrio and non-Vibrio species, allowing T6SS1 positive V. vulnificus cells to partake 
in both intra and inter-species targeting. The study has additionally demonstrated 
that V. vulnificus can produce effectors other than T6SS1 effectors which are able to 
target alternative Gram negative bacterial species.  
6.2.9 The effects of V. vulnificus T6SS2 on Galleria mellonella   
As the T6SS1 from V. vulnificus 106-2A had been shown to efficiently target 
prokaryotic cells, it was questioned whether T6SS2 from V.vulnificus 106-2A was 
able to target eukaryotic cells. To test this hypothesis the infection model G. 
mellonella was used. Preliminary experiments, demonstrated that V. vulnificus was 
virulent towards G. mellonella when challenged using a bacterial load ~107 cfu/10µl 
at 37oC in 24 hours, therefore a bacterial load of 105 cfu/10 µl was used to challenge 
G. mellonella in further studies. The lower dose was used to ensure not all strains 
were killed rapidly to allow an assessment of killing over a longer period of time. The 
infection was carried out at 37oC and not 30oC as a preliminary study shown in 
Appendix A8 with one time point assayed at 24 hours, demonstrated that the T6SS2 
mutant was attenuated at 37oC but not at 30oC. To further validate the results seen 
in the preliminary infection model a full infection study was carried out. The infection 
study was repeated three times and with groups of ten larvae used for each strain, 
larvae were monitored for death at time points, 24, 30 and 48 hours post challenge. 
Death was assessed by an unresponsiveness to touch.  
The survival graph shown in Figure 6.12 illustrates the data gained for the infection 
study using V. vulnificus 106-2A wild-type and the ∆T6SS1 and ∆T6SS2 mutants, 
∆T6SS1 was included as a control.  
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Figure 6.12: Galleria mellonella infection study using V. vulnificus 106-2A wild-type and T6SS1 and 
T6SS2 mutants incubated at 37
o
C. The survival graph demonstrates the survival (%) of G. mellonella following 
challenge with either V. vulnificus 106-2A wild-type or the ∆T6SS1 mutant or ∆T6SS2 mutant. G. mellonella were 
challenged with 10
5
 cfu/ml of each strain which had been grown to mid-log phase at 37
o
C. Shown in blue is G. 
mellonella survival following PBS injection. Larvae were assessed for death at T24, T30 and T48 hours.  
Experiments were performed three times where n=10.  
 
The results indicate that although preliminary studies suggested that ∆T6SS2 may 
be attenuated compared to the wild-type strain when incubated at 37oC, repeats of 
this study show that neither ∆T6SS1 nor ∆T6SS2 are attenuated at 37oC compared 
to the wild-type strain, as there is no statistically significant difference between the 
strains. All of the G. mellonella injected with PBS as a negative control survived, 
which demonstrate that the effects seen in the infected galleria are due to the 
bacteria and are not due to any of the other effects from the study such as the 
injecting process.  
6.3 Discussion 
Using a co-culture assay Chapter five demonstrated that T6SS1 of V. vulnificus 106-
2A can target the T6SS1 negative V. vulnificus strain, 99-743. It was therefore 
hypothesised that T6SS1 may also be able to target alternative Gram negative 
bacteria. To test this, the study explored the ability of T6SS1 to target the alternative 
Vibrio species, V. fluvialis NCTC 11327 and the alternative Gram negative species, 
B. thailandensis. The study included the ∆T6SS2 mutant as a control in all co-culture 
assays as it was further speculated that T6SS1 may be specific to targeting V. 
vulnificus and T6SS2 may be involved with targeting alternative Gram negative 
species.  
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The results from the co-culture assays demonstrated that T6SS1 was responsible for 
targeting V. fluvialis at 30oC, however T6SS2 was not. The presented data further 
revealed that at 37oC V. fluvialis can target ∆T6SS1 V. vulnificus cells. As co-
enumeration of V. fluvialis and V. vulnificus ∆T6SS1 on TCBS enumeration plates 
demonstrated that V. vulnificus ∆T6SS1 was unable to survive, as no cells were 
recovered on the enumeration plates. However, when the cells were engineered to 
contain antibiotic resistance plasmids and the cells were enumerated separately, the 
study was able to recover V. vulnificus ∆T6SS1 cells. Therefore, the study 
hypothesised that V. fluvialis may contain a T6SS that could target V. vulnificus at 
37oC when V. vulnificus T6SS1 is inactive. To identify whether V. fluvialis contained 
at T6SS, WGS and gene annotation was performed. This revealed that V. fluvialis 
contains two T6SSs, termed VF T6SS1 and VF T6SS2, both of which share synteny 
to the genetic organisation of T6SS1 and T6SS2 from V. vulnificus. A literature 
search on V. fluvialis and secretion systems found that a bioinformatic study has 
previously described the presence of the T6SS in V. fluvialis [318]. However, 
whether the T6SS is functional remains to be elucidated as the study did not follow 
up the findings with functionality tests. Therefore, although it is possible that the 
T6SSs encoded by V. fluvialis may be targeting V. vulnificus at 37oC, further 
mutagenesis studies in V. fluvialis would need to be performed to test whether the 
secretion systems are functional at 37oC and whether they are able to target V. 
vulnificus cells.  
Ingestion of V. vulnificus can lead to life threatening septicaemia that can progress to 
death [20, 36]. V. fluvialis on the other hand, is more commonly associated with 
occasional diarrhoeal diseases, and is very rarely associated with septicaemia [318, 
319]. V. vulnificus infection is often correlated with the consumption of raw or 
uncooked oysters [36], in addition to oysters containing V. vulnificus, oysters are also 
known to harbour the pathogen, V. fluvialis [319-321]. It is also documented in the 
literature that oysters are often colonised by a mixture of Vibrio species and not one 
particular strain [13, 319, 320]. As V. fluvialis can target V. vulnificus at 37oC, this 
also may provide a possible explanation of why there are relatively few serious V. 
vulnificus infections compared to the natural prevalence of this bacterium in the 
environment. 
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For example, if the majority of the V. vulnificus strains in the environment are T6SS1 
negative, then upon human ingestion of an oyster contaminated with both V. 
vulnificus and V. fluvialis, the temperature would be elevated to 37oC, a temperature 
at which V. fluvialis can target V. vulnificus. Once inside a human V. fluvialis may 
target V. vulnificus, which may lead to control of V. vulnificus within the host, which 
may contribute to the low levels of V. vulnificus disease observed. These claims 
however would need to be further assessed by carrying out experimental work to 
understand the role of the T6SS in vivo in both an oyster and human model of 
infection.  
In addition to demonstrating the ability of T6SS1 to target alternative Vibrio species, 
the current study also demonstrated that the T6SS1 of V. vulnificus 106-2A was able 
to target non-Vibrio species, by performing co-culture assays with the prey strain, B. 
thailandensis. These studies showed that V. vulnificus 106-2A was able to target B. 
thailandensis in a T6SS1 dependent manner. Furthermore the current study also 
showed that V. vulnificus produces effectors other than T6SS1 effectors that are able 
to target B. thailandensis in an antagonistic manner.   
The literature describes B. thailandensis as containing 5 T6SSs [248]. The T6SS1 
and T6SS5 of B. thailandensis have distinct roles in pathogenicity, with T6SS1 
involved in targeting prokaryotic cells and T6SS5 involved in targeting eukaryotic 
cells [248]. Although the T6SS1 of B. thailandensis can efficiently target bacteria 
species such as Pseudomonas putida, Pseudomonas fluorescens and Serratia 
proteamaculans, it was unable to successfully target Vibrio species such as V. 
cholerae and V. parahaemolyticus [248]. Therefore it is unsurprising that V. vulnificus 
was also not targeted by B. thailandensis. However, V. vulnificus could target B. 
thailandensis. The results in the current assay are comparable to the B. 
thailandensis data presented by Schwarz et al., [248] as the competition assays 
were both performed at 30oC and therefore it cannot be said that it is unlikely that the 
T6SS of B. thailandensis is inactive due to difference temperatures [248]. In addition 
to demonstrating that the T6SS1 of V. vulnificus could target B. thailandensis the 
assay conditions demonstrated that there was a significant difference in the survival 
of B. thailandensis when it was grown with either LB alone or the T6SS1 mutant. 
This would suggest that there are other factors produced by V. vulnificus other than 
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T6SS1 effectors that can target B. thailandensis. This is unsurprising as it has been 
shown that different bacterial species produce an array of antimicrobial compounds 
other than effectors from the T6SS that are involved with targeting other bacterial 
cells [322, 323].     
To further characterise the T6SSs in V. vulnificus, the wild-type strain, 106-2A and 
∆T6SS1 and ∆T6SS2 mutants were assayed in a eukaryotic model of infection. As 
previous literature reports have demonstrated that the T6SS is able to target 
eukaryotic cells [231, 237, 245, 274]. Therefore, the current study investigated the 
anti-eukaryotic properties of T6SS2 using a G. mellonella model of infection, as it 
was hypothesised that like B. thailandensis, the two T6SSs in V. vulnificus 106-2A 
may have distinct roles in virulence. Whereby T6SS1 is involved with targeting 
prokaryotic cells and T6SS2 is involved with targeting eukaryotic cells. However, the 
results from the current study demonstrated that V. vulnificus T6SS2 was not virulent 
towards G. mellonella, the ∆T6SS1 mutant was also assayed as a control which had 
no effect on the G. mellonella. This is unsurprising at T6SS1 is inactive at 37oC, 
furthermore the results for T6SS1 are in agreement with previously published data 
for S. marcescens, which demonstrated that the anti-prokaryotic T6SS of S. 
marcescens is ineffective at targeting G. mellonella [234].  
6.4 Conclusion 
In conclusion, the current study has shown that V. vulnificus 106-2A can utilise its 
T6SS1 to target a range of Gram negative bacterial species, such as B. 
thailandensis and V. fluvialis. However the study further demonstrated that at 37oC a 
∆T6SS1 mutant of V. vulnificus 106-2A can be targeted by V. fluvialis. WGS 
sequencing of this V. fluvialis strain demonstrated that V. fluvialis encodes two 
T6SSs, which share synteny with T6SS1 and T6SS2 of V. vulnificus. However, 
further mutagenesis research would be required to elucidate if these secretion 
systems are targeting V. vulnificus at 37oC.  
In addition to testing the anti-prokaryotic abilities of T6SS1, the anti-eukaryotic 
effects of T6SS1 and T6SS2 were also tested in the eukaryotic infection model, G. 
mellonella. However the results demonstrated that neither a ∆T6SS1 or ∆T6SS2 
mutant was attenuated for virulence.  
139 
 
Following on from the characterisation of T6SS1, complementation of the icmF gene 
was attempted, this was done to understand if in trans complementation of the icmF 
gene restored the ∆T6SS1 mutant phenotypes to wild-type levels.  
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Chapter 7 Complementation of T6SS1 in V. 
vulnificus 106-2A 
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7.1 Introduction and aim 
The current study generated in-frame icmF deletion mutants in T6SS1 and T6SS2 in 
V. vulnificus 106-2A. The ∆T6SS1 mutant was used in Western blot experiments to 
attribute the secretion of the hall mark Hcp protein in 106-2A wild-type to T6SS1. 
Furthermore, the ∆T6SS1 mutant was used in several co-culture assays to 
demonstrate that the T6SS1 of V. vulnificus 106-2A is responsible for targeting 
several different Gram negative species.   
To confirm that the phenotypic effects seen in the ∆T6SS1 mutant were due to the 
in-frame deletion of icmF, the ∆T6SS1 mutant strain was complemented with a wild-
type copy of the icmF gene. Previous T6SS complementation studies in V. cholerae 
have demonstrated that an icmF deletion mutant was successfully complemented 
using the arabinose inducible expression vector, pBAD24 [231]. Therefore the 
current study aimed to complement 106-2A ∆T6SS1 using a similar approach.  
7.2 Results  
7.2.1 Construction of a complementing plasmid, pSRC14 
The current study utilised the expression vector, pBAD24 for complementation. This 
method was chosen as an icmF deletion mutant in V. cholerae V52 was successfully 
complemented using a pBAD24 derivative plasmid [245, 295]. The pBAD24 vector 
contains the PBAD promotor allowing for the controlled expression of proteins. In 
addition, the vector contains a Shine-Dalgarno ribosome binding site and a start 
codon. To construct the pBAD24 complement vector the wild-type icmF gene was 
amplified from V. vulnificus 106-2A using the primers, icmF1 Final F pBAD SmaI and 
icmF1 Final R pBAD SphI, as shown in Figure 7.1.  
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Figure 7.1: Construction of the complement plasmid, pSRC14. The complementation plasmid, pSRC14 was 
generated by amplifying the V. vulnificus 106-2A wild-type icmF gene using the primers indicated. The correctly 
sequenced icmF gene was ligated into pBAD24, following digestion of the pBAD24 vector with SmaI and SphI 
restriction enzymes. The resulting complement vector, pSRC14 is shown.  
 
The ~3500bp icmF gene from T6SS1 was amplified using the KOD Xtreme™ Hot 
Start DNA Polymerase, which enables amplification of long DNA templates. 
Following PCR amplification, the gel purified icmF gene was A-tailed as detailed in 
the Materials and Methods and ligated into the pGEM-T-easy holding vector, to 
produce pSRC13. pSRC13 was then sequenced. To ensure the entire length of the 
icmF was fully sequenced, a primer walking method was utilised using the primers, 
Seq_1 - Seq_5, including M13F, M13R, icmF1 Final F pBAD SmaI and icmF1 Final 
R pBAD SphI. Correctly sequenced icmF regions were then digested with SmaI and 
SphI and ligated into SmaI and SphI digested pBAD24. These ligations were then 
transformed into E. coli S17 cells. 
Potential E. coli clones containing pSRC14 (Figure 7.1) were checked by a 
restriction digest on the mini-prepped plasmids using SmaI and SphI. The digestion 
profile shown in Figure 7.2, demonstrates that 6 clones tested gave the correct 
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digestion profile. The 3554bp band corresponds to the icmF gene, with the pBAD24 
backbone producing a 4511bp band. 
 
Figure 7.2: Gel electrophoresis image of the digestion profile for pSRC14 using SmaI and SphI. An uncut 
control of each pSRC14 clone is shown in lanes 1, 5, 9, 13, 17 and 21. A corresponding double digest, using 
SmaI and SphI is shown to the right of each uncut plasmid, lanes, 2, 6, 10, 14, 17 and 22. Control single digests 
are also shown to the right of each double digest using Smal or SphI, demonstrating that both enzymes cut. The 
DNA ladder marker used is indicated with (M). Double digests produce the 3554bp and 4511bp bands, which 
correspond to the icmF gene and pBAD24 backbone respectively. Singularly cut pSRC14 produces a band 
8065bp. 
 
pSRC14 was then conjugated into V. vulnificus 106-2A ∆T6SS1 using the helper 
strain E. coli pRK2013. Following conjugation, potential V. vulnificus clones 
containing pSRC14 were checked by PCR. Figure 7.3 is a gel electrophoresis image 
of a PCR carried out using the primers icmF1 Final F pBAD SmaI and icmF1 Final R 
pBAD SphI on mini-preps from two complemented clones. This PCR amplified the 
wild-type icmF gene from the plasmid DNA (Figure 6.3, lanes 1 and 2). In addition, 
the truncated mutated icmF gene from the mutant’s gDNA was also amplified (Figure 
7.3, lanes 1 and 2), indicating that some gDNA also came through in the plasmid 
preparation. This produced two bands as seen in the gel electrophoresis image in 
Figure 7.3. This result confirms the successful construction of a complementing 
strains containing, pSRC14.  
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Figure 7.3 Gel electrophoresis image of a PCR 
carried out on V. vulnificus 106-2A ∆T6SS1 clones 
containing pSRC14. Lanes 1 and 2 show the 
amplification of the wild-type icmF gene, 3554bp in 
length from plasmid DNA. In addition, the truncated 
icmF gene, 497bp in length was amplified from the 
gDNA which was pulled through during the plasmid 
preparation. A positive control run in lane 3 is wild-type 
gDNA showing the amplification of the wild-type icmF 
gene. Lane 3 is a negative control. Lanes M contain 
the DNA ladders. 
 
 
 
7.2.2 Complementation of ∆T6SS1 with pSRC14. 
To assess whether pSRC14 complemented V. vulnificus 106-2A ∆T6SS1, Western 
blotting using the Hcp antibody was performed to identify restored Hcp secretion. V. 
vulnificus ∆T6SS1 cells containing pSRC14 were grown as described previously in 
Chapter five, with the addition of 0.1% w/v arabinose. Cells were grown to mid-log 
phase and then prepared for protein extraction and Western blotting as detailed in 
the Materials and Methods.  
The Western blot in Figure 7.4 shows that Hcp can be detected in both the cell lysate 
and the supernatant of V. vulnificus 106-2A wild-type (lanes 1 and 2). As seen 
previously (Figure 5.7) Hcp is only detected in the cell lysate of the 106-2A ∆T6SS1 
mutant strain (lanes 3). In lane 8 it can be seen that there appears to be some Hcp in 
the culture filtrate of ∆T6SS1::pSRC14. This suggests that pSRC14 has successfully 
complemented the mutation in ∆T6SS1. There is no detection of Hcp in the 
supernatant for the empty vector control, ∆T6SS1::pBAD24 (lane 6). Therefore Hcp 
detected in the supernatant of the complement strain can be assumed to be due to 
complementation by pSRC14.  
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Figure 7.4: Western blot using anti-
Hcp antibody to detect Hcp secretion 
in a ∆icmF complement strain. V. 
vulnificus cells lysate (C) and culture 
filtrates (S) from cells grown at 30
o
C in 
LB supplemented with 0.1% arabinose. 
Hcp detection ~23 kDa, Hcp detection in 
∆T6SS1::pSRC14 is indicated with a 
white arrow ~23 ug protein/lane. 
Corresponding Ponceau S stains shown 
in Appendix A9. Protein marker is 
represented with (M).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 also shows that there is a marked difference in secretion of Hcp between 
V. vulnificus 106-2A wild-type and ∆T6SS1::pSRC14, with the latter having a 
significantly reduced amount of observed Hcp in the culture filtrate. Therefore the 
study performed an optimisation experiment to monitor levels of Hcp secretion in 
∆T6SS1::pSRC14. 
7.2.3 Optimisation of Hcp secretion by 106-2A ∆T6SS1::pSRC14 
Optimisation experiments to maximise expression levels of Hcp secretion from 
∆T6SS1::pSRC14 were conducted using the following conditions; an overnight 
culture of the complement strain was back diluted to an OD590nm of 0.03 and then 
grown to an OD590nm of 0.18. The cells were then induced with 0.1% v/v arabinose 
and at four and six hours post induction samples were taken for protein preparation 
as outlined in the Materials and Methods. During the optimisation experiment an 
additional clone was also included to see if the impaired Hcp secretion seen in the 
complement strain in Figure 7.4 was due to an irregular clone. The Western blot 
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image in Figure 7.5 demonstrates the results gained from the optimisation 
experiment using two different complemented strains.  
 
Figure 7.5: Optimisation Western blot using anti-Hcp antibody to detect Hcp secretion in an icmF 
complemented mutant. Cells lysate (C) and culture filtrates (S) from two ∆T6SS1::pSRC14 clones, A and B 
grown at 30
o
C in LB supplemented with 0.1% arabinose. T4 and T6, indicated above each lane correspond to 
samples taken for protein preparation following 0.1% arabinose induction. Hcp detection ~23 kDa, corresponding 
Ponceau S stains shown. ~ 30 ug protein/lane. Protein marker is represented with (M).  
 
Analysis of Figure 7.5 shows that Hcp can be detected in both the cell lysate and the 
supernatant at both T4 and T6 for clones A and B (lanes 1-8). However, at T6 the 
culture filtrate shows signs of cell lysis, as judged by detection of additional bands in 
the supernatant that are also present in the cell lysate, which cannot be identified at 
T4. As there was no clear differences between the clones A and B in terms of levels 
of Hcp expression, clone A was chosen for further optimisation.  
Following on from the initial optimisation experiment, the Western blot was repeated 
including the strains, 106-2A wild-type, 106-2A ∆T6SS1, ∆T6SS1::pBAD24 as 
147 
 
controls. The 106-2A wild-type, 106-2A ∆T6SS1, 106-2A ∆T6SS1::pBAD24 and 106-
2A ∆T6SS1::pSRC14 were grown in LB alone to an OD590nm of 1.5 and proteins 
extracted, no arabinose was added to the media. The complement and empty vector 
strains however were induced with 0.1% arabinose at an OD590nm of 0.18 and grown 
to an OD590nm 3.0, which is the OD at four hour post induction. 
 
Figure 7.6: Western blot using anti-Hcp antibody to detect Hcp secretion. V. vulnificus cells lysate (C) and 
culture filtrates (S) from cells grown at 30
o
C in LB, ∆T6SS1::pBAD24 and ∆T6SS1::pSRC14 were induced with 
0.1% arabinose. Hcp can be detected at ~23 kDa, corresponding Ponceau S is shown, ~30 ug protein/lane. 
Protein marker is represented with (M). Indicated above each lane are the samples run in each lane. Image is a 
representative Western blot carried out on protein extractions from two independent experiments.  
 
The results in Figure 7.6 show Hcp is detected in the cell lysate and the supernatant 
of the 106-2A wild-type strain (lanes 1 and 2), whereas Hcp is only detected in the 
cell lysate for the ∆T6SS1 mutant (lane 3). On analysis of the T6SS1 complement 
strain, ∆T6SS1::pSRC14 there was detection of Hcp in both the cell lysate and 
supernatant (lanes 7 and 8), indicating potential complementation. However, 
analysis of the empty vector strain, ∆T6SS1::pBAD24, also showed detection of Hcp 
both in the cell lysate and the supernatant (lanes 5 and 6). This was an unexpected 
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result as the empty vector strain should give results akin to the ∆T6SS1 mutant. 
Further evaluation of the Western blot in Figure 7.6 also shows a higher detection of 
Hcp in the supernatant of ∆T6SS1::pSRC14 and ∆T6SS1::pBAD24 compared to the 
wild-type strain. A possible explanation for this increase in Hcp detection maybe due 
to growth at a higher OD for ∆T6SS1::pSRC14 and ∆T6SS1::pBAD24 compared to 
the wild-type and mutant strain. Although there is equal loading of total protein for 
each sample on the Western blot, as demonstrated by the Ponceau S stain, there is 
a higher abundance of certain proteins. For example, the prominent higher molecular 
weight band which is detected in the Ponceau S stain is more prominent for samples 
grown to a higher OD. Due to the detection of Hcp in the supernatant of 
∆T6SS1::pBAD24, the Hcp identified in ∆T6SS1::pSRC14 could not be assumed to 
be due to the in trans complementation of the icmF mutation. 
Investigative work to ensure that pBAD24 had been transformed into the ∆T6SS1 
mutant strain was conducted by PCR. Primers icmF1 Final F pBAD SmaI and icmF1 
Final R pBAD SphI were used on gDNA extracted from two different stocks of 
∆T6SS1::pBAD24 to ensure the strains were of T6SS1 background. Figure 7.7 
shows the amplification of the truncated version of icmF, demonstrating that 
∆T6SS1::pBAD24 is indeed a T6SS1 mutant. Proteins were again extracted from 
both these two stocks as described previously and Hcp secretion monitored by 
Western blotting. The Western blot image shown in Figure 7.8 clearly identified Hcp 
detection in the supernatant of both stocks. 
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Figure 7.7: Gel electrophoresis image of a PCR carried out 
on V. vulnificus 106-2A ∆T6SS1 pBAD24. The gel 
electrophoresis image shows a PCR carried out using the 
primers icmF1 Final F pBAD SmaI and icmF1 Final R pBAD 
SphI on gDNA extracted from V. vulnificus 106-2A ∆T6SS1 
pBAD24. The image shows the truncated icmF gene is 
amplified at 497bp in V. vulnificus 106-2A ∆T6SS1 pBAD24, in 
lanes 1 and 2. This demonstrates that the empty vector strain, 
V. vulnificus 106-2A pBAD24, is indeed a mutant and does not 
contain a copy of the wild-type gene. As a control gDNA was 
also extracted from V. vulnificus 106-2A wild-type 
demonstrating the amplification of the wild-type gene at 
3554bp in lane 3, a negative control was also run in lane 4 
demonstrating no amplification of any bands. The 100bp plus 
ladder is indicated in lane M, with the sizes at 4000bps, 
3500bps and 500bps indicated, bps= base pairs.  
 
 
 
 
Figure 7.8: Western blot using anti-Hcp antibody to detect Hcp secretion in V. vulnificus 106-2A 
∆T6SS1::pBAD24. Cells lysate (C) and culture filtrates (S) from V. vulnificus 1062A ∆T6SS1::pBAD24 cells from 
two separate stocks grown at 30
o
C in LB supplemented with 0.1% arabinose. Hcp can be detected at ~23 kDa, 
corresponding Ponceau S is shown. Protein marker is represented with (M).  
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7.2.4 Analysis of icmF transcription from T6SS1   
Investigative PCRs had demonstrated that ∆T6SS1::pBAD24 was indeed of ∆T6SS1 
mutant background. Therefore the study sought to monitor the transcription of icmF 
in ∆T6SS1::pBAD24. icmF transcription was also evaluated in the control strains, 
106-2A wild-type, 106-2A ∆T6SS1 and ∆T6SS1::pSRC14. Transcription of icmF was 
monitored by growing cells as described previously, followed by RNA extraction 
using the Qiagen RNeasy Mini Kit according to the manufacturer’s instructions. 
Extracted RNA was treated with DNase to remove residual DNA using the Life 
Technologies TURBO™ DNase kit according the manufacturer’s instructions and 
subjected to a PCR using V. vulnificus specific housekeeping primers, vvhA forward 
and reverse to ensure complete removal of DNA from the RNA samples. RNA was 
then reverse transcribed to generate cDNA as described in the Materials and 
Methods. cDNA samples were then ethanol precipitated to concentrate the samples 
and a PCR performed using the housekeeping primers vvhA forward and reverse to 
ensure cDNA had been generated. Following a positive result using the 
housekeeping primers, a PCR was performed using the primers MutScreen Forward 
and Reverse. These primers were chosen as they bind to the tssA genes flanking 
the icmF gene. The gel electrophoresis image in Figure 7.9 shows the PCR bands 
generated with the primers MutScreen Forward and Reverse. 
 
Figure 7.9: Gel electrophoresis image on cDNA using the 
MutScreen primers. Lane 1 contains, V. vulnificus 106-2A 
wild-type, amplifying a band ~4622bp lane 2, 106-2A 
∆T6SS1 (1573bp), lane 3, 106-2A ∆T6SS1::pBAD24 
(1573bp), lane 4 106-2A ∆T6SS1::pSRC14 (1573bp) and 
lane 5 contains a negative control. Fermentas 1kb plus DNA 
ladder is shown in lane M. 
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Analysis of Figure 7.9 shows cDNA icmF bands for the strains, 106-2A wild-type, 
106-2A ∆T6SS1, ∆T6SS1::pBAD24 and ∆T6SS1::pSRC14. Truncated icmF is 
expressed in the strains, 106-2A ∆T6SS1, ∆T6SS1::pBAD24 and ∆T6SS1::pSRC14 
further demonstrating that ∆T6SS1::pBAD24 is a mutant and is not expressing a 
wild-type version of the icmF gene. Furthermore the gel image in Figure 7.9 also 
shows that the generated icmF mutation has no effected the expression of the genes 
flanking icmF. Figure 7.9 however does not show whether wild-type icmF is being 
expressed in from pSRC14 in ∆T6SS1::pSRC14, therefore a PCR was performed on 
the cDNA samples again using the primers, icmF1_screen F and icmF1_screen R. 
The primers, icmF1_screen F and icmF1_screen R were designed as they amplify a 
234bp region internal to the wild-type icmF gene, therefore a PCR product will only 
be generated when wild-type icmF is being expressed. ∆T6SS1 will not generate a 
PCR product as the internal region of the icmF has been deleted. Figure 7.10 shows 
the gel electrophoresis image of a PCR carried out on cDNA using the primers, 
icmF1_screen F and icmF1_screen R for ∆T6SS1::pBAD24 and ∆T6SS1::pSRC14 
 
 
Figure 7.10: Monitoring wild-type icmF 
expression. Lane 1 contains, 106-2A 
∆T6SS1::pBAD24, lane 2, 106-2A 
∆T6SS1::pSRC14. gDNA controls are run in 
lanes 3-4. Lane 3, 106-2A wild-type, lane 4, 
106-2A ∆T6SS1 and lane 5, negative 
control. Fermentas 100bp plus DNA ladder is 
shown in lane M.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
Figure 7.10 shows cDNA from ∆T6SS1::pBAD24 (lane 1) is negative for the internal 
region of icmF, demonstrating that this strain does not contain wild-type icmF. 
However, in ∆T6SS1::pSRC14 (lane 2) the internal region of the icmF gene is being 
amplified. The results in Figure 7.10 coupled with the results in Figure 7.9 indicate 
that the wild-type icmF gene is expressed from pSRC14. 
In conclusion, the results of these sections demonstrate that the icmF gene is being 
transcribed in ∆T6SS1::pSRC14 from pSRC14. However, Western blot analysis 
demonstrated that in addition to the observation that Hcp is secreted into the 
supernatant of this strain, Hcp is also observed in the supernatant of 
∆T6SS1::pBAD24. Due to time constraints an initial qualitative killing assay was 
performed to determine whether, ∆T6SS1::pSRC14 displayed a killing phenotype 
similar to 106-2A wild-type. 
7.2.5 V. vulnificus 106-2A ∆T6SS1 pBAD24:icmF is unable to restore the killing 
phenotype associated with T6SS1. 
Earlier experiments detailed in this Chapter show that Hcp can be detected in the 
culture filtrate of ∆T6SS1::pSRC14. Therefore due to time constrains a qualitative 
killing assay was designed to assess the killing of ∆T6SS1::pSRC14 using the prey 
strain, V. vulnificus 99-743. The qualitative assay was performed using TCBS agar 
as detailed in the Materials and Methods. TCBS agar was chosen as the prey strain 
99-743 can be distinguished from the attacker strains, 106-2A wild-type, 106-2A 
∆T6SS1, ∆T6SS1::pBAD24 and ∆T6SS1::pSRC14 based on colour differences. The 
prey strain, 99-743 appears yellow on TCBS agar whereas the attacker strains listed 
above appear green. This colour difference allowed for the growth of each strain to 
be assessed when in co-culture on TCBS agar plates. The results of the qualitative 
co-culture assays are shown in Figure 7.11.  
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Figure 7.11: Qualitative killing assay to monitor T6SS1 associated killing. Image (A) shows V. vulnificus 
106-2A wild-type is able to target V. vulnificus 99-743 as there is only green growth on the plate with minimal 
yellow growth around the perimeter of growth as indicated with white arrows. (B) The T6SS1 mutant strain, V. 
vulnificus ∆T6SS1 is unable to target V. vulnificus 99-743 as there is only yellow growth observed on the plate. 
(C) ∆T6SS1::pBAD24 co-cultured with 99-743 produces a phenotype comparable to ∆T6SS1. (D) 
∆T6SS1::pSRC14 is unable to restore the killing phenotype associated with T6SS1 as there is only yellow growth 
on the TCBS plate which is comparable to the yellow growth observed for ∆T6SS1.  
 
Co-culture of 106-2A wild-type with 99-743 shown in Figure 7.11 (A) shows mainly 
green growth on the TCBS agar plate with minimal yellow growth surrounding the 
growth perimeter. This result shows that 99-743 is unable to grow well when co-
cultured with 106-2A wild-type. However, following co-culturing of 99-743 with 106-
2A ∆T6SS1 (Figure 7.11 B) only yellow growth is observed on the plate, indicating 
that 99-743 is able to grow. The reason for no green growth observed on plates B-D 
in Figure 7.11 is due to the 24 hour incubation period used. Previous experiments 
conducted in this study have shown that leaving TCBS plates longer than overnight 
incubation causes diffusion of yellow across the plate, therefore masking the 
presences of any green growth. Comparison of the co-culture plate containing 99-
743 and ∆T6SS1 (Figure 7.11 B) with the co-culture plate containing 99-743 and 
∆T6SS1::pSRC14 (Figure 7.11 D), shows no differences in the observed yellow 
growth, indicating that pSCR14 is unable to restore the killing phenotype associated 
with 106-2A wild-type (Figure 7.11 A). This result demonstrate that successful 
complementation was not achieved.  
7.3 Discussion  
The current study aimed to complement 106-2A ∆T6SS1 using the arabinose 
inducible vector, pSRC14. pSRC14 was generated by cloning a copy of the wild-type 
icmF gene into the pBAD24 vector to produce, pSRC14. pSRC14 was conjugated 
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into 106-2A ∆T6SS1, generating 106-2A ∆T6SS1::pSRC14. To assess whether 
pSRC14 complemented 106-2A ∆T6SS1, Western blotting using the Hcp antibody 
was used to monitor Hcp secretion. Although initial experiments indicated 
complementation of 106-2A ∆T6SS1 using pSRC14, as assessed by the presences 
of Hcp in the culture filtrate, further Western blots using the control strain, 
∆T6SS1::pBAD24 were also positive for Hcp in the culture filtrate. Therefore, the Hcp 
detected in the culture filtrate of ∆T6SS1::pSRC14 could not be assumed to be due 
to complementation. Further studies monitoring icmF transcription identified 
expression of the icmF gene from pSRC14, however a quantitative co-culture killing 
assay demonstrated that ∆T6SS1::pSRC14 is unable to restore T6SS1 killing to 
levels that are comparable to the wild-type strain.  
The current study hypothesised that Hcp detection in the culture filtrate of 
∆T6SS1::pSRC14 and ∆T6SS1::pBAD24 may be due to cell lysis, therefore future 
work for the current study would be to repeat the Western blots using a control 
antibody to monitor cell lysis. An example of a lysis control protein is cytosolic RNA 
polymerase. For example, if RNA polymerase, an internal cytosolic protein is 
identified in the culture filtrate in addition to the Hcp protein, then this may suggest 
cell lysis.   
A similar approach to complementing a T6SS icmF mutant in V. cholerae has been 
demonstrated [295]. This study amplified the wild-type icmF gene which was ligated 
into pBAD24. The resulting complement vector was able to successfully restore Hcp 
secretion in a T6SS icmF mutant as monitored by Western blotting. In addition to 
monitoring Hcp secretion, the study used an antibody against the internal cytosolic 
protein RNA polymerase to monitor for cell lysis. The same study also reported 
partial complementation of the killing phenotype [245, 295]. Conversely the current 
study was unable to restore the killing phenotype using the complement strain 
∆T6SS1::pSRC14. 
The current study speculated the ampicillin added to the media as a selection 
pressure for the vectors, pSRC14 and pBAD24 may have caused cells lysis, leading 
to detection of Hcp in the culture filtrate. This was hypothesised as ampicillin is a 
bacteriocidal antibiotic which causes lysis of bacterial cells by interfering with the 
proper arrangement of bacterial cell walls [92, 324].  
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Although it is possible that ampicillin may cause cell lysis of ∆T6SS1::pBAD24 and 
∆T6SS1::pSRC14, leading to detection of Hcp in the culture filtrate, this is unlikely as 
pBAD24 and pSRC14 contain the bla gene. This gene encodes for β-lactamase, an 
enzyme that provides resistance to the antibiotic ampicillin [325]. Therefore it is 
unlikely that the ampicillin which is added to the media is causing the cells to lyse. In 
addition the cells containing pSRC14 and pBAD24 are growing exponentially in 
media containing ampicillin which is evident by the increasing OD readings, therefore 
it is unlikely that the cells are lysing. Furthermore, the detection of Hcp in the culture 
filtrate is comparable to the levels of Hcp in the culture filtrate of the wild-type strain, 
indicating that the Hcp is likely being secreted and is not due to residual Hcp from 
lysed cells.  
An alternative hypothesis for the detection of Hcp in the culture filtrate of 
∆T6SS1::pBAD24, is ampicillin causing activation of an alternative secretion system 
such as T6SS2, which may cause secretion of the internally accumulated Hcp from a 
mechanism other than T6SS1. This study hypothesis that ampicillin may cause 
activation of T6SS2 as previous research has demonstrated that sub-inhibitory levels 
of kanamycin can activate HSI-I T6SS genes in P. aeruginosa [326]. Therefore, the 
current study hypothesis that ampicillin may cause activation of an alternative 
secretion system in V. vulnificus, possibly T6SS2, as antibiotics have been shown to 
effect T6SS activation in P. aeruginosa [326]. Therefore if ampicillin activates 
T6SS2, it is possible that Hcp from T6SS1 is trafficked out of the cell via T6SS2. An 
example of a protein in the literature being secreted by a mechanism other than its 
cognate system is the EspC protein of enteropathogenic E. coli, where it has been 
shown that EspC is secreted to the by the T5SS, but is then translocated by the 
T3SS. Therefore it is possible that the Hcp from T6SS1 may be incorporated and 
secreted out of cells by T6SS2 [327]. 
As with the data presented for P. aeruginosa, the current study also did not observe 
any killing of the prey strain, V. vulnificus 99-743 when co-cultured with either the 
complement strain, ∆T6SS1::pSRC14 or the ∆T6SS1::pBAD24. Therefore this may 
suggest that pSRC14 is unable to fully complement ∆T6SS1. However, as 
suggested above, ampicillin may activate T6SS2 which may lead to the secretion of 
the T6SS1 protein, Hcp. However, the hypothesis of T6SS2 activation would need to 
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be followed up with further work to assess whether T6SS2 are activated in the 
presences of ampicillin and furthermore, a key experiment would be to monitor Hcp 
secretion in a double T6SS1 and T6SS2 mutant containing pBAD24, to observe 
whether Hcp is able to be secreted.     
7.4 Conclusion  
The results from the current study demonstrated that the icmF gene encoded on 
pSRC14 is expressed. However, the ability for pSRC14 to complement the secretion 
of Hcp is inconclusive, as Hcp is also observed in the culture filtrate of the control, 
strain ∆T6SS1::pBAD24. Furthermore a qualitative killing assay showed that the 
strain, ∆T6SS1::pSRC14 is unable to restore phenotypic co-culture killing to wild-
type levels.   
Future work for the complementation study would be to repeat Western blots with an 
internal control antibody to monitor for cell lysis. In addition, the co-culture assays 
should be repeated to give quantitative data as this would identify if 
∆T6SS1::pSRC14 is able to partially restore killing, a phenotype which the qualitative 
assay cannot determine. In addition to this, complementation with an alternative 
expression vector should also be attempted as a different vector may be able to 
better complement icmF.  
7.5 Concluding summary and future work 
V. vulnificus biotype 1 strains are known to vary significantly in virulence potential. 
Therefore the initial aim of this PhD was to characterise 5 clinical and 5 
environmental isolates in several in vitro phenotypic assays, to identify whether any 
in vitro assay correlated with either, the published in vivo mouse data on virulence 
groupings of the V. vulnificus isolates, or with source of isolation. However, the data 
from these analyses demonstrated that not one phenotypic assay could accurately 
predict source of isolation or virulence potential of a strain. The study therefore 
performed WGS to identify genetic differences between the strains, with the aim of 
identifying genetic makers which correlated with either source of isolation or 
virulence potential of the strains.  
WGS comparison data demonstrated that the V. vulnificus isolates tested contained 
many genetic differences. In addition to WGS comparison the study also carried out 
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WGS gene annotation. The gene annotation method quickly led to the discovery of 
previously undescribed novel T6SSs in V. vulnificus. Therefore the study halted 
further bioinformatic investigation into evaluating the genetic differences between the 
strains, and instead focused attention on the T6SSs. Although the study identified 2 
T6SSs, termed T6SS1 and T6SS2, the study chose to investigate T6SS1, as T6SS1 
shared synteny to the previously described T6SS in V. cholerae. In addition to this 
finding, it was noted that T6SS1 was only present in environmental isolates, with a 
predominance to be associated with lesser virulent strains.  
The functionality of T6SS1 was assessed by Western blotting to monitor the 
expression and secretion of the T6SS associated protein, Hcp. This demonstrated 
that T6SS1 displayed thermoregulation, whereby T6SS1 was active at 23oC and 
30oC, but was inactive at 37oC. Further phenotypic characterisation using co-
culturing assays showed that T6SS1 displayed anti-prokaryotic properties which 
allowed a T6SS1 positive V. vulnificus strain to target B. thailandensis, V. fluvialis 
and a T6SS1 negative V. vulnificus strain.     
The findings presented in this thesis contributes to the V. vulnificus field of research 
as WGS comparison data has demonstrated that V. vulnificus strains harbour 
genetic differences. Future bioinformatic studies analysing these genetic differences 
may identify genetic markers which could potentially distinguish hyper virulent strains 
that are hazardous to human health from lesser virulent strains that do not pose a 
risk to human health. The current study has also identified novel previously 
undescribed T6SSs in V. vulnificus, termed T6SS1 and T6SS2. Although T6SS2 was 
not characterised extensively in the current study, this is an area of research that 
could be explored in the future.  
Based on the phenotypic T6SS1 data presented in this thesis, the current study 
hypothesises that this newly characterised secretion system may play a role in 
understanding one of the major questions surrounding V. vulnificus, “why are there 
relatively few serious human infections attributed to V. vulnificus, given the natural 
occurrence and virulence potential of this pathogen?” The following paragraphs will 
outline the new hypothesis that the current study has generated as well as the future 
work that would need to be employed to elucidate these hypotheses.  
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Analysis of the current study’s cohort of strains found that T6SS1 is only found in 
environmental isolates with a predominance to be associated with strains exhibiting 
lower virulence. As the T6SS1 was rarely identified among hyper virulent strains, the 
current study hypothesises that in the natural marine environment, lesser virulent 
T6SS1 positive strains can target the hyper virulent T6SS1 negative strains. This 
would allow for the lesser virulent strains to predominate in the environment. If this 
statement is true then the likelihood of humans being exposed to a hyper virulent 
strain would be low. As a result there would be a much lower incidence of humans 
presenting with septicaemia, a disease symptom more commonly associated with 
hyper virulent strains. Instead the majority of humans would present with 
gastroenteritis and disease symptoms which are more commonly associated with 
lesser virulent strains. Therefore, it is proposed that although there is a high 
abundance of V. vulnificus bacteria occurring in the environment, the prevalence of 
hyper virulent strains is low, maybe potentially as a result of the T6SS1 dependent 
intra-species killing, resulting in only a few serious human infections occurring.  
 
In order to test the hypothesis outlined above, a study identifying the prevalence of 
the T6SS1 among V. vulnificus strains of known isolation and virulence would need 
to be performed. This would identify whether the T6SS1 is found solely in 
environmental isolates as well as elucidate the prevalence of the T6SS1 among 
hyper and lesser virulent strains. In addition an in vivo co-culturing infection model 
would need to be designed to test whether the killing that occurs in vitro can also 
occur in vivo.  
In addition to the finding that T6SS1 is involved with intra-species targeting, the 
study also found that that a lesser virulent pathogen, V. fluvialis could target a 
∆T6SS1 mutant strain. This observation may also provide an explanation as to why 
there is relatively few serious human infection attributed to V. vulnificus given the 
natural prevalence and virulence potential of V. fluvialis. For example, the current 
study identified that at 30oC V. vulnificus could target V. fluvialis in a T6SS1 
dependent manner. However, at 37oC V. fluvialis was able to target the ∆T6SS1 
mutant strain. Due to this finding, the current study speculates that if a human 
ingests a contaminated oyster containing both V. vulnificus and V. fluvialis, upon 
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entry into the human host the temperature would be elevated to 37oC, allowing V. 
fluvialis to target V. vulnificus.  
Therefore the current study hypothesises that in vivo V. vulnificus may be displaced 
by V. fluvialis, allowing V. fluvialis to predominate. V. fluvialis is often associated with 
milder disease symptoms such as gastroenteritis and is rarely associated with 
septicaemia. With this in mind, the disease symptoms displayed in the human host 
would be that of V. fluvialis. In order to test this hypothesis, experiments would need 
to be performed to understand the natural microflora in oysters. In addition to this an 
in vivo co-culturing study would also need to be performed to test whether the 
targeting ability of V. fluvialis displayed in vitro also occurs in vivo.  
Further T6SS1 characterisation work could lead to the identification of T6SS1 
effectors. Preliminary mass spectrometry data analysing the secretome of 106-2A 
wild-type and 106-2A ∆T6SS1, demonstrated that T6SS1 proteins such as Hcp could 
be identified in the culture filtrate of the wild-type strain but not in the mutant strain. 
However, a more thorough and in depth analysis of the two secretomes would need 
to be performed to fully elucidate novel effectors of T6SS1.  
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8.1 Bacterial strains and mammalian cell lines  
8.1.1 Bacterial strains 
All bacterial strains used in the current study are listed in Table 8.1.  
Table 8.1: Bacterial strains used in this study 
Bacterial strains Description Source 
V. vulnificus  
  
ORL-1506 Wild-type, clinical isolate CEFAS 
ATL-9832 Wild-type, clinical isolate CEFAS 
NSV-5830 Wild-type, clinical isolate CEFAS 
DAL-79087 Wild-type, clinical isolate CEFAS 
DAL-79040 Wild-type, clinical isolate CEFAS 
S3-16 Wild-type, environmental 
isolate 
CEFAS 
S2-22 Wild-type, environmental 
isolate 
CEFAS 
99-796 Wild-type, environmental 
isolate 
CEFAS 
99-743 Wild-type, environmental 
isolate  
CEFAS 
106-2A Wild-type, environmental 
isolate 
CEFAS 
106-2A ∆T6SS1 106-2A with in-frame 
deletion of icmF from 
T6SS1 
This study 
106-2A ∆T6SS2 106-2A with in-frame 
deletion of icmF from 
T6SS2 
This study 
106-2A pSCrhaB3 Wild-type strain containing 
pSCrhaB3 (Tpr)  
This study 
106-2A ∆T6SS1 
pSCrhaB3 
106-2A ∆icmF1 containing 
pSCrhaB3 (Tpr) 
This study 
106-2A ∆T6SS2  
pSCrhaB3 
106-2A ∆icmF2 containing 
pSCrhaB3 (Tpr) 
This study 
V. vulnificus 99-743 
pBHR4-RFP 
V. vulnificus 99-743 
containing pBHR4-RFP 
(Cmr) 
This study 
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8.1.2 Mammalian cell lines 
All mammalian cell lines used in the current study are listed in Table 8.2 
Table 8.2. Mammalian cell line used in this study 
Cell line Description Source 
 
CaCo-2 
Human cells originally 
derived from a colorectal 
adenocarcinoma from a 
72year old Caucasian 
male 
 
Lab stock 
 
8.2 Media  
All media used in the current study is listed in Table 8.3  
Table 8.3. Growth media for bacterial and mammalian cells used in this study 
E. coli    
DH5α Cloning host Lab stock 
TOP10 Cloning host Invitrogen 
S17 λpir Cloning host and donor 
strain 
Lab Stock 
V. cholerae 
  
V52 Wild-type strain (Smr) Dr. S. Pukatizki 
V52 ∆hcp1 ∆hcp2 V52 with in-frame deletion 
of hcp1 and hcp2 (Smr) 
Dr. S. Pukatizki 
C. difficile    
630 Δerm 630 containing a deletion 
of a gene encoding an 
erythromycin cassette  
Dr. S.Michell  
V. fluvialis   
NCTC 11327 Wild-type strain CEFAS 
NCTC 11327 pBHR-RFP V. fluvialis NCTC 11327 
containing pBHR4-RFP 
(Cmr) 
This study 
B. thailandensis   
E264  pBHR-RFP B. thailandensis containing 
pBHR-RFP (Cmr) 
Dr. Claudia Hemsley  
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Media Composition Supplier 
LB broth 10g peptone, 5g yeast 
extract, 5g sodium 
chloride, made up to 1 L 
with Milliq water and 
autoclaved 
Fisher Scientific 
LB agar 10g peptone, 5g yeast 
extract, 5g sodium 
chloride, 20g agar made 
up to 1 L with Milliq water 
and autoclaved 
Fisher Scientific 
2% NaCl LB broth 10g peptone, 5g yeast 
extract, 25g sodium 
chloride, made up to 1 L 
with Milliq water and 
autoclaved, supplemented 
with 2% (w/v) NaCl 
Fisher Scientific 
supplemented 2% Sodium 
chloride, from Sigma-
Aldrich 
2% NaCl LB agar 10g peptone, 5g yeast 
extract, 25g sodium 
chloride, 20g agar made 
up to 1 L with Milliq water 
and autoclaved, 
supplemented with 2% 
(w/v) NaCl  
Fisher Scientific 
supplemented 2% Sodium 
chloride, from Sigma-
Aldrich 
TCBS agar Peptone from casein 5g, 
peptone from meat 5g, 
yeast extract 5g, sodium 
citrate 10g, sodium 
thiosulfate 10g, ox bile 5g, 
sodium cholate 3g, 
sucrose 20g, sodium 
chloride 10g, iron(III) 
citrate 1g, thymol blue 
0.04g, bromothymol blue 
0.04g, agar-agar 14g, 1L 
Milliq water 
Thermo Scientific  
10% Sucrose Agar 10g Tryptone, peptone, 5g 
yeast extract, 266 mL 
Water and autoclaved, 
supplemented with 133 
mL of filter sterilised  
30% sucrose solution 
All reagents are from 
Oxoid, except sucrose 
from Sigma 
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0.3% Motility agar 5g Tryptone, 10g sodium 
chloride, 1.675g bacto 
agar, 500 mLs Milliq water 
and autoclaved 
Oxoid 
EMEM 1 mM sodium pyruvate, 2 
mM L-glutamine, 1500 
mg/L sodium bicarbonate 
ATCC 
Leibovitz’s Medium (L-15) Supplemented with 
10% non-heat treated fetal 
bovine serum 
Life Technologies  
8.3 Routine culturing of bacterial strains 
8.3.1 Culturing of V. vulnificus cells 
The 10 V. vulnificus strains were received into the laboratory from CEFAS on LB-
agar slopes. Strains were inoculated into 2% LB broth and incubated overnight at 
37oC with agitation.  2 mL aliquots of overnight broth cultures were then stored at -
80oC, in 12% glycerol. Re-culturing of strains from -80oC was performed by re-
streaking strains onto either TCBS agar or 2% NaCl LB agar and incubating 
overnight at 37oC or 30oC where indicated. Where appropriate media was 
supplemented with trimethoprim at 100 µg/mL or chloramphenicol at 10 µg/mL. 
8.3.2 Culturing of other Vibrio species and Burkholderia thailandensis  
V. cholerae was routinely cultured on LB agar or in LB broth supplemented with 
streptomycin at 50 mg/mL and incubated at 37oC. V. fluvialis was routinely cultured 
in LB broth or on LB agar supplemented with chloramphenicol at 10 µg/mL where 
appropriate and incubated at 30oC. B. thailandensis was routinely cultured in LB 
broth or on LB agar supplemented with chloramphenicol at 50 µg/mL and incubated 
at 30oC.  
8.3.3 Culturing of E. coli cells 
E. coli strains were generally cultured in LB broth or on LB agar and where 
appropriate supplemented with antibiotics at the following concentration, ampicillin, 
100 µg/mL, chloramphenicol 35 µg/mL, kanamycin 50 µg/mL and trimethoprim 100 
µg/mL and incubated at 37oC.  
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8.4 Routine culturing of mammalian cells 
8.4.1 Routine culturing of CaCo-2 cells 
For long term storage CaCo-2 cells were stored either in liquid nitrogen or in glycerol 
at -80oC in 90% non-heat treated foetal bovine serum (FBS) and 10% DMSO. Re-
culturing of CacCo-2 cells was performed by culturing cells in a T25 culture flask with 
5 mL of 37oC pre-warmed EMEM supplemented with 10% non-heat treated FBS and 
incubated at 37oC in a humidified incubator aerated with 5% CO2.  At 80% 
confluence, cells were passaged into T75 flasks. CaCo-2 cells were not passaged 
past passage 20 (P20). 
8.4.2 Passaging of CaCo-2 cells 
CaCo-2 cells were washed with 5 mL PBS and detached using 1.5 mL trypsin with 
incubation at 37oC for 5 minutes. Following detachment cells were re-suspended in 
10.5 mL 37oC pre-warmed EMEM supplemented with 10% non-heat treated FBS. 
CaCo-2 cells were then split 1:3 into T75 flasks and suspended in 12 mL pre-
warmed EMEM supplemented with 10% non-heat treated FBS. Passages were non 
performed passed P20.  
8.5 In vitro phenotypic assays 
8.5.1 V. vulnificus growth curves 
Growth curves were routinely performed by sub-culturing 2-3 colonies into 2% NaCl 
LB broth or LB only broth. Broths were incubated overnight at either 37oC or 30oC 
where indicated with agitation and OD590nm read. At T0 25 mL of 2% NaCl broth or 25 
mL of LB broth was inoculated to OD590nm 0.03 with overnight V. vulnificus cultures 
and incubated at either 37oC or 30oC. Samples were taken at designated hourly time 
points, OD590nm read and Miles and Misra serial dilutions (1:10) performed. Triplicate 
10 µl dilutions were spotted onto LB agar plates and incubated. Average cfu/ mL for 
each triplicate time point was recorded.  
8.5.2 Capsule colony morphology  
Streaks of V. vulnificus strains were performed on 2% NaCl LB agar plates. 
Following incubation at 37oC colony morphology was assessed and images recorded 
using BioRad ChemiDocTM using the Quantity One version 4.6.9. 
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8.5.3 India ink staining of capsule 
V. vulnificus cells grown on 2% NaCl LB agar were sub-cultured into 2% NaCl LB 
broth and incubated at 37oC. Overnight broths were inoculated to OD590nm 0.03 and 
grown to mid-log (OD590nm 1.0). 1 µl cultures were then mixed with 10 µl of India ink 
spotted onto a glass microscopy slide. India ink cultures were smeared across the 
slide and allowed to air dry. Air dried slides were then saturated with 1 mL of crystal 
violet for 1 minute. Slides were then washed with distilled water and air dried. 
Capsule was imaged using the brightfield settings of the Zeiss Axioplan 
Epifluorescence Microscope.   
8.5.4 Azocasein protease assay 
Total protease activity in V. vulnificus supernatant was determined according to the 
protease protocol described by Shao and Hor (2000) [328]. In brief, 2 mL overnight 
V. vulnificus  broths grown in 2% NaCl LB at 37oC were centrifuged and washed 3 
times in 2% NaCl LB broth and inoculated into 2% NaCl broth at dilution of 1 in 100 
and incubated at 37oC 200 rpm. At T0, T4, T8, T24 and T30 the growth OD590nm was 
read and triplicate 500 µl samples of bacterial supernatant were mixed with equal 
volumes of azocasein solution (5 mg/mL), incubated at 37oC for 15 minutes and 
protein precipitated with 1 mL trichloroacetic acid (TCA). Samples were then 
centrifuged and the supernatant mixed with equal volumes of 0.5 M NaOH. OD450nm 
was then read. A negative control reading at OD450nm was also conducted at each 
time point by mixing 500 µl 2% NaCl broth with 500 µl azocasein, incubated at 37oC, 
protein precipitated with 1 mL TCA and equal volumes of 0.5 M NaOH added. 
8.5.5 Motility assay  
Motility agar described in Table 8.3 was melted, cooled to ~50oC and 25 mL poured 
into agar plates. Plates were air-dried in a laminar flow hood for 40 minutes and 
inoculated with 2 µl of mid-log V. vulnificus (OD590nm 1.0) cultures (1 inoculation per 
agar plate x3 plates for each strain). Inoculated plates were then incubated at 37oC 
for 24 hours before motility recorded in mm.  
8.5.6 LDH cytotoxicity assay 
CaCo-2 cells were harvested from a T75 routine culturing flask as detailed in section 
8.4.1, with minor alterations. Following detachment, CaCo-2 cells were re-
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suspended in 4.5 mL of EMEM supplemented with 10% non-heat treated FBS and 
enumerated using a haemocytometers.  Cells were then seeded into 24 well plates 
at a density of 1.4x105 / mL, and incubated at 37oC overnight with 5% CO2 to allow 
for attachment.   
Following attachment, CaCo-2 cells were overlaid with 1 mL mid-log phase V. 
vulnificus cultures re-suspended in L-15 media at a density of 1.4x107 cfu/mL 
equating to a MOI of 100 (V. vulnificus cells were also enumerated in parallel by 
plating out using serial dilutions of to ensure the MOI equated to 100). Bacterial 
infected CaCo-2 cells were then incubated at 37oC for 6 hours without aeration. 
Infections were performed in triplicate for each strain and negative control consisting 
of CaCo-2 cells overlaid with 1mL L-15 media performed on each 24 well plate. At 
T6 the supernatant was removed and centrifuged at 5000 rpm for 5 minutes. LDH 
release from the CaCo-2 cells was then determined using the Promega CytoTox 96® 
Non-Radioactive Cytotoxicity Assay kit in accordance with the manufacturer’s 
instructions. In brief, 50 µl of supernatant was removed and mixed with 50 µl of LDH 
substrate in a 96 well plate and incubated in the dark at room temperature for 30 
minutes. Following incubation 50 µl of stop solution was added and the absorbance 
read at OD490nm using the Bio-Rad model 680 microplate reader recorded.    
8.5.7 G. mellonella infection assay 
Prior to infection waxmoth larvae, G. mellonella were weighed and only larvae 
between 2.0 - 3.0 g with no signs of melanisation were used for infection studies. 
Overnight cultures of V. vulnificus grown in LB at 37oC were re-adjusted to a cell 
density of ~ 1x107 cfu/ mL and G. mellonella larvae were challenged with 10 µl 
(equating to ~ 1x105 cfu/10 µl) doses of V. vulnificus cells into the upper right 
abdominal proleg using a 25 µl Hamilton Microlitre™ syringe 800 series with 
removable needle (Sigma). V. vulnificus cells were also enumerated in parallel by 
plating out using serial dilutions of the infective dose to ensure ~ 1x105 cfu/10 µl was 
the input. Infected larvae were then incubated at 37oC and monitored for signs of 
infection, death was recorded when larvae failed to respond to touch.  
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8.5.8 Co-culture killing assays 
Overnight cultures of prey (either V. vulnificus 99-743, V. fluvialis NCTC 11327 or B. 
thailandensis E264) and attacker strains (V. vulnificus 106-2A wild-type, ∆T6SS1 or 
∆T6SS2) grown in LB with antibiotics where appropriate at 30oC were re-adjusted to 
an OD590nm 0.03 and grown to OD590nm 1.0. Cells were then re-adjusted to OD590nm 
0.8 and mixed at a ratio of 3:1, attacker to prey. 200 µl of mixed cultures were then 
spotted onto LB agar plates, 3 plates per co-culture and incubated at 30oC for 5 
hours. Following incubation the co-culture growth was scraped off and re-suspended 
in 1 mL PBS.  Subsequent 10-fold serial dilutions were performed and triplicate 10 µl 
spots spotted onto enumeration plates for prey and attacker strains. Enumeration 
plates were then incubated at 37oC overnight. The average cfu/ mL was recorded for 
each triplicate dilution.   
8.5.9 Qualitative co-culture killing assay 
Prey and attacker strains were prepared as described in section 8.5.8, with the minor 
alteration that 200 µl of mixed cultures were spotted onto TCBS agar plates and 
incubated at 30oC for 24 hours. Following incubation the colour of each co-culture 
growth was assessed and recorded.  
8.5.10 Plasmid stability testing 
Overnight broth culture of V. fluvialis NCTC11327::pBHR-RFP grown in LB 
supplemented with 10 µg/mL chloramphenicol at 30oC, was re-adjusted to OD590nm 
0.03 and grown to OD590nm 1.0. Cells were then adjusted to OD590nm 0.8 and 1 mL 
samples mixed with 3 mL LB. 200 µl was spotted onto LB agar and incubated at 
30oC for 5 hours. Following incubation the growth was re-suspended in 1 mL PBS 
and Miles and Misra serial dilutions (1:10) in PBS performed. Triplicate 10 µl spots of 
the dilutions were then inoculated onto both LB only agar plates and LB agar plates 
containing 10 µg/mL chloramphenicol. The inoculation plates were then incubated at 
37oC and the growth for each recorded. The average cfu/mL was recorded for each 
triplicate dilution. 
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8.6 Molecular genetics  
8.6.1 gDNA extraction  
All gDNA in this study was extracted using the Promega Wizard® Genomic DNA 
Purification Kit according to the manufactures instructions for Gram negative 
bacteria. Eluted gDNA was quantified using the Nanodrop reader and stored at 4oC. 
gDNA preparations for WGS analysis were further quantified using Qubit® 
Fluorometric Quantitation and analysed using gel electrophoresis to ensure the 
gDNA was of high quality and not fragmented.  
8.6.2 Plasmid extraction  
All plasmid preparation for this study were performed using the Qiagen QIAprep Spin 
Miniprep Kit, according to the manufacturer’s instructions, with the minor 
adjustments of 10 mL starting cultures used instead of 1-5 mL and DNA elution 
performed using 35 µl of nuclease free water. Preparations were stored at 4oC. 
8.6.3 PCR for fragments less than 1000bps  
PCR amplification of DNA regions less than 1000bps were routinely performed using 
1 µl of 5 U/µl HotStartTaq polymerase (Qiagen), 10 µl of 10X HotStartTaq polymerse 
buffer, 5X Q Solution, 1µl forward and 1µl reverse oligonucleotides (50 pmol/µl), 1 µl 
dNTPs (20 Mm each), 5 µl DNA and nuclease free water to a final volume of 50 µl. A 
typical reaction consisted of an initial denaturation at 96o C for 15 minutes, followed 
by 30 cycles of denaturation at 94oC for 1 minute, annealing at 65oC for 1 minute, 
extension at 72oC for 1.5 minutes and a final extension at 72oC for 7 minutes.  
8.6.4 PCR for fragments greater than 1000bps  
PCR amplification of DNA regions greater than 1000bps were routinely performed 
using 0.5 µl of 1 U/µl KOD Xtreme™ Hot Start DNA Polymerase (Novagen), 12.5 µl 
2X Xtreme buffer, 0.25 µl forward and 0.25 µl reverse oligonucleotides (50 pmol/µl), 
0.5 µl dNTPs (20 mM each), 2 µl DNA and nuclease free water to a final volume of 
25 µl. A typical reaction consisted on an initial denaturation step at 94o C for 2 
minutes followed by 35 cycles of denaturation at 98oC for 10 seconds, annealing at 
57oC for 30 seconds and an extension at 68oC for 6.5 minutes.  
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8.6.5 Agarose gel electrophoresis  
Separation of DNA fragments based on size was performed using agarose gel 
electrophoresis. 0.8%-1% w/v agarose (Sigma) was dissolved in 100 mL 1X TAE 
(Tris-acetate 40 mM, EDTA 1mM made up in Milliq water to 1X solution) with 10 µl 
10X SYBR®Safe DNA gel stain (Invitrogen). Following separation DNA was 
visualised using the UV transilluminator, BioRad ChemiDocTM and imaged using 
Quantity One version 4.6.9. 
8.6.6 DNA gel purification  
DNA bands excised from 0.8% w/v agarose gels were processed using QIAquick Gel 
Extraction kit (Qiagen) as per manufacturer’s instructions. 
8.6.7 Restriction digestion 
A typical digest of 1 µg of DNA was mixed with 10X restriction enzyme digest buffer, 
10X BSA, 1 µl restriction enzyme and nuclease free water to a final volume of 50 µl. 
Reactions were incubated as per manufacturer’s instructions, followed by gel 
electrophoresis to either visualise or purify fragments.  
8.6.8 Ligation 
Ligations typically consisted of 150 ng of digested vector, 1 µl T4 ligase (New 
England BioLabs) 10X T4 DNA ligase buffer, enzyme and insert to a final volume of 
20 µl. Reactions were incubated at 15oC overnight. Amount of insert was calculated 
using the equation detailed below, to give 150 ng of insert at a vector to insert ratio 
of 3:1.  
Amount of insert = (150 ( size of insert kb / size of vector kb)) x 3 
8.6.9 A-tailing of PCR fragments 
1–4  µl of gel purified PCR product was mixed with 2 µl 5X GoTaq® buffer, 2 µl 1 
mM dATP, 1 µl of 5 u/µl GoTaq Flexi® DNA Polymerase, 0.6 µl of 25 mM MgCl2 (All 
reagents Promega ®) and made up to a final volume of 10µl with nuclease free 
water.  Samples were then incubated at 70oC for 15-30 minutes. A 1-2 µl sample 
was then used in downstream ligation reactions. 
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8.6.10 Reverse transcription PCR (RT-PCR) 
Total RNA was extracted from overnight V. vulnificus 106-2A wild-type and 106-2A 
∆T6SS cells that had been adjusted to OD590nm 0.03 and grown to OD590m 1.5, for 
106-2A ∆T6SS1::pBAD24 and 106-2A ∆T6SS1::pSRC14 cells were grown to 
OD590nm 3.0. Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s instructions. RNA was subjected to DNase treatment using the 
Turbo™ DNase (Life Technologies) according to the manufactures instructions. A 
PCR was carried out using the species specific V. vulnificus housekeeping primers 
vvhA forward and reverse to ensure RNA samples were DNA free. DNA-free RNA 
was then reverse transcribed into cDNA using SuperScript™ III Transcriptase 
(Invitrogen), according to the manufacturer’s instructions. In brief, 5 µl RNA was 
mixed with 2 µl random primers (Invitrogen), 1 µl dNTPs (10 mM each) and 12 µl 
nuclease free water and heated to 65oC for 5 minutes, incubated on ice for 1 minute 
and centrifuged briefly. The sample was then mixed with 4 µl 5X First Strand Buffer, 
1 µ 0.1 M DTT, 1 µl RNase OUT, 1 µl SuperScript III Reverse Transcriptase. The 
sample was then incubated at 25oC for 5 minutes, followed by 50oC for 30 minutes 
and 70oC for 15 minutes. 1.5 µl of RNase H was added to a 30 µl sample and cDNA 
was ethanol precipitated at -20oC overnight.  
8.6.11 Production of chemically competent E. coli  
Overnight cultures of E. coli were inoculated into LB broth (1:100) and incubated at 
37oC to OD590 0.5 – 0.7, followed by incubation on ice for 30 minutes and 
centrifugation at 3000 rpm for 10 minutes at 4oC. Centrifuged samples were re-
suspended in 30 mL ice cold 0.1 M CaCl2 and incubated on ice for 30 minutes. Cells 
were then centrifuged at 3000 rpm for 10 minutes at 4oC, and samples re-suspended 
in 700 µl 0.1 M CaCl2 and 300 µl of 50% glycerol. 50 µl aliquottes cells were stored 
at -80oC.  
8.6.12 Heat shock transformations  
Chemically competent E. coli cells were thawed on ice and mixed with 2 µl of ligation 
reaction and incubated on ice for 30 minutes, heat shocked at 42oC for 30 seconds 
and returned to ice. 250 µl of 37oC pre-warmed LB was immediately added to 
recover cells, followed by incubation at 37oC for 1 hour at 200 rpm. 500-700 µl of 
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37oC pre warmed LB was then added and 200 µl spread onto LB agar plates 
containing appropriate antibiotic selection and incubated for at 37oC.  
8.6.13 Tri-parental conjugation of plasmids into Vibrio strains 
The helper strain E. coli pRK2013 harbouring a kanamycin resistance cassette was 
used for all tri-parental conjugations. 1 mL samples from overnight cultures of the 
helper strain, donor strain and Vibrio strain were grown at 37oC in LB, and 
supplemented with antibiotics where appropriate. Overnight broth cultures were 
centrifuged at 13,000 rpm for 2 minutes and samples were re-suspended in 200 µl 
LB media. 100 µl from the donor and helper strain were then added to a 1 mL 
centrifuged sample of the Vibrio strain. 100 µl of each suspension was then spotted 
onto LB plates and incubated at 37oC overnight. Following incubation the growth 
from each plate was re-suspended in 1 mL PBS and 100 µl spread onto TCBS agar 
plates containing appropriate antibiotics. Following 2-3 days incubation at 37oC, 
potential transformant colonies were re-streaked onto TCBS agar supplemented with 
appropriate antibiotics. Transformants positive for antibiotic resistance were mini-
prepped to ensure the presence of the resistance plasmid. V. vulnificus colonies 
were also species checked by PCR using the housekeeping primers, vvhA forward 
and reverse.  
8.6.14 Generation of deletion constructs in V. vulnificus  
Unmarked in-frame deletion mutants of icmF in T6SS1 and T6SS2 were constructed 
using pSRC10 and pSRC11, listed in Table 8.5. In brief, flanking primers with 
incorporated restriction enzymes listed in Table 8.4 were used to amplify icmF 
flanking regions. These regions were ligated into the intermediate constructs, 
pSRC6-9 listed in Table 8.5. Correctly sequenced flanking regions were digested 
and ligated into pDM4 generating, pSRC10 and pSRC11. pSRC10 and pSRC11 
were mobilised into V. vulnificus by tri-parental mating (section 8.6.12). First cross 
over integrants were checked by PCR using the MutScreen primers listed in Table 
8.4 and plating integrants onto chloramphenicol plates to check for resistance. The 
excision of the deletion plasmid from the first cross over integrants was induced by 
plating onto 5% sucrose agar listed in Table 8.3. PCR using the MutScreen primers 
listed in Table 8.4 were used to distinguish wild-type revertants from mutants.   
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8.7 Primers and plasmids 
8.7.1 Primers  
All primers used in the current study are listed in Table 8.4 
Table 8.4. Primers used in this study 
Primer Name Description Primer Sequence 5’–3’ 
 
vvhA Forward 
V. vulnificus 
housekeeping 
gene 
 
ACTGCGGTACAGGTTGG 
 
 
vvhA Reverse 
V. vulnificus 
housekeeping 
gene 
 
CGCCACCCACTTTCGGGCC 
 
 
LFF 106-2A 
icmF1 SmaI 
 
106-2A T6SS1 
left flanking 
region IcmF 
forward 
 
TGCCCGGGAGTGATTGGTCTGAGGCCATTG 
LFR 106-2A 
icmF1 NdeI 
106-2A T6SS1 
left flanking 
region IcmF  
reverse 
 
TGCATATGTATCGGGTCTTGACGTAACTGG 
 
 
RFF 106-2A 
icmF1 NdeI 
106-2A T6SS1 
right flanking 
region IcmF 
forward 
 
TGCATATGTGGGCATTCTTTCGATTGTTAG 
 
 
RFR 106-2A 
icmF1 ApaI 
106-2A T6SS1 
right flanking 
region IcmF 
reverse  
 
TTGGGCCCCTCGGCACGATAAAGCTCTCTC 
 
 
LFF 106-2A 
icmF2 SmaI 
106-2A T6SS2 
right flanking 
region IcmF2 
forward 
 
TGCCCGGGACCAGAGTGCGGATTATATTTC 
 
 
LFR 106-2A 
icmF2 NdeI 
106-2A T6SS2 
left flanking 
region IcmF2 
reverse 
 
TGCATATGAATAACCAACAAACGGTTAAAG 
 
 
RFF 106-2A 
icmF2 NdeI 
106-2A T6SS2 
right flanking 
region IcmF2 
forward 
 
TACATATGGCAAGGCCGCAATCTCGCAAAG 
 
 
RFR 106-2A 
icmF2 ApaI 
106-2A T6SS2 
right flanking 
region IcmF2 
reverse 
 
TCGGGCCCTGCCAATTTGAGGTAAACCATC 
 
 
M13 Forward 
Sequencing 
primer 
 
TGTAAAACGACGGCCAGT 
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M13 Reverse 
Sequencing 
primer 
 
 
CAGGAAACAGCTATGAC 
 
LFF_icmF 
_MutScreen 
 
T6SS1 cross 
over 
confirmation 
primer 
 
GGCGGAAAGTGGAACAAAGC 
 
RFR_icmF 
_MutScreen 
T6SS1 cross 
over 
confirmation 
primer 
 
TACTCGGTTTGCTGGTACTC 
 
LFF_icmF2 
_MutScreen 
T6SS2 cross 
over 
confirmation 
primer 
 
CGGCTGTGTTAGTCAGTGTG 
 
RFR_icmF2 
_MutScreen 
T6SS2 cross 
over 
confirmation 
primer 
 
CTCATTCGATCACCGTTACC 
 
CmF 
 
First crossover 
integrant  
primer forward 
 
ATGGAGAAAAAAATCACTGGATATACCACC 
 
 
CmR 
 
First crossover 
integrant 
primer reverse 
 
TTACGCCCCGCCCTGCCACTCATCGCAGTA 
 
 
icmF1 Final F 
pBADSmaI 
 
Complement 
icmF gene 
 
ACGTCCCGGGATGTGGAAATTCATTGTCGG 
 
icmF1 Final 
pBADSphI 
 
Complement 
icmF gene 
 
CTGAGCATGCTTAATAAAGAGTTTTAGACA 
 
 
icmF_screen F 
 
RNA screening 
primer 
 
 
CCATTGGCCCTAAAGTTG 
 
 
icmF_screen R 
 
RNA screening 
primer 
 
 
GATCTGCGGTTAAATCGG 
 
  
 
Seq_1 
Primer walking 
sequencing 
primer for icmF 
in pBAD24 
 
GTGCTCGTTTACGAG 
 
Seq_2 
Primer walking 
sequencing 
primer for icmF 
in pBAD24 
 
TTTGGCGGGAACTTG 
Seq_3 Primer walking 
sequencing 
TCAGCGTGTCTACAG 
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primer for icmF 
in pBAD24 
 
Seq_4 
Primer walking 
sequencing 
primer for icmF 
in pBAD24 
 
GATCCAAGATGCGCC 
 
Seq_5 
Primer walking 
sequencing 
primer for icmF 
in pBAD24 
 
TGGCTTATAGCCATG 
 
8.7.2 Plasmids  
All plasmids used in the current study are listed in Table 8.5 
Table 8.5. Plasmids used in this study 
Plasmid Description Source 
 
pGEM-T Easy  
 
High copy number cloning 
vector (Ampr) 
 
 
Promega 
pDM4 Suicide vector (Cm
r, sacB) [303] 
 
pRK2013 
 
Conjugation, helper strain 
(Kmr) 
 
Lab stock  
 
pSRC6 
 
pGEM®-T Easy containing 
106-2A IcmF2 left flanking 
region from T6SS2 
 
This Study 
 
pSRC7 
pGEM®-T Easy containing 
106-2A IcmF2 right 
flanking region from 
T6SS2 
 
This Study 
 
pSRC8 
pGEM®-T Easy containing 
106-2A IcmF1 left flanking 
region from T6SS1 
 
This Study  
 
pSRC9 
pGEM®-T Easy containing 
106-2A IcmF1 right 
flanking region from 
T6SS1 
 
This Study  
 
pSRC10 
 
 
pDM4 containing 
containing NdeI 
ligated106-2A IcmF2 left 
flank and right flank from 
T6SS2 
 
This Study 
 
pSRC11 
 
 
pDM4 containing 
containing NdeI 
ligated106-2A IcmF1 left 
flank and right flank from 
T6SS1 
 
This Study 
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pSCrhaB3 
Vector containing Tpr 
cassette 
 
 
Dr. C. Hemsley 
 
pBHR4-RFP 
Vector containing Cmr 
cassette 
 
 
Dr. C. Hemsley 
 
pSRC13 
pGEM-T-easy vector 
containing icmF gene from 
T6SS1 
 
This study 
 
pBAD24 
Arabinose inducible 
expression vector (Ampr) 
 
 
LGC Standards 
 
pSRC14 
pBAD24 vector containing 
icmF1 complement gene 
 
 
This study  
8.8 Preparation of protein samples  
8.8.1 Culture filtrate and cell lysate preparations  
Overnight LB broth cultures of V. vulnificus grown at 30oC were re-adjusted to 
OD590nm 0.03 in 25 mL and grown to OD590nm 1.5. A 21 mL sample was centrifuged at 
4000 rpm for 5 minutes at 4oC. The supernatant was filter sterilised using a Millipore 
0.22 µm filter and protein precipitated by adding 5 mL of 100% TCA (w/v) dissolved 
in distilled water. The proteins were precipitated overnight at 4oC.  
A 1 mL sample from the overnight bacterial culture was adjusted to OD590nm 1.0, 
centrifuged at 5000 rpm for 3 minutes and re-suspended in 50 µl BugBuster® 
Protein Extraction Reagent (Novagen) and incubated at room temperature for 20 
minutes with rocking. Following incubation, 25 µl of PBS and 25 µl 4X NuPAGE® 
LDS Sample Buffer (Invitrogen) was added to the cell lysate and stored at 4oC 
overnight.  BugBuster was prepared by adding 1 µl Benzonase® (Novagen) and 1 µl 
rLysozyme ™ (Novagen) to 1 mL 1X BugBuster® Protein Extraction Reagent.  
Following overnight protein precipitation, a 2 mL sample was centrifuged at 20, 000 g 
for 5 minutes at 4oC, the supernatant removed and an additional 2 mL sampled 
added and centrifuged. This was repeated for the entire ~26 mL precipitated protein 
solution. The final centrifugation step used 1 mL of ice-cold acetone to wash the cells 
and performed at 20,000 g for 5 minutes. The acetone was removed and the protein 
dried at 95oC for ~ 50 seconds and re-suspended in 100 – 200 µl of PBS. Proteins 
were then quantified using the BCA assay.  
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8.8.2 Quantification of proteins 
Culture filtrate proteins were quantified using the Thermo Scientific ™ Pierce ™ BCA 
™ Protein Assay Kit prepared according to the manufacturer’s instructions. 
Quantification of proteins was achieved in a 96-well plate containing 180 µl of 
working BCA reagent mixed with 10 µl of protein (highly concentrated protein was 
diluted to 1 in 10 or 1 in 100) and incubated at 37oC. Absorbance of the samples was 
read at OD570nm.  
8.8.3 SDS-PAGE  
Quantified protein samples were mixed with 4X NuPAGE® LDS Sample Buffer to a 
final 1X concentration and heated at 95oC for 10 minutes with the cell lysate 
preparations. Prior to loading pre-cast NuPAGE® 4-12 % Bis-Tris Gels 1.0 mm x 12 
wells (Novex) were rinsed with distilled water and secured into a XCell SureLock ® 
mini cell. The gel was submerged in 1X NuPAGE ® MES SDS Running Buffer (Life 
Technologies) and a 3 µl sample of the Odyssey ® One-Color Protein Molecular 
Weight Marker (Licor) was loaded onto the gel with10 µl of each sample loaded  per 
lane, the gel was then run at 180 V for 50 minutes.   
8.8.4 Western blotting  
SDS-separated proteins were transferred to a nitrocellulose membrane included in 
the iBlot® Transfer Stacks (Novex) using the iBlot® Dry Blotting System (Invitrogen). 
The protein membrane was then rinsed with water and stained with Ponceau S to 
ensure equal loadings of protein samples. The Ponceau S strain was removed using 
0.1% (w/w) sodium hydroxide and rinsed with water. Membranes were blocked with 
blocking buffer PBS-T( 0.1% (v/v) Tween-20 in PBS) supplemented with1.5% (w/v) 
of skimmed milk powder and incubated for 30 minutes at room temperature with 
rocking. Membranes were then incubated overnight at 4oC. Following incubation 
membranes were incubated at room temperature for 30 minutes rocking and then 
rinsed with PBS-T washing buffer. Membranes were then incubated with primary 
Hcp antibody made up in blocking solution at a 1:500 dilution for 90 minutes at room 
temperature with rocking. Following incubation the membrane was washed with 
PBS-T for 5 minutes rocking and removed, the wash step was repeated a further 2 
more times before the secondary IRDye 680LT Goat anti-Rabbit IgG (H + L) (Licor) 
fluorescent antibody made up in blocking buffer at a 1:20,000 dilution was applied for 
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90 minutes at room temperature with rocking. The secondary antibody was then 
removed following the wash steps as descried previously. The membrane was 
scanned using the Odyssey CLx infra-red scanner (Licor) and imaged using Image 
Studio, version 4.0.  
8.9 Bioinformatic methods 
8.9.1 Whole genome sequencing  
Whole genome sequencing was performed by Exeter Sequencing Services at the 
University of Exeter using 250bp paired end reads on the Illumina MiSeq Desktop 
Sequencer.  
8.9.2 Assembling and annotating scaffolds 
Raw sequencing reads were assembled into scaffolds using the automated pipeline 
a5 [221]. Assembled a5 scaffolds were automatically annotation using RAST version 
2.0 [229]. Both a5 and RAST were used according to the default setting.  
8.9.3 Generating phylogenetic trees 
Phylogenetic trees were constructed using the automated pipeline, SNPhylo [223]. 
Raw sequencing reads were first trimmed using Trim Galore and aligned to the 
reference genome, YJ016 using Bowtie version 2.0. Following alignment, SNPs were 
called using SAMtools. SAMtools view was used to convert files from .SAM to .BAM 
format. .BAM files were sorted using SAMtools sort and indexed using SAMtools 
index. Finally SAMtools mpileup was utilised to compute and store all possible 
genotype variants into Variant Call Format (VCF), which is the required format for 
SNPhylo. Following SNPhylo process according to the default setting the 
phylogenetic trees were visualised using FigTree version 1.4.2. 
8.9.4 WGS comparison to identify gaps in the alignment between the query 
sequences and the reference genome  
WGS comparison was performed using the programme MUMmer. Prior to 
comparison, assembled scaffolds were aligned to the reference genome, YJ016, 
using NUCmer according to the fairly similar sequences default setting. Alignments 
were then parsed using show-coords and filtered using deltafilter. A MUMmerplot 
was used to visualise the query sequences alignment against the reference strain in 
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a scatter plot format. Data was then imported into Excel and sorted according to the 
start of the alignment in YJ016. Gaps were calculated by extracting the “gap” co-
ordinates from Excel and uploading to Circos. Circos was utilised to visualise the 
comparison of gaps between the query sequences and the reference genome. The 
forward and reverse tracks on the WGS comparison for the reference strain 
represent CDS features extracted from Genbank.  
8.9.5 WGS comparison between ∆T6SS1 mutant and wild-type strain.  
Comparison was performed as detailed in section 8.9.4, however gaps were not 
calculated in Excel and the instead co-ordinates were uploaded to Circos for 
visualisation.   
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Appendix 
Appendix A1: Statistical 2-way ANOVA analysis of V. vulnificus growth curve data. The OD growth curves carried out for the 10 V. vulnificus strains were analysed using 
a 2-way ANOVA followed by a post-hoc Tukey test using GraphPad 6. Highlighted in yellow are the strains which demonstrated a statistical significance, shown in red and 
green is whether the strain was clinical or environmental respectively. The “Summary” column gives an indication of significance which is denoted with an asterisk(s) and “ns” 
denotes a non-significant difference between the strains. The corresponding P-value for the significance is shown in the last column entitled, “Adjusted P-Value”.  The “Row” 
corresponds to the Time (hours), where Row1 = 0 hours, Row2 = 2hours, Row3 =4 hours and Row4 = 6 hours.  
 
Within each row, compare columns 
(simple effects within rows)             
              
Number of families 4           
Number of comparisons per 
family 45           
Alpha 0.05           
              
Tukey's multiple 
comparisons test Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value   
              
Row 1             
ORL-1506 vs. S3-16 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-OO  ORL-1506 vs. 106-2A 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-1506 vs. NSV-5830 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-1506 vs. S2-22 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-1506 vs. DAL-79040 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-1506 vs. 99-743 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-1506 vs. DAL-79087 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-1506 vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
ORL-1506 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
S3-16 vs. 106-2A 0.0 -1.925 to 1.925 No ns > 0.9999   
S3-16 vs. NSV-5830 0.0 -1.925 to 1.925 No ns > 0.9999   
S3-16 vs. S2-22 0.0 -1.925 to 1.925 No ns > 0.9999   
S3-16 vs. DAL-79040 0.0 -1.925 to 1.925 No ns > 0.9999   
S3-16 vs. 99-743 0.0 -1.925 to 1.925 No ns > 0.9999   
S3-16 vs. DAL-79087 0.0 -1.925 to 1.925 No ns > 0.9999   
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S3-16 vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
S3-16 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
106-2A vs. NSV-5830 0.0 -1.925 to 1.925 No ns > 0.9999   
106-2A vs. S2-22 0.0 -1.925 to 1.925 No ns > 0.9999   
106-2A vs. DAL-79040 0.0 -1.925 to 1.925 No ns > 0.9999   
106-2A vs. 99-743 0.0 -1.925 to 1.925 No ns > 0.9999   
106-2A vs. DAL-79087 0.0 -1.925 to 1.925 No ns > 0.9999   
106-2A vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
106-2A vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
NSV-5830 vs. S2-22 0.0 -1.925 to 1.925 No ns > 0.9999   
NSV-5830 vs. DAL-79040 0.0 -1.925 to 1.925 No ns > 0.9999   
NSV-5830 vs. 99-743 0.0 -1.925 to 1.925 No ns > 0.9999   
NSV-5830 vs. DAL-79087 0.0 -1.925 to 1.925 No ns > 0.9999   
NSV-5830 vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
NSV-5830 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
S2-22 vs. DAL-79040 0.0 -1.925 to 1.925 No ns > 0.9999   
S2-22 vs. 99-743 0.0 -1.925 to 1.925 No ns > 0.9999   
S2-22 vs. DAL-79087 0.0 -1.925 to 1.925 No ns > 0.9999   
S2-22 vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
S2-22 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
DAL-79040 vs. 99-743 0.0 -1.925 to 1.925 No ns > 0.9999   
DAL-79040 vs. DAL-79087 0.0 -1.925 to 1.925 No ns > 0.9999   
DAL-79040 vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
DAL-79040 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
99-743 vs. DAL-79087 0.0 -1.925 to 1.925 No ns > 0.9999   
99-743 vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
99-743 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
DAL-79087 vs. ATL-9824 0.0 -1.925 to 1.925 No ns > 0.9999   
DAL-79087 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
ATL-9824 vs. 99-796 0.0 -1.925 to 1.925 No ns > 0.9999   
              
Row 2             
ORL-1506 vs. S3-16 0.5970 -1.328 to 2.522 No ns 0.9909   
ORL-1506 vs. 106-2A 0.4913 -1.434 to 2.417 No ns 0.9979   
ORL-1506 vs. NSV-5830 0.3137 -1.612 to 2.239 No ns > 0.9999   
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ORL-1506 vs. S2-22 -0.4590 -2.384 to 1.466 No ns 0.9987   
ORL-1506 vs. DAL-79040 0.3410 -1.584 to 2.266 No ns 0.9999   
ORL-1506 vs. 99-743 0.4810 -1.444 to 2.406 No ns 0.9982   
ORL-1506 vs. DAL-79087 0.4843 -1.441 to 2.410 No ns 0.9981   
ORL-1506 vs. ATL-9824 0.5310 -1.394 to 2.456 No ns 0.9961   
ORL-1506 vs. 99-796 0.7510 -1.174 to 2.676 No ns 0.9576   
S3-16 vs. 106-2A -0.1057 -2.031 to 1.820 No ns > 0.9999   
S3-16 vs. NSV-5830 -0.2833 -2.209 to 1.642 No ns > 0.9999   
S3-16 vs. S2-22 -1.056 -2.981 to 0.8695 No ns 0.7425   
S3-16 vs. DAL-79040 -0.2560 -2.181 to 1.669 No ns > 0.9999   
S3-16 vs. 99-743 -0.1160 -2.041 to 1.809 No ns > 0.9999   
S3-16 vs. DAL-79087 -0.1127 -2.038 to 1.813 No ns > 0.9999   
S3-16 vs. ATL-9824 -0.06600 -1.991 to 1.859 No ns > 0.9999   
S3-16 vs. 99-796 0.1540 -1.771 to 2.079 No ns > 0.9999   
106-2A vs. NSV-5830 -0.1777 -2.103 to 1.748 No ns > 0.9999   
106-2A vs. S2-22 -0.9503 -2.876 to 0.9752 No ns 0.8412   
106-2A vs. DAL-79040 -0.1503 -2.076 to 1.775 No ns > 0.9999   
106-2A vs. 99-743 -0.01033 -1.936 to 1.915 No ns > 0.9999   
106-2A vs. DAL-79087 -0.007000 -1.932 to 1.918 No ns > 0.9999   
106-2A vs. ATL-9824 0.03967 -1.886 to 1.965 No ns > 0.9999   
106-2A vs. 99-796 0.2597 -1.666 to 2.185 No ns > 0.9999   
NSV-5830 vs. S2-22 -0.7727 -2.698 to 1.153 No ns 0.9494   
NSV-5830 vs. DAL-79040 0.02733 -1.898 to 1.953 No ns > 0.9999   
NSV-5830 vs. 99-743 0.1673 -1.758 to 2.093 No ns > 0.9999   
NSV-5830 vs. DAL-79087 0.1707 -1.755 to 2.096 No ns > 0.9999   
NSV-5830 vs. ATL-9824 0.2173 -1.708 to 2.143 No ns > 0.9999   
NSV-5830 vs. 99-796 0.4373 -1.488 to 2.363 No ns 0.9991   
S2-22 vs. DAL-79040 0.8000 -1.125 to 2.725 No ns 0.9377   
S2-22 vs. 99-743 0.9400 -0.9855 to 2.865 No ns 0.8496   
S2-22 vs. DAL-79087 0.9433 -0.9822 to 2.869 No ns 0.8469   
S2-22 vs. ATL-9824 0.9900 -0.9355 to 2.915 No ns 0.8068   
S2-22 vs. 99-796 1.210 -0.7155 to 3.135 No ns 0.5706   
DAL-79040 vs. 99-743 0.1400 -1.785 to 2.065 No ns > 0.9999   
DAL-79040 vs. DAL-79087 0.1433 -1.782 to 2.069 No ns > 0.9999   
DAL-79040 vs. ATL-9824 0.1900 -1.735 to 2.115 No ns > 0.9999   
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DAL-79040 vs. 99-796 0.4100 -1.515 to 2.335 No ns 0.9995   
99-743 vs. DAL-79087 0.003333 -1.922 to 1.929 No ns > 0.9999   
99-743 vs. ATL-9824 0.05000 -1.875 to 1.975 No ns > 0.9999   
99-743 vs. 99-796 0.2700 -1.655 to 2.195 No ns > 0.9999   
DAL-79087 vs. ATL-9824 0.04667 -1.879 to 1.972 No ns > 0.9999   
DAL-79087 vs. 99-796 0.2667 -1.659 to 2.192 No ns > 0.9999   
ATL-9824 vs. 99-796 0.2200 -1.705 to 2.145 No ns > 0.9999   
              
Row 3             
ORL-1506 vs. S3-16 0.6427 -1.283 to 2.568 No ns 0.9847   
ORL-1506 vs. 106-2A 0.8767 -1.049 to 2.802 No ns 0.8954   
ORL-1506 vs. NSV-5830 -0.2000 -2.125 to 1.725 No ns > 0.9999   
ORL-1506 vs. S2-22 -0.2117 -2.137 to 1.714 No ns > 0.9999   
ORL-1506 vs. DAL-79040 -1.078 -3.004 to 0.8472 No ns 0.7190   
ORL-1506 vs. 99-743 -1.778 -3.704 to 0.1472 No ns 0.0952   
ORL-1506 vs. DAL-79087 -2.045 -3.970 to -0.1195 Yes * 0.0283   
ORL-1506 vs. ATL-9824 -1.878 -3.804 to 0.04716 No ns 0.0619   
ORL-1506 vs. 99-796 -1.045 -2.970 to 0.8805 No ns 0.7537   
S3-16 vs. 106-2A 0.2340 -1.691 to 2.159 No ns > 0.9999   
S3-16 vs. NSV-5830 -0.8427 -2.768 to 1.083 No ns 0.9159   
S3-16 vs. S2-22 -0.8543 -2.780 to 1.071 No ns 0.9092   
S3-16 vs. DAL-79040 -1.721 -3.646 to 0.2045 No ns 0.1202   
S3-16 vs. 99-743 -2.421 -4.346 to -0.4955 Yes ** 0.0038   
S3-16 vs. DAL-79087 -2.688 -4.613 to -0.7622 Yes *** 0.0008   
S3-16 vs. ATL-9824 -2.521 -4.446 to -0.5955 Yes ** 0.0021   
S3-16 vs. 99-796 -1.688 -3.613 to 0.2378 No ns 0.1370   
106-2A vs. NSV-5830 -1.077 -3.002 to 0.8488 No ns 0.7208   
106-2A vs. S2-22 -1.088 -3.014 to 0.8372 No ns 0.7083   
106-2A vs. DAL-79040 -1.955 -3.880 to -0.02950 Yes * 0.0436   
106-2A vs. 99-743 -2.655 -4.580 to -0.7295 Yes *** 0.0010   
106-2A vs. DAL-79087 -2.922 -4.847 to -0.9962 Yes *** 0.0002   
106-2A vs. ATL-9824 -2.755 -4.680 to -0.8295 Yes *** 0.0005   
106-2A vs. 99-796 -1.922 -3.847 to 0.003829 No ns 0.0509   
NSV-5830 vs. S2-22 -0.01167 -1.937 to 1.914 No ns > 0.9999   
NSV-5830 vs. DAL-79040 -0.8783 -2.804 to 1.047 No ns 0.8943   
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NSV-5830 vs. 99-743 -1.578 -3.504 to 0.3472 No ns 0.2048   
NSV-5830 vs. DAL-79087 -1.845 -3.770 to 0.08050 No ns 0.0717   
NSV-5830 vs. ATL-9824 -1.678 -3.604 to 0.2472 No ns 0.1420   
NSV-5830 vs. 99-796 -0.8450 -2.770 to 1.080 No ns 0.9146   
S2-22 vs. DAL-79040 -0.8667 -2.792 to 1.059 No ns 0.9017   
S2-22 vs. 99-743 -1.567 -3.492 to 0.3588 No ns 0.2133   
S2-22 vs. DAL-79087 -1.833 -3.759 to 0.09216 No ns 0.0754   
S2-22 vs. ATL-9824 -1.667 -3.592 to 0.2588 No ns 0.1485   
S2-22 vs. 99-796 -0.8333 -2.759 to 1.092 No ns 0.9211   
DAL-79040 vs. 99-743 -0.7000 -2.625 to 1.225 No ns 0.9729   
DAL-79040 vs. DAL-79087 -0.9667 -2.892 to 0.9588 No ns 0.8274   
DAL-79040 vs. ATL-9824 -0.8000 -2.725 to 1.125 No ns 0.9377   
DAL-79040 vs. 99-796 0.03333 -1.892 to 1.959 No ns > 0.9999   
99-743 vs. DAL-79087 -0.2667 -2.192 to 1.659 No ns > 0.9999   
99-743 vs. ATL-9824 -0.1000 -2.025 to 1.825 No ns > 0.9999   
99-743 vs. 99-796 0.7333 -1.192 to 2.659 No ns 0.9634   
DAL-79087 vs. ATL-9824 0.1667 -1.759 to 2.092 No ns > 0.9999   
DAL-79087 vs. 99-796 1.000 -0.9255 to 2.925 No ns 0.7976   
ATL-9824 vs. 99-796 0.8333 -1.092 to 2.759 No ns 0.9211   
              
Row 4             
ORL-1506 vs. S3-16 0.06333 -1.862 to 1.989 No ns > 0.9999   
ORL-1506 vs. 106-2A 0.8777 -1.048 to 2.803 No ns 0.8947   
ORL-1506 vs. NSV-5830 -0.6700 -2.595 to 1.255 No ns 0.9797   
ORL-1506 vs. S2-22 -1.943 -3.868 to -0.01717 Yes * 0.0462   
ORL-1506 vs. DAL-79040 -2.543 -4.468 to -0.6172 Yes ** 0.0019   
ORL-1506 vs. 99-743 -3.143 -5.068 to -1.217 Yes **** < 0.0001   
ORL-1506 vs. DAL-79087 -2.709 -4.635 to -0.7838 Yes *** 0.0007   
ORL-1506 vs. ATL-9824 -3.243 -5.168 to -1.317 Yes **** < 0.0001   
ORL-1506 vs. 99-796 -3.043 -4.968 to -1.117 Yes **** < 0.0001   
S3-16 vs. 106-2A 0.8143 -1.111 to 2.740 No ns 0.9309   
S3-16 vs. NSV-5830 -0.7333 -2.659 to 1.192 No ns 0.9634   
S3-16 vs. S2-22 -2.006 -3.931 to -0.08050 Yes * 0.0343   
S3-16 vs. DAL-79040 -2.606 -4.531 to -0.6805 Yes ** 0.0013   
S3-16 vs. 99-743 -3.206 -5.131 to -1.281 Yes **** < 0.0001   
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S3-16 vs. DAL-79087 -2.773 -4.698 to -0.8472 Yes *** 0.0005   
S3-16 vs. ATL-9824 -3.306 -5.231 to -1.381 Yes **** < 0.0001   
S3-16 vs. 99-796 -3.106 -5.031 to -1.181 Yes **** < 0.0001   
106-2A vs. NSV-5830 -1.548 -3.473 to 0.3778 No ns 0.2276   
106-2A vs. S2-22 -2.820 -4.746 to -0.8948 Yes *** 0.0003   
106-2A vs. DAL-79040 -3.420 -5.346 to -1.495 Yes **** < 0.0001   
106-2A vs. 99-743 -4.020 -5.946 to -2.095 Yes **** < 0.0001   
106-2A vs. DAL-79087 -3.587 -5.512 to -1.662 Yes **** < 0.0001   
106-2A vs. ATL-9824 -4.120 -6.046 to -2.195 Yes **** < 0.0001   
106-2A vs. 99-796 -3.920 -5.846 to -1.995 Yes **** < 0.0001   
NSV-5830 vs. S2-22 -1.273 -3.198 to 0.6528 No ns 0.4982   
NSV-5830 vs. DAL-79040 -1.873 -3.798 to 0.05283 No ns 0.0635   
NSV-5830 vs. 99-743 -2.473 -4.398 to -0.5472 Yes ** 0.0028   
NSV-5830 vs. DAL-79087 -2.039 -3.965 to -0.1138 Yes * 0.0291   
NSV-5830 vs. ATL-9824 -2.573 -4.498 to -0.6472 Yes ** 0.0016   
NSV-5830 vs. 99-796 -2.373 -4.298 to -0.4472 Yes ** 0.0050   
S2-22 vs. DAL-79040 -0.6000 -2.525 to 1.325 No ns 0.9906   
S2-22 vs. 99-743 -1.200 -3.125 to 0.7255 No ns 0.5822   
S2-22 vs. DAL-79087 -0.7667 -2.692 to 1.159 No ns 0.9518   
S2-22 vs. ATL-9824 -1.300 -3.225 to 0.6255 No ns 0.4672   
S2-22 vs. 99-796 -1.100 -3.025 to 0.8255 No ns 0.6956   
DAL-79040 vs. 99-743 -0.6000 -2.525 to 1.325 No ns 0.9906   
DAL-79040 vs. DAL-79087 -0.1667 -2.092 to 1.759 No ns > 0.9999   
DAL-79040 vs. ATL-9824 -0.7000 -2.625 to 1.225 No ns 0.9729   
DAL-79040 vs. 99-796 -0.5000 -2.425 to 1.425 No ns 0.9976   
99-743 vs. DAL-79087 0.4333 -1.492 to 2.359 No ns 0.9992   
99-743 vs. ATL-9824 -0.1000 -2.025 to 1.825 No ns > 0.9999   
99-743 vs. 99-796 0.1000 -1.825 to 2.025 No ns > 0.9999   
DAL-79087 vs. ATL-9824 -0.5333 -2.459 to 1.392 No ns 0.9960   
DAL-79087 vs. 99-796 -0.3333 -2.259 to 1.592 No ns > 0.9999   
ATL-9824 vs. 99-796 0.2000 -1.725 to 2.125 No ns > 0.9999   
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Appendix A2: Ponceau S stain for Western blot images demonstrating expression and secretion of Hcp. 
(A) V. vulnificus cells lysate (C) and culture filtrates (S) from cells grown at 23
o
C and 30
o
C in LB with and without 
3% NaCl. (B) Cell lysate (C) and supernatant (S) from V. vulnificus cells grown as 30
o
C in LB and LB 
supplemented with 3% NaCl. V. cholerae V52 cell lysate run as a positive control (V. cholerae WT). Negative 
controls provided by V. cholerae ∆hcp1∆hcp2 (V. cholerae ∆hcp), and C. difficile. Protein samples loaded 
equalled 14 µg of protein/lane Protein marker is represented with (M). Indicated above each lane are the 
temperature and media conditions.  
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Appendix A3: Gene sequence of icmF gene from V. vulnificus 106-2A T6SS1. The sequence below shows 
the gene sequence encoding for icmF including the flanking genes, tssA from T6SS1 of V. vulnificus 106-2A. 
GGAGTCGAGATGGAAATAAACCAATATCGTCAGTGCATTTCCAAACCTGT 
TACCAATGACAATCCAATTGGAGAGCGATTGGTCGATCACCCGCTGTTTG 
ATTTCATTGAAGAGCAAATGATGAAAGTTGGATCACTTTCTCATGCTACG 
GTGCAGTGGGAAGAGGTTGAGCATAGTACGATTAAGTTACTTAGCGAGCA 
AAGTAAAGACATCAAGCTATTGGTTTATCTGCTTCAATGCTTGCATAACC 
AAATTACCCCTTTGCGCTTCATTACTTCTTTTTTAGTGATGAGCGAGTTT 
ATCGAGCAGTATTGGAATGAGTCTTACCCTGCACCAGGTGCTCGTGGCAA 
CCTACCTAGGCGCAAGTATTTTAGTCAGATGACACAACGTTTTAGTACGG 
TTGTTGATAAGTTTGATTTTTGCCATCTTGACGCAGCTGATCGTCAAGCG 
TTGCAAGCAGCTGTTGGGGAATGGAAACTTGTAATCGAAAAGCAGGGGCT 
GTTATCAGATTTAGTTGAATCAATAGCGGTCCGTATCGAAGCGGAGATTC 
AACGTGCAGAAAAGCAGCAGTCATCGGTTCAGAACGTAGAACAAATGACG 
CCAAGCATGCCAGCAACGACTCCTAGTTCCAGTATTGTAGCTGACCACTC 
TAGCGATAAAGCAGCAAAGCAGACACTACTCAAAGTTGCTGATTTTTTAG 
CTGAGCAAGATTTTGGAATACCACTATCTATTCGGTTACGGCGTTTTGCA 
GTATGGGGCAGTATTACTTCTCTTCCGGATCATAACCCTGATGGTCAAAC 
TCTACTAAGAAGTATGCAAGCAGATCGTGTCAAAGATTACCAAGCGCAAC 
TGCGTCATGCAGATTTAGCACTATGGCGGAAAGTGGAACAAAGCTTAACG 
ATGTCTCCGTACTGGTTTGAAGGTCAGTGGATGAGCTACACCATTGCCCA 
GCAACTTGGGAAAAGTGATTGGTCTGAGGCCATTGCAGAAGAGACACAAT 
CCTTCTTACATCGTCTACCTTCATTGTTTGACCTCAAATTCAAAGATGGA 
GACCCTTTTGTGAGCGAATCAGTTAAAGAGTGGTTAGCCACTATCGGACA 
AAAGGAATCATCCTCTGTACAAGCAATAGAGGGAGGTTGGCAAGAAAAAC 
GAAAAGTCGCATTCCAACTTGCTAAGGAAGGAGGAATTGCTGTGGCACTT 
TCCATGCTGAACGATGGATTAGTTGGAGCAGTAGAACCACGTGACAAGTT 
TTACTGGAGATTATTATCAGCTGATTTGTTACGTGCGAATCATCTTGATG 
CGATGGCTGGTGAACAGTACCAAACTTTGCTCGAGCAGGCGACGACAATG 
TCAGTGCCTGAGTGGGAGCCAAGCTTAATTGAACAAATTCAAAGATATAC 
AACGTCAGAGTAAACAAGGACACAATTCATGTGGAAATTCATTGTCGGAA 
206 
 
TAGTAAAGCGGCTCAAACCCACAGTGGTCGCTGCATTACCAATTTTGCTA 
TTCACTACGTTCATATTGTTGAACGTCGCCATTTGGTGGGCAGGCCCCTG 
GTTAGAATTCGCCGGTTATAAACCTTTGGAGTCTATTGTGGCTCGAGTTG 
TGGCGAGTAGCTTATTTACTCTCAGTTGTCTAGCCATTTGGGGCATTTGG 
CAATGGCGAAAACTGCAAACTTTTCGAGCGGAACAAAAACGTGAAGACCA 
GTTACGTCAAGACCCGATAAAAGTGTATGAAGAAAGACAAGAAGTTGAGT 
TGAATCAGGTCATGAACAACATGAAGCAGAACCTGAACAAACACAACTAC 
TTATACGCGTTACCATGGTACTTAGTATTGGGGTTAGAAAACGCAGGAAA 
AACCAGCTTAATCAACCGTTCAGGACAAAATTTTGTTTTTTCTTCAGTAA 
TGCGAGCGTCGGGTCAAAAAAGTGAAAATCCGTATTCATTTGATTGGTGG 
ATTGGTGACGAATCTGTGTTAATTGACCCTGATGGTGAGTTATTAACCCA 
AGGTAATCGAAGTGAAGACAACAACGGGGCAATGGAACGTCGTTTATGGT 
TACATTTTGTAGATTGGCTTGACCGTACGCGGAGTAGGCGTCCCCTTAAT 
GGAATAGTACTAGCTCTCGATGTTTCCCACCTTGCAACGGCTACGGCATC 
CGAGCGTAAAGCTTATGCTAGTTTACTGCGTGCTCGTTTACGAGAACTGA 
TGGAGACACTATCGACTCGTTTACCAGTCTATATTGCTCTAACTAAACTC 
GATCTTCTTCATGGTTTTGACCCCTTCTTTAAGCACTACACTAAAAGTCA 
GAGAGAAGAGGTGTTAGGTTTCACATTCTCAATGGATTCGTTAGATAACC 
TTGATTCATGGTTAGATGAATTTGCAGAGGAATATGCACAATTTGTTGAA 
CGGATGAATCGAATGCTACCACATGCAGTAGCAATGCCGATGACGTTGGA 
AGAGCGAAACGCGATTTATAGTTTTACTCGGCAGCTATTTGGCCTAAAAG 
ATATTCTTCAGCAGTTTTTCAAAGAAGCGTTGGAGAGTGATCAGTTTTCT 
ACTTCTGCCTTGGTGAGGGGAGCGTACTTTACTTCTGTTTATCAGCAAGG 
CGTTCCTACAAATGCCTTTGATGATGCAGCTTCACGTCGTTATAGTCTCT 
CACACGCGATTAATACTGCGCAGAGAGCGAAAAACTCAACCGTCTATTTC 
ACACAGAAATTGTTTACGCACATAATTTATCCAGAAGCAGGTTTGGCTTC 
GGATAACTTTCGTGTTGCAAGAAATAAACGTCGTTTAATTGGACTTTCCT 
TCATTGCATGTACAATTGCAACATTACTTTTGGCGGGAACTTGGCATCGT 
AGTTATATTAACAATGTGCAACATGCCGATGCAGTATTAGAAAAAGTAAA 
CCAGTATAAAGAGCAGTTTTCGAGCAATCGCAATCTTGCCTCTCAGAAAG 
ACGTACTAGAACCGCTGAATAAGATTCGTGAAGCGACTCTAGAATTTGGT 
207 
 
TTCTTTAGAGATAAGCCGAAATATGTTTCAGATTTTGGTCTTTACCAAGG 
GCATACCATTGGCCCTAAAGTTGAAGAAACCTACCTCAATTTACTTGAAA 
ACCGTTTTTTGCCCTTACTCATGGCCGATGTGGTAGTGGCTTTAAATCAA 
GCGCAGAGTGATGAGGAGAAGCTTGCGGTCCTTCGTGTCTATCGAATGTT 
GGTAGATAAAAGTGGTCGATACCAAGATTACGTGATGGATTATTTCGCTA 
AGTATTGGCAGATGTCTTTTTCGGGTCAACGCAAAACTCAAGAGGAATTA 
CTAGGGCACTTGGATTATGCGATGCGTCATACCGATTTAACCGCAGATCG 
TCTAAACGATGATAAAGGGGCTGAAAAGGTTATGCGTCCATACGATAAAG 
TGATCGCGAAAGCCCAGGTTGAGTTGAGTTCAATGCCAAACGATCAGCGT 
GTCTACAGAAACCTTAAGCTGAGTGCGCAAACGGTTCTAGGTCCTCCAGT 
GAATCTTAGAAGCTTGATTGGTCCGGTTTTTGATGTCGTTTTTGAAGAAC 
GGGTACTGAATAGCAAGAATTTGTATATTCCTCAAATGTTAACCAAACGT 
GGGTTTGATGACTATTTTATGCCGCAGTCTGAATCAGTTTCCGAGTTGGC 
TTTGATTGATAGCTGGGTATTGGGTCAAAGTAAAACGGCACAATTTAGTG 
AAGCTGACAAACAGGCACTGCGCGACAAAATACGAGATCTCTACGTCGCT 
GATTATACAAACACATGGCGCTCAGCACTGAACGAGATAGATGTTAAGTA 
TTTTAATGATATCAATGATGCAGTTATGGTGTTAGAGAACATCACGAGTA 
ATCTCGAACCAATGCAACGCTTACTTCGTACTCTAGAGGATAATACGCAA 
CTGTATAGCGCGTTACCTAAAGACGAAGCTGCAATCAAAGAATTGCTGAA 
AAATCCAAAGTACAAAGTGGCTTCTATGATAGAAACACCATTTGCTGAAC 
TTAACAGTATGCTCCAGTCTGCTGACAGTAAGCCAGCATACATGACAGAA 
GTGCTCGCATCGGTTGATGAGTTAAAGAGTTATCTAAAATCGATCCAAGA 
TGCGCCGGATGTTGGCATGGCTGCATTAGATGCGACCAAAGCGCGAGTAA 
AACTAGTCAACGCGGATCCTATTTATACATTAAAGCGCGTCTCATCTGGG 
TTACCTAAACCACTGGATACAATGATGACGAAAATTGCAGATGAGAGCTG 
GTATGTTGTTAAACAAGAAGCGATCAAGCATCTTGAAGTGCGCTGGGCTG 
AAGACGTTTATGACACGTTCCAAAGTAAATTAGCAGGACGTTATCCATTT 
AATTCTGCTTCCAATAAAGATGTTTCCTTGGAAGATTTTGAAACTTTCTT 
TGCGCCTAATGGTACGCTGGATAACTTTTATAATCATCAGTTAAAGATGT 
TTATTGAAGAGAATATAACTGTTTCAGCAGATGACTCTACGCAATCAATT 
GTCCGTAAAGAGGTACTAGAGCAGATTGAACAAGCACAAAAAATTCGAGA 
208 
 
AGCATTCTTTAATCGTAAAGGTATCTTAGATGTTAGTTTCTCCGTCGAAC 
CGCTTAGTCTGAGTAACAACAAACGGCGGAGTGTATTGAATGTCGACGGT 
CAGTTTTTGGCTTATAGCCATGGACAGCGTGAAAATGTTGAATTGATTTG 
GCCAAATACTCTACGTGATTCCGCTGTTTCTAAAGTCACGTTGGTACCGA 
CTCAAAGCAACATGTCGCCACGCAGTATACAGATACAAGGGCCTTGGGCA 
TTCTTTCGATTGTTAGATGAAGGAGATGTGGTTGCGGCTAGTCAGACGTC 
AGTAGATTTTAAGTTCATAGTTGATGGTGGTGAAATGATCTACAGAATTA 
ACTCAGAAGCGGATGCAAATCCTTTTACTGAACGTCTTTTCAAGTCATTC 
AAACTGTCTAAAACTCTTTATTAATTGTTATCAGAGCGAGATTCTCGCTC 
TATTCCTTTAGGAAGAAGTCGCGATGTCTAATGTAATTTTCATTGACAAT 
CTTTGTTATCGGTTAACCTCAGATTCGCAAGAAATTAGAGGGTTAGAACC 
TTACTTTAAAATTCGAGAAGAAATAAACCGCCGCTTCAATCCTATTGTAG 
GTGGTACGGATTGGCAGTGTGTAAAAGAGCAATGTGAACTACTCGCTTTT 
CATCAAGGAATGGATTTCTTGGTATGTGGCTACTATGCGGTAGCTTGCCT 
AAAAACTCAGGGCTTATCTGGTTACGCTAAAGGTATGGAATTAATGAGTG 
CTAGCCTTGCTAATCAAGGTGAATGTGATGTCAAAAGTGCCAAAATACGT 
AAAGAGATTCTAGATTGGGTGAATGCACGTGTCGTACATGAATTGAAAAC 
GCTCAAACCTAATTATGAATCATTGAGAGAGCTTTATCGTGCCGAGCGTT 
ATTGTGAGCGTCTACATCAGTTATTTGAGTACCAGCAAACCGAGTACAAA 
GTTGATTTTGAGGGCGTCGGTTTTGCACTGTTTGAGCATATTGACAGGAT 
CGAAACTCATTATCACAGTTTGCTTAAAAAACAGGAGAAAAATCAACTTC 
CCGAGCTCAAGTTATGGCAAAGACATTATGGTCTGGCAATGCTTGGTGGA 
TTGGGTATTGTAATAGGTCTAATTGGCGGATATTGGGTGTGGCCTTGGTT 
ACATACCACACCGTATGCAGCTCCACAAATTGTAACAACGCTAAATGACG 
AAACAAAATCTCACTCTTTGATCGCTGAATCATCTCAAGCTGAACGACTT 
CGTTGGCAAAATACTCTTATTCCACTTTATCGCTCTACTCTAGAGCAAAA 
TTTATCAGCTCCTTTTAATGCCTCAAAACAACAGGCCAACAGCCATCTTA 
TATTGCTGAAAAAACTGTACCCTAAGGATGAGCGAGTTACTACTCTTAGC 
CAAGAGTTCAGTCAGAAGCAACAAATTGCGTTGGAACAAACGGAAATGTT 
TGTTAGCAAATTTAGTGAAATAAGGACCAAAATGGCCAATATTGCGCTGC 
TTGCAAAAAAGGGCAGATGGAAGGAACTGGAAAAACAAACCAAATCGCTC 
209 
 
GAAGATTTTGCAGTGAGCCTGTCACCGATTTATGGCAGGGTTGATTATGT 
GCAAGGCTTAATTCGGCAAGGTGACATTTCTAGCGCAGAGAAAGAGCTAT 
CAATTCTTCAACAAAGACTAGATAGTTTGAGCTGGAAAATTGTTGAACTG 
GAACTGAGTATCCGCAATAAATCGAAACAGCAGTAACCAC 
Appendix A4: icmF gene sequence from V. vulnificus 106-2A T6SS2. The gene sequence below encodes for 
icmF and flanking genes from V. vulnificus 106-2A T6SS2.  
TAAGTGAAGCTATGGACGAAACGATTGTAAAACCAACCCCTGGGCGTAAA 
AAAGCACCGCAGTCGACACCTGTTGCATCGCTTGAAAGCGATAACACGGT 
TCTCTTTACGCAAAATAGTAAAGAAACGCGTGAAACGAGTATCATCGCGT 
TTGGCAATAACGTACTGCTGGCAGAAGCGAATGTCATTGTTTCCTTGCTT 
GGCCAAATTAGAGCGACGGCCACGCACAGTGATGTCAAACAGTTACGTGA 
AGCATTTGTGCAAAAAATGCGTGACTATGAAAACCGGTTGAGATTACAAG 
GCGCAAATAGCAAGCAGATCGATATCGCACGCTACTGTTTATGTAGTGCT 
ATCGATGAAGCCGTCCTAAATACCGAATGGGGAAGTCAATCCGTTTGGGG 
ACACAACTCGTTATTGTCGACATTCTATTCCAATACTCAAGGCGGTGAGC 
AGTTCTTCATACATCTCGATGAAAGCCTTGCCGAACCCAATAAGCACTTA 
GATCTGCTAGAAGTCATGTATATCTGCATGAGCTTAGGTTTTTTGGGGCA 
ATTTCGAGTTCGAGAAAATGGAATCGAGCAACATCGTTCCTTAAAAAACC 
GCGTAATGGATGTCCTTAAATCGCACGGTCGGGACTACAGTCCTTCACTC 
AACGATGATGCGTTAGCCAAAGTATTGGTTGGTGAGCAGATCGCAGAAAA 
AGCACCATTGTGGGTTGTTTTATCAATTACCGCGGCTGTGTTAGTCAGTG 
TGTACATGTACTTAAGTTATAGCCTAAACGAAAAATCCGATCAGACCTTT 
AGTCAGTTAATGAACTTAGTGCCGAGCAAAGAGATAGAGAACCAGAGTGC 
GGATTATATTTCGTCTCTTGCCGTAGCAAATCAAATCCAACGCTCGTTGG 
CAACGGAAATAGAAATGGGTTTGCTAAAAGTCGATGCATTACCCGATAGA 
GTGCGTATTACTTTTCAGTCCAATGATCTGTTTGAATCGGGCAGTGCGGA 
GCTTGTCGCGCATATATTCCCTGTGGTTTCGAAAGTGGCCAGAGCACTCG 
AGGCGACCAATGGAAAAATATTGGTTGTCGGACATACCGATAATAACCCC 
ATTTTTACCAGTAAATTCCCTTCTAACTGGCATTTATCTCTCGCCAGAGC 
210 
 
GACAGCGCTAACCGATCGCTTAGCATCAGCAGGCAAATTGAGTGGGCGTG 
TCATTCCGGAAGGAATGGGAGATGCGAGACCTTTGGTATCAAATGAAACC 
GCAGAAGGAAAAAGCATCAACCGTAGAGTCGAAATCGATCTCCTAGTTCA 
AACCCAATCAAAAATGGATGCAAACAATGGCAAAGATTAAACGTTTATTG 
GGGCAAAAATGGCTGATTAGCTTGATCGGGCTTGGGGCAATTTCTATTTT 
TATTTGGTTTGTCGGACCATTGATCGCGATAGCAGGCATAGAGCCACTGA 
AATCTGACTTTAACCGTTTGTTGGTTATTGTGGTTTTAGTCTTCATTTGG 
GGCGTGACGAATGTTGTCCGTCAACAGAAGGAGCGAAAGGAACAAGATGA 
AAGCATCCAAAGCCTATTAGAGGTGGATGCCCTGACCGATAAAGAAGCGG 
CGGCAGAAATAGACGTCATGCGCGAAAGAATTGAGAAGGCGATTCAAGTC 
GTGACGAAAGGTGGAAAGCGTAAGAGTCATCTCTACGAGTTGCCTTGGTA 
TGTACTTATTGGTCCTCCTGGAACAGGTAAAACGACGGCATTAAAAGAAT 
CGGGTCTCGAGTTTCCTCTATCAGATTCAATGGGTGTTGACTCGGTTTCT 
GGTATTGGCGGTACGAGAAATTGTGATTGGTGGTTTACCAATAAAGCGGT 
GTTGATTGATACGGCTGGCCGATACACCACGCAAGACAGCCAAGCTCATG 
TCGATTCAAAAGCATGGTATGGATTCTTAGGCTTATTGAAGCAATACCGT 
AAACAGCGTCCTATTAATGGTGCGATTGTTACCGTCAGCATCGCAAGTAT 
GCTCACACAAACTCGCACCGAACGAGGCATGCATGCAAGAGCGATAAAAA 
ATCGGCTACAAGAACTGAAAAATCAATTGGGTATGCAGTTCCCAATCTAC 
GTTGTGTTGACTAAGGCTGATCTCATTGCTGGTTTTAGTGAGTTTTTTAC 
GGAACTGACCAAGGAAGAGCGTGAGCAGTTATTAGGTTTTATGTTTCCAC 
CTTCAACAGAAGACGAGCGAGGCGTCATCTCTCTATTTAACAAAGAGTTT 
CATGACTTACTGGAGAGACTTGATCGCCGCATGATGCAAAGGCTTGAAAC 
GGAGCATGACCTTGACAAACGATCTTTAATTTTTGAATTTCCAAAACAAT 
TGCGTTGTCTTCAAGCGAATCTAGACGAGTTTCTGAACGACATTTTTGCC 
CAAAACAAGTTTGAAGAATCTTCAATGATTCGCGGCGTCTTTATTGTGAG 
TTCATTGCAAGAAGGCACGCCGGTTGATCGTATTATGTCTGAAACATCCC 
AAGGGCTGGGGTTGGGCAAACCTCTACTGCGGTTAAGTTCCAAAGAATCA 
211 
 
AGCAGCTATTTTGTAAAAAACTTGTTTGAAAACGTCATCTTTAAAGAACA 
GTTTTTAGGGACGGTCAATCGTCATCATCAAAAGCAAAGTGGCTGGATTC 
GAAAAGGCGTCTACTGCTCGTGCATGGCACTGTCTGGGGCTGCGATCACA 
CTGTGGATGATGAGTTATCAGTGGAACAATCAACTCATTGATGAAACGGA 
TCGTCAAGTGACTGTGGTGAATGACTTACTTGCTAAGTCTGGTCTGGACT 
TCGAAAACGACTTGATCCCCTCGATAAACATTCTCAATCACATCATGCGT 
TTCCCTATGGGTTATAGACAGCAAGATGACGAGAGAGATCGTGTGACATC 
GTTTGGTTTTTTTCAAGGTGAAAAAATTGGCCAATCAGCGAAGAGTGCTT 
ATCACCAAGCACTGACAAATTACTATTCATCCTATGTTGAATCGGTACTT 
CTCAGTGAAATGAAGAACAATGAACAACACCGAGAATATTTGTACGAAAC 
ACTCAAAACATATTTGATGCTTTTCAACGATGATAAATTTGAGCGTGAAC 
ATGTTCTTGGTTGGTTCAATTATTTCTTTGAAAGGCAGTATCCCGGCGAA 
TTGAATGAAGAGTTAAGAGAGCAACTCTACGCTCATACCGAAAACTTTTT 
GTCGCAGGCAGACAGAGGCTTATATATCAACAACGATTCAGTAACCGCTG 
CCAGATTGGTTCTAACAGAAATGTCGTTGTCGGAAAGGGCTTACCAAAGA 
ATGAAACTGCAGTTCCTTAAAAGTCATGTGCCTTCATTCCGTTTAACGGA 
CGTTCTAGGGGCTAGGGGAGTTGAGCAGTTTGAGCGAAAAAGTGGCAAGC 
CATTATCGATGGGGATTTCCGGTTTCTACACGTACAACGGTTTCCATAGC 
ATCTTCCAATTGCAACTGGGTCGTATGGTAAAAGCCTTGATGGAAGAAAA 
CTGGGTGTATGGGGATGAGATTGACGCCCAAAACATCGACAATGATCTCG 
CTTTGCAAGGTGTGAGAGAGCGCTACTATCGTGACTATGTCTATGAATGG 
AAGACACTGCTCAATGATATCCAACTCAAAGCGGCACCCAGTTTGAAACT 
AAGTTTAGAGCAGAGTATGACATTAGCGGGCTCTGAGCGACCAATTGAAT 
CGCTGCTTAAAGCGGTACAAAAAGAGGTGGCATTAACGAAAATTTCGCTA 
AGCAACAACGAAAAAGCGGCAGCAGAAGTCGCTGGTAAAGTTGCCAAAGT 
AAAATTTTCAAATACGGCGGACAAACTTGATTTATATCGTCCGGAAGAGG 
GCAATACGTTTGATATTGCGCTTCCTGGAAAAGAAGTGGAAGCCGAGTTT 
GACGATCTTGTTAGGATGACAGACCAAGACTTTGACGATATTCATCTCGC 
212 
 
ACTGAGCGGTTTAAAAAGTTATTTGGCCGATCTCTCTAGCTCAGGAAATA 
ATCAGAAAGTCGCCTACAAGAGCATCTTAAATGGCACCGTGACAGGAGAA 
GTTGCCGCGTCAATTGAACATGCTAAACAGCTTTTACCCGCTCCGTTTAA 
CAACTGGCTAGGTGAACTTTCCGAGGAATCGGTCAAGTTAGCGGAAAAAG 
GATCGCGATCTCACCTTAATACGCTATGGGTTAACAAGGTTCTTAAACCT 
TATGAGCGCAGCATCAAAGGCAGGTATCCGTTTGAGCCAAGAGCGAAAAC 
AGAAGTGACGTTAAAGGACTTCAGTCGATTCTTTGGCTACGGCGGAACAC 
TTGATGCGTTCTTTGTCGAATACTTGGAACCGTTTGTCGATACGTCGAGA 
AGTGTGTGGCGCTTCGAGAAGGAAATCGGTGTCAGTCAAGAAACCCTCGC 
CGTATTTCAACGCGCAGATCGCATCCGACAATCGTTTTTCGAACTCGACA 
ATACACTAAAAGTCGATTTTGCAATGAAACCGATATACCTCGACCAACAT 
ATAACCAGTTTTGTACTGGAAGTCGGGGGGCAGAATCTTGCATACCGACA 
TGGGCCGGCAAGAGTAAAAAATCTGTCTTGGCCAGCTAAGCGTTCAGCGA 
CAAGAGTGGTCTTCACACCACCTGATTCGATTCGTGAAATTGCTTATACC 
TATGAGGGCGAATGGGGCATTTTTAAGTTGCTTGATCAATCTCTGAAAGC 
AAGGCCGCAATCTCGCAAAGACAATATCGTCATGATTGATTTGAAAGGCA 
ACAAAGTTCAACTGGAATTGATTCCTAAAAGTACGATGAACCCATTTTGG 
TCGAGTGATATGGAGAGTTTCCGATGTCCGCAAACGCTATAACACCAAGT 
TGGGGCTTTATAGGCAAAATTCCTGCGAAAGGGGATTTTATCAAGCAAGA 
CTTGCCGAAACCTTTTGCGGATCTTTTCCACGACTGGCAGCAGGCGATTA 
TCGCCGTTAGCAAAGAACAGCTACAGGAAACATGGCAAAGCCATTTTCTA 
AATGCGCCAATTTGGCATTTCGCATTGGACAGTGGTGTAACCAATGACGC 
CACGATCATCGGAACGATGATTCCTAGCGTAGATGCCGCTGGACGGTACT 
TCTTTTTTGCATTAGCCAGGCCCGTTCTTGGTGATGCCGTGAGCTATTGG 
AGCTGTCGAGATTGGGCCAACGAATCGCAAGAGCTGGCGTTAACCGTGCT 
GGACGACCATTTTACCTTCGACGTTTGGAGTCAGAATCTACAGTCCGGTA 
CAGAGTTAATTAACGCTATTTCGGCAGAAACGTTACCGGTTTCCCAAAAG 
AAACTGAGCGGAGAAAACCTCTTTATTAAGGAACATACAGAAACCGATGT 
213 
 
GATGAGTTTGCTCTCTCATGTTGTACGACAGCAGTTCCCTAAGCCGTGCT 
ACTGGTGGACGGATGGTAATGATGCCATCGAGCCGATGATGCTCGTCATG 
GATGGTTTACCTCAAATTGGCAAATTTGCCGCAATGTTGGATGGGCAATG 
GCAGAAATGGAATTGGTAACGGTGATCGAATGAGTTG 
214 
 
 
Appendix A5: Gel electrophoresis image of PCR to confirm an icmF mutant in V. vulnificus 106-2A T6SS1 
and V. vulnificus 106-2A T6SS2. (A) PCR bands generated when using the MutScreen forward and reverse 
primers for the icmF gene in T6SS1. Lane 1, wild-type icmF gene, 4622bps; lane 2, mutated icmF gene, 
1555bps; lane 3, negative control (B) PCR bands generated when using the MutScreen forward and reverse 
primers for the icmF gene of T6SS2. Lane 1, wild-type icmF gene, 4802 bps; lane 2, mutated icmF gene, 
1573bps; lane 3, negative control. Lane M contains the Fermentas 1kb plus ladder in both images (A) and (B).  
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Appendix A6: Statistical two-way ANOVA analysis of data from V. vulnificus 106-2A, 99-743, ∆T6SS1 mutant, ∆T6SS2 mutant and V. fluvialis NCTC 11327 grown in 
LB at 30
o
C. The OD growth curves carried out for the strains, V. vulnificus 106-2A, 99-743, ∆T6SS1 mutant, ∆T6SS2 mutant and V. fluvialis NCTC 11327 were analysed using 
a two-way ANOVA followed by a post-hoc Tukey test using GraphPad 6. Highlighted in yellow are the strains which demonstrated a statistical significance. The “Summary” 
column gives an indication of significance which is denoted with an asterisk(s) and “ns” denotes a non-significant difference between the strains at the designated time point. 
The corresponding P-vale for the significance is shown in the last column entitled, “Adjusted P-Value”.  The “Row” corresponds to the Time (hours), where Row1 = 0 hours, 
Row2 = 2hours, Row3 =4 hours and Row4 = 6 hours, Row5 = 8 hours and Row6 = 24 hours.  
Within each row, compare columns 
(simple effects within rows)           
            
Number of families 6         
Number of comparisons per family 10         
Alpha 0.05         
            
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value 
            
Row 1           
106-2A WT vs. 106-2A:IcmF1 
mutant 0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A WT vs. 106-2A:IcmF2 
mutant  0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A WT vs. 99-743 0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A WT vs. V.fluvialis 0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A:IcmF1 mutant vs. 106-
2A:IcmF2 mutant  0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A:IcmF1 mutant vs. 99-743 0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A:IcmF1 mutant vs. V.fluvialis 0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A:IcmF2 mutant vs. 99-743 0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A:IcmF2 mutant vs. V.fluvialis 0.0 -1.229 to 1.229 No ns > 0.9999 
99-743 vs. V.fluvialis 0.0 -1.229 to 1.229 No ns > 0.9999 
            
Row 2           
106-2A WT vs. 106-2A:IcmF1 
mutant 0.01000 -1.219 to 1.239 No ns > 0.9999 
216 
 
106-2A WT vs. 106-2A:IcmF2 
mutant  -0.04333 -1.272 to 1.186 No ns > 0.9999 
106-2A WT vs. 99-743 -0.006667 -1.236 to 1.222 No ns > 0.9999 
106-2A WT vs. V.fluvialis -0.8333 -2.062 to 0.3957 No ns 0.3249 
106-2A:IcmF1 mutant vs. 106-
2A:IcmF2 mutant  -0.05333 -1.282 to 1.176 No ns > 0.9999 
106-2A:IcmF1 mutant vs. 99-743 -0.01667 -1.246 to 1.212 No ns > 0.9999 
106-2A:IcmF1 mutant vs. V.fluvialis -0.8433 -2.072 to 0.3857 No ns 0.3131 
106-2A:IcmF2 mutant vs. 99-743 0.03667 -1.192 to 1.266 No ns > 0.9999 
106-2A:IcmF2 mutant vs. V.fluvialis -0.7900 -2.019 to 0.4390 No ns 0.3788 
99-743 vs. V.fluvialis -0.8267 -2.056 to 0.4024 No ns 0.3329 
            
Row 3           
106-2A WT vs. 106-2A:IcmF1 
mutant -0.06667 -1.296 to 1.162 No ns 0.9999 
106-2A WT vs. 106-2A:IcmF2 
mutant  -0.06667 -1.296 to 1.162 No ns 0.9999 
106-2A WT vs. 99-743 -0.3667 -1.596 to 0.8624 No ns 0.9173 
106-2A WT vs. V.fluvialis -2.500 -3.729 to -1.271 Yes **** < 0.0001 
106-2A:IcmF1 mutant vs. 106-
2A:IcmF2 mutant  -7.947e-008 -1.229 to 1.229 No ns > 0.9999 
106-2A:IcmF1 mutant vs. 99-743 -0.3000 -1.529 to 0.9290 No ns 0.9587 
106-2A:IcmF1 mutant vs. V.fluvialis -2.433 -3.662 to -1.204 Yes **** < 0.0001 
106-2A:IcmF2 mutant vs. 99-743 -0.3000 -1.529 to 0.9290 No ns 0.9587 
106-2A:IcmF2 mutant vs. V.fluvialis -2.433 -3.662 to -1.204 Yes **** < 0.0001 
99-743 vs. V.fluvialis -2.133 -3.362 to -0.9043 Yes **** < 0.0001 
            
 
Row 4           
106-2A WT vs. 106-2A:IcmF1 
mutant 0.03333 -1.196 to 1.262 No ns > 0.9999 
106-2A WT vs. 106-2A:IcmF2 
mutant  0.03333 -1.196 to 1.262 No ns > 0.9999 
217 
 
106-2A WT vs. 99-743 0.1333 -1.096 to 1.362 No ns 0.9981 
106-2A WT vs. V.fluvialis -2.200 -3.429 to -0.9710 Yes **** < 0.0001 
106-2A:IcmF1 mutant vs. 106-
2A:IcmF2 mutant  0.0 -1.229 to 1.229 No ns > 0.9999 
106-2A:IcmF1 mutant vs. 99-743 0.1000 -1.129 to 1.329 No ns 0.9994 
106-2A:IcmF1 mutant vs. V.fluvialis -2.233 -3.462 to -1.004 Yes **** < 0.0001 
106-2A:IcmF2 mutant vs. 99-743 0.1000 -1.129 to 1.329 No ns 0.9994 
106-2A:IcmF2 mutant vs. V.fluvialis -2.233 -3.462 to -1.004 Yes **** < 0.0001 
99-743 vs. V.fluvialis -2.333 -3.562 to -1.104 Yes **** < 0.0001 
            
Row 5           
106-2A WT vs. 106-2A:IcmF1 
mutant 0.03333 -1.196 to 1.262 No ns > 0.9999 
106-2A WT vs. 106-2A:IcmF2 
mutant  0.06667 -1.162 to 1.296 No ns 0.9999 
106-2A WT vs. 99-743 2.133 0.9043 to 3.362 Yes **** < 0.0001 
106-2A WT vs. V.fluvialis 0.5333 -0.6957 to 1.762 No ns 0.7396 
106-2A:IcmF1 mutant vs. 106-
2A:IcmF2 mutant  0.03333 -1.196 to 1.262 No ns > 0.9999 
106-2A:IcmF1 mutant vs. 99-743 2.100 0.8710 to 3.329 Yes *** 0.0001 
106-2A:IcmF1 mutant vs. V.fluvialis 0.5000 -0.7290 to 1.729 No ns 0.7824 
106-2A:IcmF2 mutant vs. 99-743 2.067 0.8376 to 3.296 Yes *** 0.0001 
106-2A:IcmF2 mutant vs. V.fluvialis 0.4667 -0.7624 to 1.696 No ns 0.8221 
99-743 vs. V.fluvialis -1.600 -2.829 to -0.3710 Yes ** 0.0047 
            
Row 6           
106-2A WT vs. 106-2A:IcmF1 
mutant 0.1667 -1.062 to 1.396 No ns 0.9954 
106-2A WT vs. 106-2A:IcmF2 
mutant  0.2000 -1.029 to 1.429 No ns 0.9907 
106-2A WT vs. 99-743 0.5333 -0.6957 to 1.762 No ns 0.7396 
106-2A WT vs. V.fluvialis -0.7667 -1.996 to 0.4624 No ns 0.4094 
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106-2A:IcmF1 mutant vs. 106-
2A:IcmF2 mutant  0.03333 -1.196 to 1.262 No ns > 0.9999 
106-2A:IcmF1 mutant vs. 99-743 0.3667 -0.8624 to 1.596 No ns 0.9173 
106-2A:IcmF1 mutant vs. V.fluvialis -0.9333 -2.162 to 0.2957 No ns 0.2188 
106-2A:IcmF2 mutant vs. 99-743 0.3333 -0.8957 to 1.562 No ns 0.9402 
106-2A:IcmF2 mutant vs. V.fluvialis -0.9667 -2.196 to 0.2624 No ns 0.1894 
99-743 vs. V.fluvialis -1.300 -2.529 to -.07096 Yes * 0.0331 
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Appendix A7: Stability of the plasmid pBHR-
RFP in V. fluvialis. Stability tests demonstrate 
that pBHR-RFP is not stable in V. fluvialis during a 
5 hour co-culture assay when no antibiotic 
selection pressure is present. Experiments were 
performed three times in triplicate, error bars show 
standard error of the mean. Statistics were 
performed using the unpaired 2-way Student’s t-
test, * P < 0.05. 
 
 
 
 
 
 
Appendix A8: Preliminary challenge of G. 
mellonella with V. vulnificus 106-2A wild-
type ∆T6SS1 and ∆T6SS2 mutants. The 
graph demonstrates the % survival of G. 
mellonella following a challenge with either V. 
vulnificus 106-2A wild-type indicated by “106-
2A WT” or the T6SS1 or T6SS2 mutants 
indicated by “106-2A:IcmF1” and “106-
2A:IcmF2” respectively. G. mellonella were 
challenged with 10
5
 cfu/ml of each strain which 
had been grown to mid-log phase at either 
37
o
C or 30
o
C. Following inoculation G. 
mellonella were incubated at their respective 
temperature either 30
o
C or 37
o
C for 24 hours. 
Following incubation the survival of G. 
mellonella from each was assessed. The 
preliminary experiment suggested that the 
T6SS2 mutant was attenuated when incubated 
at 37
o
C. PBS negative control shown in blue. 
The results shown are from 1 experiment 
where n=5.  
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Appendix A9: Western blot using anti-Hcp antibody to detect Hcp secretion in 106-2A ∆T6SS1::pSRC14. 
V. vulnificus cells lysate (C) and culture filtrates (S) from cells grown at 30
o
C in LB supplemented with 0.1% 
arabinose. Hcp detection ~23 kDa, Hcp detection in ∆T6SS1::pSRC14 is indicated with a white arrow. Protein 
marker is represented with (M).  
 
 
 
 
 
 
 
 
 
 
 
